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ABSTRACT 
 
Environmental factors interact with the genome to influence gene expression, 
tissue function and also disease risk. External stimuli may affect the phenotype 
through epigenetic mechanisms that provide an interface with the genome. Indeed, 
epigenetic modifications represent a mechanism through which both genetic and 
environmental cues, including dietary factors, are integrated at specific genomic 
loci and affect individual phenotypes, contributing to susceptibility to obesity and 
type 2 diabetes. Recently, alterations of Ankyrin repeat domain 26 (Ankrd26) gene 
expression and function have been associated with the onset of these metabolic 
disorders. However, whether external cues can affect its expression remains 
unclear. Therefore, the aim of this study is to evaluate whether the administration 
of a high fat diet (HFD) in mice could affect Ankrd26 expression and function, and 
whether chromatin remodeling and epigenetic modifications take part in this 
regulation. Particularly, I examined the correlation between obesity and 
inflammation with defective regulation of Ankrd26 gene in visceral adipose tissue 
(VAT) depots, aiming at identifying epigenetic mechanism that might underpin the 
development of VAT dysfunctions induced by overnutrition. Using the HFD-
induced obesity mouse model, I reported evidence of detailed epigenetic changes 
of Ankrd26 promoter. Indeed, I demonstrated that the HFD-induced Ankrd26 
down-regulation in VAT was directly caused by specific hyper-methylation of -
436 and -431 cytosine residues at its promoter region, that was followed by 
chromatin reorganization. Indeed, DNA methylation of these specific CpG sites 
impaired binding of the histone acetyltransferase/transcriptional coactivator p300 
to this region, both in vitro and in vivo, causing hypo-acetylation of histone H4 at 
the Ankrd26 promoter and loss of binding of RNA Pol II at the Ankrd26 
Transcription Start Site in obese mice. Furthermore, the HFD treatment increased 
binding of DNA methyl-transferases 3a and 3b and methyl-CpG-binding domain 
protein 2 to the Ankrd26 promoter. To evaluate the functional consequences of 
these changes, the HFD-induced Ankrd26 down-regulation was mimicked by 
silencing Ankrd26 gene expression in vitro in 3T3-L1 adipocytes. This silencing 
caused enhanced secretion of the pro-inflammatory chemokines KC/IL-8, Eotaxin, 
MCP1 and Rantes.  The relevance of these observations to humans is supported by 
other findings in obese individuals, revealing that the reduction of ANKRD26 
expression in VAT negatively correlates with serum concentrations of 
inflammatory markers. Taken together, my data provide evidence for 
environmentally induced DNA changes at Ankrd26 promoter and, for the first time, 
highlight a role for Ankrd26 epigenetic silencing in raising and/or sustaining VAT 
inflammation following unhealthy dieting and in development of obesity-related 
insulin resistance. Since direct evidence linking specific environmental cues and 
metabolic disorders are still limited, addressing this issue will provide new insight 
into the molecular basis of obesity as well as create novel translational perspective. 
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1. BACKGROUND 
 
 
1.1 Obesity 
Obesity, considered by the World Health Organization (WHO) as a 21st century 
global epidemic [1], is defined as excessive adiposity in relation to lean mass 
throughout the body, that is usually accompanied by mild, chronic, systemic 
inflammation [2]. The current classification of overweight and obesity in adults is 
based on the body mass index (BMI) [3,4]. BMI is an indirect measure of body fat, 
equals an individual's weight in kilograms, divided by the square of height in 
meters (kg/m2).  According to WHO classification [3], overweight is defined as a 
BMI of 25 or more, and includes pre-obesity (25-29.9), and obesity that is divided 
into three categories: Class I (30–34.9), Class II (35–39.9) and Class III (>40) [5]. 
High BMI is an important risk factor for cardiovascular and kidney diseases, 
diabetes, some cancers, and musculoskeletal disorders. Concerns about the health 
and economic burden of increasing BMI have led to adiposity being included 
among the global non-communicable diseases, with a target of halting, by 2025, 
the rise in the prevalence of obesity at its 2010 level [1]. 
Increased fat deposition, according to a simplistic view based on the first law of 
thermodynamics, results from an imbalance between the caloric intake and energy 
expenditure, driven by the consumption of high-energy-yielding foods above the 
needs of the individual and a sedentary lifestyle [6]. However, the etiology of 
obesity is more complex. Indeed, circumstances such as socioeconomic status, 
environment and personal behaviors, and genotype–phenotype interactions have 
to be taken into account to understand obesity, as all these factors affect food 
intake, nutrient turnover, thermogenesis, lipid utilization, and also differential fat 
storage in regional adipose depots versus non-adipose tissues [2]. Multiple and 
complex mechanisms have evolved to regulate energy intake and expenditure and 
fat deposition to maintain body weight [7]. Several cues affect these regulatory 
processes: environmental factors, diet quality, level of physical activity, the gut 
microbiota, endocrine disruptors, drugs, reproductive factors and assortative 
mating, intrauterine and epigenetic intergenerational effects (fig. 1) [2]. Another 
problem concerning the obesity study and management is the marked 
heterogeneity of individuals with obesity. Examples of obesity types are 
subcutaneous obesity, in which excess subcutaneous fat is found around the hip 
and thigh areas, and visceral obesity, in which fat is mainly accumulated in the 
abdominal region. Visceral obesity is more common in men and tends to be more 
pernicious in health terms [2]. However, different strategies and treatments at the 
individual level have been developed and prescribed: dietary education and 
control, physical activity programs, pharmacological treatments and bariatric 
surgery. 
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Figure 1. Key factors involved in the regulation of energy balance. The energy balance is 
influenced by several biological factors. The pyramid holding the balance emphasizes the notion 
that we need to go beyond individual factors to ultimately have an optimal effect on the energy 
balance equation. Nat Rev Dis Primers. 2017; 3:17034.  
 
Actually, 39% of the world population is obese or overweight, despite decades 
of efforts to slow the progress of the epidemy. According to the WHO, >2.1 billion 
adults were overweight or obese globally in 2014, of which 1.5 billion were 
overweight and 640 million were obese [3]. In the same year, the age-standardized 
prevalence of obesity in 2014 was estimated to 10.8% among adult men and 14.9% 
among adult women. These data suggest that female sex is associated with higher 
risk of obesity [1]. Furthermore, several studies conducted in the United States, 
indicate that African Americans exhibited a higher prevalence of extreme obesity 
than other ethnicities [8]. Asian populations have lower BMI than white 
individuals, but they have been shown to be prone to visceral fat deposition, 
making this populations more susceptible to developing T2D at lower BMI than 
white individuals [9]. Although the prevalence of obesity is likely to increase as 
the population ages dramatically in coming years [10], in 2013–2014, the 
worldwide number of children and adolescents with obesity has doubled since 
1980 and was estimated to be 110 million [2]. Childhood and adolescence obesity 
has been associated with metabolic complications and chronic disease in 
adulthood. 
Critical windows in the onset of obesity have been identified in the prenatal 
period, infancy, childhood and adolescence. The programming of metabolism 
during the prenatal and neonatal periods at both the genomic and epigenomic level 
(metabolic imprinting) might permanently influence future disease risk and health, 
according to the developmental origins of health and disease hypothesis [11,12]. 
Indeed, it has been shown in literature that the type and amount of energy-yielding 
nutrients consumed by the mother during pregnancy and lactation, and even by 
both parents before pregnancy, is associated with the development of metabolic 
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complications in adulthood [13,14]. Also, an earlier adiposity during childhood 
has been associated with a high BMI, a high amount of subcutaneous adipose tissue 
and a high waist circumference in adulthood [15]. 
State‑of‑the-art epidemiological approaches, such as integrated bioinformatics 
system analyses, need to be used to better understand the causes of obesity, 
including the complex interplay between behavioral, environmental, 
physiological, genetic, social and economic factors.  
Several biological and environmental factors have an effect on energy intake and 
expenditure (fig. 1). For example, eating behaviors are determined not only by 
genetic factors and other biological factors but also by the opportunities to eat and 
food availability. The food choices among energy-yielding food is enormous. 
Physical activity, another behavioral component, is also conditioned by 
socioeconomic and cultural factors. An increasing trend toward sedentary 
lifestyles coupled with increases in energy intake is able to explain the observed 
enhancement in mean BMI in high-income countries, but also probably in most 
low- and middle-income countries [16]. In addition to the amount of calories, the 
type and quality calorie, such as saturated versus non-saturated lipids, as well as 
the source of fats, carbohydrates and proteins also affects the energy balance and 
body weight [17]. However, this area is still controversial; indeed, whether the 
caloric overload with the diet or the impact of a particular nutrient by a direct 
metabolic effect, is important in obesity development, is unclear [18]. A high-
quality dietary intake. defined by a balanced consumption of macronutrients, is 
inversely associated with weight gain and the risk of developing obesity. Several 
lines of evidence support the importance and benefits of consuming health meals 
and high-quality, sustainable dietary regimens in preventing obesity [19,20]. 
Obesity prevention should focus on maintaining weight loss or controlling 
excessive weight gain. In general, the preventive strategies are health promotion 
programs or marketing, addressing lifestyle behaviors and policies that target the 
environment. At the population level, public policies and economical strategies are 
needed to improve food and physical environments, the food system and the health 
system to control the global obesity epidemic. The complexity of obesity requires 
multilevel approaches by acting on multiple frameworks: in practice, going from 
the individual, often children or adolescents, schools or occupational environments 
and the communities. Drugs, such as amphetamines, methamphetamine and 
phenmetrazine, are approved by the US FDA for short-term treatment (usually <12 
weeks) of the patient with obesity for the treatment of obese patients, as adjuncts 
to diet and exercise [21]. Use of bariatric surgery has become rapidly adopted for 
the treatment of severe obesity, and this has increased with the reduction of 
laparoscopic procedure risk [21]. Several studies have reported improvements in 
biochemical and metabolic outcomes following bariatric surgery. Mortality was 
reduced by 24%, mainly by reducing the risk of myocardial infarction and, in 
women, cancer, and many other comorbidities, such as T2D are also ameliorated 
[22]. 
To improve prevention and treatment strategies, a better knowledge of factors 
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contributing to the development of obesity is essential. A deeper understanding of 
appetite and energy expenditure, as well as the physiopathological role of adipose 
tissue in the regulation of metabolic function is needed. In this regard, the role of 
genetics, epigenetics, nutrigenomics or personalized nutrition is crucial to be better 
understood to improve obesity management. 
1.2 Biology and pathophysiology of obesity 
Being a complex and heritable disorder, obesity results from the interplay 
between genetic susceptibility, epigenetics, metagenomics and the environment. 
These factors act through physiological mediators of food intake and energy 
expenditure, affecting fat deposition [2]. 
1.2.1 Adipose Tissue 
Adipose tissue is a complex organ with profound effects on physiology and 
pathophysiology. This tissue has a central role in the regulation of energy balance 
and nutritional homeostasis, serving as site of calorie storage after feeding and as 
source of circulating mediators, by which critical metabolic processes are 
coordinated locally and systemically [23].  The mammalian adipose tissues have 
been divided into two major types: the white adipose tissue (WAT) and brown 
adipose tissue (BAT), that are functionally involved in sensing and responding to 
changes in systemic energy balance [2,23]. Brown adipocytes contribute to energy 
expenditure via thermogenesis to maintain body temperature. BAT is the site of 
adaptative thermogenesis, providing extra heat in hibernating animals, cold-
exposed mammals and human newborns (cold-induced thermogenesis), as well as 
maintaining energy balance in response to diet (diet-induced thermogenesis). The 
brown fat depots are abundant in newborn babies and are located in the 
interscapular and supraclavicular regions, as well as around the several organs; 
these depots decrease with age, but can still be found in adults [24,25]. Although 
BAT has been negatively correlated with the BMI [25], its role in the etiology of 
obesity is still unclear. White adipocytes are the most abundant adipocytes in 
humans. The main functions of WAT are: i. to store calories as lipid droplets after 
feeding; ii. to release free fatty acids during fasting; and, iii. to cushion body parts 
exposed to high levels of mechanical stress [23]. However, recent research has 
revealed that white adipocytes synthetize and secrete various bioactive mediators, 
hormones and cytokines (adipocytokines) such as leptin, interleukin 6 (IL6), 
adiponectin, monocyte chemoattractant protein 1 (MCP1) and tumor necrosis 
factor alpha (TNFα), required for the regulation of metabolic processes, such as 
glucose and lipid metabolism, insulin sensitivity, feeding behavior, inflammation, 
immunity, angiogenesis and blood pressure (fig. 2) [23,26]. 
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Figure 2. Physiological and metabolic processes regulated by adipocyte-secreted mediators. 
The interactions may be autocrine, paracrine, or endocrine. Physiol Rev. 2013; 93(1):1-21. 
 
Intracellular WAT lipid homeostasis is a key determinant of body weight and 
insulin sensitivity both in mice and humans. Excessive lipid load causes adipocyte 
stress, which in turn accounts for many adverse effects of obesity, particularly 
alterations in adipocytokine release and a low-grade inflammatory response, 
ultimately leading to the development of metabolic dysfunction such as insulin 
resistance and glucose intolerance. Due to their critical role in the maintenance of 
proper adipocyte function, both storage and release of lipids in WAT are 
physiologically under tight hormonal control [27].  
WAT develops in multiple discrete and specific depots [23]. Based on their 
anatomic locations, the most common classification distinguishes between 
subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) [2,23]. SAT 
accumulates more than 80% of total body fat in the body and is located beneath 
the skin. VAT include intra-abdominal (mainly mesenteric adipose tissue), 
perirenal and pericardial adipose tissue and comprises less than 10% of the total 
fat mass. However, the visceral versus subcutaneous scheme is oversimplified. In 
addition, many depots in human have no precise correlation in mice, an vice versa. 
A large percentage of VAT in humans is contained in the omentum, which is 
scarcely present in rodents; conversely, the large epidydimal adipose tissue (eAT), 
representative of VAT in mice, does not exist in humans [23].  
Subcutaneous and visceral adipose depots are very different in terms of their 
effects on metabolism [28]. In mice, transplantation of subcutaneous fat into the 
visceral depot of recipient mice caused improvements in glucose homeostasis as 
well as decreased body weight and fat mass; conversely, placing visceral fat into a 
subcutaneous depot of recipient mice, had very little effect [29]. In human, 
peripheral obesity is characterized by an accumulation of SAT and is more frequent 
in women. This type of obesity is not associated with an increased risk of related 
pathologies. However, central or abdominal obesity is more common in men and 
consists of an accumulation of VAT [28]. This type of obesity has been associated, 
through epidemiological studies, with a higher risk of diseases such as insulin 
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resistance, T2D and hypertension [28], and is closely correlates with the 
development of the various metabolic abnormalities, commonly referred to as the 
metabolic syndrome [2]. 
Adipose tissue has the unique attribute of remodeling, by changing its 
dimensions in response to nutritional demands. Adipose tissue remodeling can be 
accomplished by increasing the size of cells (hypertrophy) or by recruiting new 
adipocytes from the resident pool of precursor cells (hyperplasia). In response to 
caloric overload, adipose depots expand first by hypertrophy until a critical 
threshold is reached. The hypertrophy is followed by cell death and by secretion 
of several mediators, that increase the proliferation and/or differentiation of 
preadipocytes [23]. This cycling between hypertrophy and hyperplasia as obesity 
progresses is supported by rodent studies indicating that eAT, along with other 
murine VAT depots, responds to high-fat diet (HFD) feeding through different 
time-dependent changes, contributing to the inflammatory and metabolic 
complications in obesity [30,31]. It has been demonstrated that upon short-term 
HFD exposure (8-12 weeks), the eAT expansion is accompanied by hypertrophy. 
However, after a more prolonged exposure (20 weeks), the eAT is characterized 
by an increased rate of adipocyte dying (up to 80%), paralleled by enhanced 
adipogenesis, so that the fat mass continues to expand as obesity progresses 
[23,30,31]. Emerging evidence in literature indicates a role for the 
microenvironment and the transient local inflammation in triggering the adipose 
tissue remodeling in the context of hyperplastic expansion [30]. Remarkably, the 
observation that obesity can be associated with adipocyte hyperplasia has been 
supported by findings showing that manipulation of several genes causes obesity 
in vivo and increases adipogenesis in vitro. The increased adipogenesis is not the 
primer driver of obesity in these in vivo models: the overnutrition is the culprit and 
the adipogenesis is induced by the need to store excess calories (fig.3) [23]. 
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Figure 3. Obesity in light of the adipose tissue expandability hypothesis. Obesity is caused by 
adipose tissue dysfunction due to insufficient storage capacity, and this results in dyslipidemia, 
systemic inflammation and altered adipokine profiles. Combination of these factors promotes the 
development of insulin resistance and the metabolic syndrome, which further impairs adipose tissue 
function, creating a futile cycle. HIF, hypoxia-inducible factor; IL-6, interleukin-6; TNF-a, tumor 
necrosis factor-alpha; CRP, C-reactive protein. Adapted from EMBO J. 2017; 36(14):1999-2017. 
 
Although it is difficult to translate findings from rodents when examining 
visceral (epidydimal) and subcutaneous (inguinal) fat, consistent evidence in 
humans shows that the number and severity of health complications, associated 
with obesity, seem to be dependent on the additional presence of excess fat stored 
in the VAT depots and in and around lean tissues, such as the heart, the liver and 
the kidneys (ectopic fat deposition) [23,32]. Also in humans, the number of 
adipocytes depends on the balance between cell death and adipogenesis. Adipocyte 
progenitors have been recently identified in vivo as immature mesenchymal 
stromal cells associated with the vasculature. The turnover rate in adult humans 
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has been estimated at 10% per year and, in any case, the size of fat depots correlates 
with the number of adipocytes [33]. Importantly, obese individuals have higher 
total adipocyte numbers, and this becomes evident already in childhood obesity 
[34]. Human studies focusing on adipose tissue cellularity have demonstrated a 
marked fat depot-specificity of the hyperplastic response to the diet. Indeed, 
increased adipocyte number has been detected in the femoral subcutaneous fat 
depot in humans but not in the upper abdominal subcutaneous depot [35]. As above 
mentioned, in male mice, higher rate of proliferation/adipogenesis has been shown 
in the intraabdominal gonadal fat depot but not in the posterior subcutaneous depot 
[30,31,33]. These differences can have substantial impact on the systemic 
adaptation of metabolism given the pathophysiological relevance of the individual 
depots. Accumulation of fat in the intra-abdominal/visceral depots is a central 
feature of the metabolic syndrome and is associated with insulin resistance and 
increased risk for diabetes and cardiovascular disease. Conversely, higher 
subcutaneous fat mass is associated with improved metabolic parameters including 
insulin sensitivity and blood lipid profiles. Taken together, location specific 
hyperplastic expansion of adipose tissue can affect body fat distribution, contribute 
to systemic metabolic homeostasis and influence pathogenesis [33]. Furthermore, 
Lotta et al. [36] have identified a genetic association of 53 loci with traits related 
to insulin resistance, T2D and coronary heart disease. Remarkably, genetic 
predisposition for insulin resistance predicted by these loci was associated with 
reduced fat deposition in peripheral “metabolically safe” depots. Moreover, the 
same study revealed common links to insulin resistance associated with 
lipodystrophy, highlighting the importance of adipose tissue function for 
maintenance of systemic homeostasis [36].  
Taken together, these observations emphasize the role of adipose tissue depots 
as key checkpoints in systemic energy homeostasis. The way by adipose tissue 
depots manages the excess calories and the oxygen tension generated by the 
pathological growth of the adipocytes impacts on individual’ s cardiometabolic 
risk, insulin sensitivity and dyslipidemia [32,37]. When the SAT responds to 
energy excess by fat cell hyperplasia, acting as a ‘metabolic sink’ , lean tissues are 
protected against ectopic fat deposition. Conversely, if SAT cannot properly 
expand through hyperplasia, the stored triglycerides drive adipocyte hypertrophy 
until these enlarged fat cells become saturated, leading to either death and 
macrophage invasion and/or increased release of pro-inflammatory adipokines. 
These phenomena determine a pro-inflammatory and insulin-resistant milieu in 
inner adipose depots [35]. Furthermore, the excess triglyceride molecules, that 
have no place in the SAT, will be ectopically stored contributing to an atherogenic, 
diabetogenic and inflammatory environment in the cell [23,37]. By comparison, 
increased risk of metabolic dysfunction, as obesity, is associated with expansion 
of the omentum and increased deposition of fat in the liver, heart and kidneys 
(fig.4) [38]. However, more complex scenarios are also plausible, because genetic 
and environmental factors may influence the individual’ s regional adipose tissue 
accumulation capacity. 
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Figure 4. Pathological changes in adipose tissue. The value of visceral fat area correlated with 
the risk of obesity-associated complications. Adipose tissues in subcutaneous fat obesity might 
function normally with the expected release of anti-inflammatory adipokines, whereas adipose 
tissues in visceral fat obesity is increased the secretion of pro-inflammatory adipokines and 
suppressed the secretion of anti-inflammatory adipocytokines, raising and sustaining the low-grade 
inflammation, which contributes to obesity-related disorders. Pathological changes in visceral 
adipose tissue show higher levels of adipocyte necrosis and the recruitment of macrophages with 
an inflammatory phenotype (M1 macrophages). IL-6, interleukin-6; TNF, tumour necrosis factor; 
PAI1, prothrombin activator inhibitor 1. Adapted from Nat Rev Dis Primers. 2017; 3:17034. 
1.2.2 Genetic of obesity  
Genetic factors contribute to obesity-susceptibility, with heritability estimates 
ranging between 40 and 70% across populations [2,39,40]. The evidence for 
genetic component of BMI/overall obesity is substantial and come from a variety 
of population, family and twin-based studies [41]. In 1894, for the first time, Sir 
Francis Galton reported the familial aggregation of body size [42].  Since then, 
family history of obesity has become a well-established risk factor for childhood 
obesity [43]. The ethnic dependent pattern of obesity prevalence further supports 
an important contribution of genes in obesity heritability [43]. Furthermore, twin 
studies have shown that monozygotic twins display more similar body fat 
acquisition in comparison with dizygotic twins, indicating that this trait is highly 
influenced by the genotype [43,44]. Moreover, adoption studies confirm the 
genetic component of obesity, as the BMI of adopted children correlates more to 
the BMI of their biological parents than their adopted parents [43]. Although 
heritability studies have been important in understanding of the genetics of obesity, 
interpreting these studies requires attention, because some heritability estimates 
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may be amplified by unaccounted shared environment [41].  
The completion of the human genome sequence, combined with technological 
and methodological developments has led to the identification of numerous genes 
associated with syndromic monogenic, non-syndromic monogenic, oligogenic and 
polygenic obesity [43]. 
Syndromic monogenic obesity is exceptionally rare and is characterized by 
mental retardation, dysmorphic features and organ specific abnormalities, in 
addition to obesity. More than 30 syndromes have been described in literature, but 
many of these have not been genetically elucidated. The most common forms of 
early-onset syndromic obesity including Bardet-Bield, WAGR (Wilm’ s tumor, 
aniridia, genitourinary anomalies and mental retardation), Prader-Willi, Altröm 
and Cohen syndromes. The genetic basis of these disorders is extremely 
heterogeneous [43]. To give an example, the Bardet-Biedl syndrome (BBS) was 
the first obesity syndrome reported, it is a genetically and clinically heterogeneous 
ciliopathy with an autosomal recessive inheritance. Clinical features include retinal 
degeneration, cognitive disability, polydactyly and genital and renal anomalies. 
Also, the 72–92% of BBS patients are characterized by central and peripheral 
obesity, appearing due to hyperphagia. To date, 19 BBS genes have been identified 
to encode the BBS proteins that are implicated in the assembly and function of 
primary cilia [43]. Due to the physiologic role of primary cilium, the pathogenesis 
of obesity in BBS is attributed to a defect in the regulation of food intake and 
adipocyte differentiation [45].  
Non-syndromic monogenic obesity refers to a single gene disorder that leads to 
a highly penetrant form of the disease [43]. More than 200 single-gene mutations 
have been found to cause autosomal recessive and dominant forms of human 
obesity. Interestingly, these mutations have been identified in only ten genes and 
eight of these explain up to 10 % of cases with early-onset extreme obesity [46]. 
These genes include the leptin (LEP) and its receptor (LEPR), the melanocortin 4 
receptor (MC4R) and pro-opiomelanocortin (POMC) genes, among others that 
code for proteins with a central role in the leptin–melanocortin signaling pathway 
present in the hypothalamus. Mutations in these genes affect body weight through 
pathways regulating food intake and energy expenditure in the central nervous 
system [2,46]. Homozygous/compound heterozygous loss-of-function mutations 
in monogenic obesity genes from the leptin/melanocortin pathway lead to a rare 
form of fully penetrant obesity in humans. A substantially higher proportion of 
obesity is observed in subjects carrying heterozygous deleterious coding mutations 
in these genes, resulting in non-fully penetrant oligogenic obesity [43]. 
Polygenic obesity is caused by multiple gene defects with modest effects that 
interact with the environment [43]. Several approaches, such as linkage/positional 
cloning, candidate gene and genome-wide association study (GWAS) have been 
used to identify >300 genetic loci for obesity traits [2], providing to better clarify 
the genetic architecture and pathophysiology of these traits. The first important 
success of GWAS was the identifications of a cluster of common non-coding 
variants in obesity-associated (FTO) locus showed a highly significant association 
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with obesity risk in children and adults [2,43]. The biology that underlies this 
association is only partially described: the FTO genotype may contribute to body 
weight, by regulating appetite, thermogenesis, adipocyte browning and epigenetic 
mechanisms related to obesity [47,48]. Since the discovery of FTO, additional 
GWAS have identified many other genetic loci associated with BMI, adult obesity, 
childhood obesity and waist-to hip ratio (WHR) [2,39-41,43,46]. By using 
different BMI thresholds based on the ethnicity/age group under investigation, 
GWAS have identified 135 variants associated with BMI level and/or obesity 
status so far (89 loci associated only with BMI, 21 loci only with obesity, 24 loci 
with both BMI and obesity) (fig.5). Single nucleotide polymorphisms (SNPs) in 
most Mendelian non-syndromic genes (BDNF, NTRK2, LEPR, MC4R, PCSK1, 
POMC, SH2B1, TUB) and some Mendelian syndromic genes (SDCCAG8, BBS4) 
contribute towards polygenic obesity [43]. 
 
 
 
Figure 5: Venn diagram of genes involved in monogenic, oligogenic and polygenic obesity. 
Monogenic/ oligogenic obesity genes are showed in blue, polygenic BMI-related genes in yellow, 
overweight or obesity-related genes in purple and fat distribution-related genes in green. Clin Sci 
(Lond). 2016; 130(12):943-86. 
 
Pathway and tissue enrichment analyses applied to the BMI-associated 
strengthen the role of the central nervous system in body weight regulation. The 
pathways are related to synaptic function and neurotransmitter signaling, and the 
tissues with enriched expression of these genes include the hypothalamus, the 
pituitary gland and the hippocampus. The same analyses applied to loci associated 
with the WHR point to pathways regulating adipocyte differentiation, 
angiogenesis, insulin sensitivity and fat distribution [2]. In particular, the WHR 
adjusted for BMI (WHRadjBMI) seems to be a highly valuable tool for evaluation 
of fat distribution, because it combines the negative effects of the abdominal fat 
and the beneficial effects of gluteal subcutaneous fat, independent of overall 
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adiposity [43]. Considering the ethnic specificity of body fat distribution, FTO, 
MC4R and CTSS (Cathepsin S) were identified by a GWAS for fat mass in a 
multiethnic population [43].  
However, some findings from GWASs have to be interpreted with caution. For 
instance, rare mutations are not detected in GWASs since SNP genotyping arrays 
are usually designed to capture common SNPs [41]. By using sequencing 
technologies, it is possible to detect rare variants. Recent advances in next 
generation sequencing (NGS) technologies are allowing researchers to extend their 
genome-wide analyses beyond common SNPs to assess the contribution of rare 
variants in disease predisposition in a fast way. However, population-based 
approaches to mapping rare variants for complex disease from NGS data require a 
large number of samples to provide sufficient statistical power for rare variants 
detection. Moreover, Hagg et al. [49] have performed a meta-analysis of GWAS 
using the ‘VErsatile Gene-based Association and adult severe obese patients. 
These VNTRs account Study’  (VEGAS) approach looking for genetic loci that 
could not be detected by standard single-marker analyses due to allelic 
heterogeneity, and found six novel loci associated with BMI missed by 
conventional GWAS [43,49]. For instance, using a variable number tandem repeats 
(VNTRs) association method, have been identified significant associations 
between dedicator of cytokinesis 5 (DOCK5) VNTRs and childhood for nearly 
0.8% of BMI variance [43].  
Another source of heritability often missed by GWAS is the contribution of 
CNVs, that are chromosomal segments encompassing large replications or 
deletions in genetic loci, with a size of about 500 kb, present in 5-10% of the 
population. As many CNVs encompass genes and/or regulatory regions, they may 
result in alteration of gene dosage and/or disruption of gene structure and/or 
regulation. Therefore, CNVs may account for significant normal phenotypic 
variation within a species, susceptibility or resistance to disease, variation in drug 
response. In relation to obesity, common bialleleic CNVs, identified in more than 
5% of the population, have been reported in association with BMI and obesity. 
Similarly to common SNPs, these common CNVs had small effect sizes on obesity 
risks. However, some CNVs associated with obesity are difficult to replicate across 
populations, because they can have ethnicity-specific impacts. For example, the 
PCSK1 SNP rs6234/rs6235 was found to be associated with obesity in white 
Caucasian, African and Hispanic ethnic groups, but not in the East Asian 
populations [43].  
1.2.3 Epigenetics: gene-environment interactions in obesity 
The threatened recent and rapid increase in the worldwide prevalence of obesity 
indicates that this disease is becoming the normal metabolic fate of a large fraction 
of human populations. Genetics alone cannot explain this escalation in frequency, 
because the emergence over the past 30 years has been too rapid to allow for the 
appearance of new mutant genes [2,43]. Although considerable efforts have been 
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made into identifying loci and variants contributing to individual risk of obesity, 
only a small proportion of observed familial aggregation may be explained by these 
established loci (~2%) [41]. For instance, FTO has the largest, but still small, effect 
on obesity susceptibility: each risk allele increases the risk of obesity by 1.20–
1.32-fold [2]. Moreover, all combined BMI-associated variants account for <5% 
of BMI variance, and a similar effect sizes has been reported for the variants associ-
ated with WHR [2].   
The increasing worldwide prevalence of obesity, in particular in developing 
countries associated with urbanization, and the inverse relationship between this 
disease and socioeconomic class, provide strong evidence of the environmental 
influences on weight gain [50]. It has become clear that obesity results from the 
complex interplay between several susceptibility genes and biological factors, such 
as age and sex, obesogenic environment and lifestyle factors. The term 
‘obesogenic’  includes major societal and environmental changes as the excessive 
consumption of energy dense foods, sedentary lifestyles, urbanization and 
socioeconomic-dependent access to a healthy diet [2]. There is accumulating 
evidence, for example, that the overall contribution of genes towards the BMI 
increases from childhood to early adulthood. Moreover, a sexual dimorphism has 
been identified for half of the WHRadjBMI-associated loci, showing higher effect 
sizes in women compared to men. Importantly, the genetic influence on BMI and 
adiposity is significantly increased in an obesogenic environment. and a pre-
existent obesity can further amplify the effect of same risk alleles, exacerbating the 
body weight gain [43]. For instance, obesity genetic variants of FTO, MC4R, 
TMEM18, BDNF, TNNI3 interacting kinase (TNNI3K), neurexin 3 (NRXN3), 
SEC16B and glucosamine-6-phosphate deaminase 2 (GNPDA2) were found to be 
more strongly associated with increasing BMI in children with higher BMI [51]. 
In addition, there are increasing data that the susceptibility to obesity in adult life 
has early development origins and reflects an intergenerational cycle. Indeed, 
several epidemiological studies have shown that exposure to an adverse nutritional 
environment during intrauterine development, as a consequence of either an excess 
or deficient maternal caloric or micronutrient intake, is associated with an 
increased risk of a range of chronic diseases, including obesity. This evidence has 
led to the developmental origins of health and disease hypothesis [52]. In 1990, 
David Barker first proposed that in utero metabolic adaptation defines a trajectory 
of growth that prepares the fetus for its likely adult environment [53]. The 
environmental exposures in early life can induce the “metabolic reprogramming” 
of fetus that depends on the mother’ s and the father’ s behaviors before conception 
and the mother’ s during pregnancy [41,43,53]. This hypothesis was supported by 
solid epidemiological data from the Dutch “Hunger Winter”. The offspring of 
mothers who were exposed to the famine during early gestation have higher rates 
of subsequent obesity and coronary heart disease were observed, linking early life 
events (e.g., maternal nutrition) to offspring’ s disease risk in later life [41,43]. 
Additional observations results from the follow-up data of members of the Pima 
Native American community in Arizona, a population with a very high prevalence 
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of obesity and T2D. There was a higher risk of both obesity (58 vs. 17%) and T2D 
(45 vs. 1.4%) in the offspring of mothers affected by T2D during pregnancy than 
in the offspring of women nondiabetic during pregnancy. Moreover, the offspring 
born after the mother was diagnosed with T2D have higher risk of obesity and T2D 
than their siblings born while their mother was nondiabetic [41]. Taken together, 
these observations emphasize the role of intrauterine environment as an important 
factor in predisposition to obesity and T2D. 
The mechanisms underpinning this “nutritional memory response” are not 
completely clear, but may include alterations of the developmental fate of tissues, 
reprogramming of stem cells, changes in neural, endocrine and metabolic 
regulatory circuits. Epigenetic processes, including DNA methylation, histone 
modification and non-coding RNAs, that change gene expression and cellular 
phenotype without changing the DNA sequence, are sensitive to external factors 
(e.g., diet, physical activity) and internal factors (e.g., hormones, genetic factors), 
are reversible and can be mitotically stable and/or passed on to subsequent 
generations [2,41,43]. Accordingly to this, epigenetic modifications of gene 
structure through nutritional and physiological stress provide mechanisms for 
inducing obesity, that are independent of new mutations to the genome (fig.6). 
Thus, epigenetics has become a leading candidate for the development and/or 
progression, and possibly inheritance, of obesity.  
The role of epigenetics in obesity has been well demonstrated, largely, in animal 
models and, only occasionally, in humans; >600 articles have already been 
published in this area [2].  Animal studies provides experimental support for a 
causal link between early nutritional status, maternal under- or over-nutrition (e.g., 
high-fat diet, maternal obesity) and epigenetic changes that can be transmitted 
through successive generations, predisposing to obesity risk in later life. For 
instance, the agouti viable yellow (Avy/a) mice, in spite of an identical genotype, 
exhibit color differences of fur coat, ranging from yellow to brown, that are 
correlated with adult body weight. The variation in phenotypes is caused by an 
epigenetic modification of the Avy allele transmitted by the germline from the 
female (stable intergenerational transmission) [41]. In this model, the maternal diet 
may affect the methylation status of “metastable” Avy [41], changing the animal's 
coat color, demonstrating as an environmental factor interacts with a single 
genotype by epigenetic modifications to produce a different phenotype [54]. 
Moreover, epigenetic changes have been detected at genes that regulate growth 
factors, adipogenesis, brain appetite and satiety/reward pathways and glucose 
homeostasis. 
To date, there are relatively few human studies in this area, but one of the most 
significant was performed on the sons of women exposed to severe undernutrition 
during the first half of pregnancy, as a result of the Dutch Hunger Winter during 
World War II. This intergenerational study demonstrated that these individuals as 
adults showed a reduced DNA methylation of the imprinted gene IGF2, associated 
with an increased risk of obesity or glucose intolerance. Conversely, the later 
exposure during the pregnancy was not associated with IGF2 methylation, 
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demonstrating that the early development period is crucial for establishing and 
maintaining epigenetic marks [55].  
On the other hand, the percentage of phenotypic variance that cannot be 
explained by inherited epigenetic trans-generational variation, may be due by the 
impact of acquired epigenetic changes later in life. Analysis of DNA methylation 
and histone acetylation patterns in a large cohort of monozygotic twin pairs showed 
that even if twins were epigenetically indistinguishable during the early years of 
life, older monozygous twins exhibited remarkable differences in their DNA 
methylation and histone acetylation profile, providing explanations of how 
different phenotypes, in terms of differences in susceptibilities to disease and a 
wide range of anthropomorphic features, can be originated from the same genotype 
[56]. Thus, external and/or internal cues may impact on the individual phenotype 
by altering the pattern of epigenetic modifications and modulating the genetic and 
genomic information. 
 
 
 
Figure 6. The interplay of genetics, epigenetics and environments. In monogenic and syndromic 
obesity, a single gene mutation causes severe obesity, regardless of environmental stimuli. In 
oligogenic and polygenic obesity, environmental factors can exacerbate the progression of obesity 
in individuals with a genetic predisposition to weight gain by inducing epigenetic modifications. 
Clin Sci (Lond). 2016; 130(12):943-86. 
 
Several studies have also demonstrated the association between genetic and 
epigenetic factors. An interesting example came from the obesity risk alleles of 
FTO, representing a good model of haplotype-specific methylation, in which the 
methylation status of the region is determined directly by the sequence of allelic 
variants, that create or abrogate methylation sites, exerting their downstream 
effects through epigenetic mechanisms [41]. Other studies have reported a strong 
association between obesity-associated SNPs discovered in GWAS and 
methylation levels at proximal CpG sites. Indeed, several known obesity-
associated SNPs are associated with DNA methylation levels at proximal CpG 
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sites. Interestingly, these SNPs were associated with CpGs that were in the 
promoters of genes known to take part in the pathogenesis of obesity, such as 
POMC, BDNF and SH2B1; or were located in regions that interact with such genes. 
In the paradigm of genetics–epigenetics–environment interplay, it is still unclear 
whether obesity-associated SNPs directly cause differential DNA methylation at 
genes or if the observed differential methylation levels are a consequence of a 
modified gene regulation caused by the presence of a specific risk alleles. It has 
been proposed that mutations within regulatory regions may affect the binding of 
transcription factors, which in turn influence DNA methylation. If DNA 
methylation does not necessarily actively impact on gene expression, it may be 
considered at least an informative marker of the underlying regulatory activity 
[57].  
As DNA methylation represents a key mechanism to provide a more 
comprehensive and systemic view of the contribution of epigenetics to obesity risk 
and/or pathogenesis, several approaches have been developed to study the 
associations between DNA methylation levels and obesity, including the candidate 
gene approaches and epigenome-wide association studies (EWAS). Some of these 
studies are targeting disease-relevant tissues (e.g., VAT, SAT, specific blood-cell 
components), others focused on whole blood despite the necessity to evaluate the 
capacity of circulating leukocytes to reflect the DNA methylation status of specific 
disease-relevant tissues not easy to accessible. The main long-term goals in this 
field are the identification of epigenetic marks that could be used as early 
predictors of obesity risk and the development of drugs or diet-related treatments 
able to delay these epigenetic changes and even reverse them. 
To summarize as outlined above, it should be clear that familial aggregation of 
obesity does not be used as a proxy for overall genetic influences. Indeed, non-
genetic familial aggregation may also be explained by the effect of a shared 
environment resulting from epigenetic influences [41]. Thus, epigenetics conveys 
specific environmental influences into phenotypic obesity traits through a variety 
of mechanisms that are often installed in early life and then persist later in the life 
in differentiated tissues, with the power to modulate the expression of many genes.     
1.3 Epigenetics 
Genetic information encoded in DNA sequence is largely identical in every cell 
type of a multicellular eukaryotic organism. However, despite an identical 
genomic sequence, the cells in different tissues and organs exhibit a substantially 
different profile of gene expression and specialized functions. Moreover, specific 
gene expression patterns need to be appropriately induced and maintained and also 
need to respond to changing developmental and environmental stimuli. Therefore, 
most of the differences among specialized cells are epigenetic and non-genetic 
[57].  
The term “epigenetics” was coined in the 1940s to describe the events that could 
not be explained by traditional genetics. Conrad Waddington defined epigenetics 
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as “the branch of biology which studies the causal interactions between genes and 
their products which bring the phenotype into being” [58]. The epigenetic field 
now actively discloses the molecular mechanisms underlying these phenomena. 
Today, the epigenetics has been defined “the study of changes in gene function 
that are mitotically and/or meiotically heritable and that do not entail a change in 
DNA sequence” [59]. In other words, epigenetics is the study of changes in gene 
expression or phenotype, caused by mechanisms other than changes in the 
underlying DNA sequence, and some of these epigenetic changes have even been 
shown to be heritable [60].  
1.3.1 Epigenetic modifications 
This highlights the role of “epigenetics” and its stable and inheritable information 
that is distinct from DNA sequence and fostered by specialized mechanisms. These 
mechanisms include DNA methylation, small interfering RNA (miRNAs), and 
histone posttranslational modifications (PTMs). To date, however, only DNA 
methylation has been shown to be stably inherited. While some histone PTMs are 
expected to contribute to the transmission of epigenetic information, others 
actively participate within the process of transcription and others are likely to be 
restricted to “structural functions”, altering chromatin conformation [57]. 
 
 
Figure 7. Schematic representation of epigenetic modifications. Epigenetic modifications 
include DNA methylation, histone modifications and miRNAs. Ac: acetylation, Me: methylation, 
P: phosphorylation. J Endocrinol Invest. 2016; 39(10):1095-103. 
 
DNA methylation occurs principally at a cytosine residue, mainly the cytosine–
guanine nucleotide pair (CpG) sites along the DNA chain in vertebrates. It is a 
covalent modification, resulting in the attachment of a methyl (CH3) group at the 
5' carbon position of the cytosine ring, and generally contributes to the 
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transcriptional silencing of genes [61]. 
Noncoding RNAs (ncRNAs) are another type of epigenetic factors, regulating 
gene expression by cis- and trans-acting mechanisms [62]. Some ncRNAs act in 
concert with components of chromatin and the DNA methylation machinery to 
establish and/or sustain gene silencing. They can also regulate RNA processing, 
mRNA stability, translation, protein stability and secretion. Noncoding RNAs 
include micro-RNAs (21–25 nucleotide, miRNAs) and long noncoding RNAs 
(lncRNAs). The miRNAs can regulate gene expression by transcriptional 
regulation and translational inhibition, that are accomplished through direct base 
pairing with the DNA or RNA target, or by functioning as a component of an RNA-
protein complex [63]. The lncRNAs act as tethers and guides to bind proteins 
responsible for modifying chromatin and mediate their deposition at specific 
genomic locations [64]. 
A large number of several PTMs can occur on nucleosomal histone tails. These 
modifications modify the inter-nucleosomal interactions, altering the overall 
chromatin architecture. Thus, these modifications contribute to the gene expression 
control through influencing chromatin compaction or signaling to other protein 
complexes [65]. Nucleosome is the fundamental unit of chromatin and it is 
composed of two copies each of the four core histone proteins (H3, H4, H2A, H2B) 
around which 147 base pairs of DNA are wrapped. Nucleosomes are connected by 
DNA linker, 10 to 80 base pairs (bp) long.  The histone H1 is associated with the 
DNA linker as well as with the nucleosome core particle itself, thus it plays an 
important role in the compaction of DNA beyond the nucleosomal level. Indeed, 
it is well demonstrated that chromatin structure is dynamic and this feature is 
required to regulate several biological processes essential for normal cellular 
functions (e.g., gene transcription, DNA replication, repair and recombination) 
[66].  As histone post-translational modifications can control the packaging of 
DNA around histone proteins through dynamic modifications of these proteins, 
they exert an essential role in chromatin structure regulation. The nucleosomal 
histone tails are unstructured and protrude from nucleosome cores, thus may be 
targeted by modifying enzymes (epigenetic modifiers), resulting in acetylation, 
methylation, phosphorylation, sumoylation, ubiquitylation, ADP-ribosylation, 
deamination   and proline isomerization [58]. The combinatorial histone 
modifications affect the binding of regulatory protein end/or transcription factors 
to chromatin, thereby influencing gene expression. The most studied histone 
modifications so far are methylation, acetylation and phosphorylation. Regarding 
histone acetylation, it is the processes by which the lysine residues on the N-
terminal tails protruding from the histone core of the nucleosome are acetylated by 
the histone acetyltransferases (e.g., p300). This epigenetic modification has the 
most potential to unfold chromatin since it neutralizes the basic charge of the 
lysine. As a consequence, histone acetylation alters nucleosomal conformation, 
promotes the DNA accessibility to the cell transcriptional machinery elements and 
enhances gene transcription [65]. 
In this scenario, combinatorial histone modifications function as codes in 
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targeting transcription factors to DNA by recruiting specific adaptors. Therefore, 
alterations in these epigenetic processes could lead to the deregulation of gene 
transcription.  
1.3.2 DNA Methylation 
DNA methylation was the first epigenetic modification to be discovered and it is 
the most studied so far. In humans, the predominant form of DNA methylation 
occurs on the 5th carbon of the cytosine in CpGs along the DNA chain [61]. In the 
human genome, the total number of CpGs is estimated to be around 28 million, 
and 60–80% of them are generally methylated [67]. Less than 10% of CpGs falls 
in CG-rich regions, known as CpG islands. The CpG islands characterize the 
transcription start sites (TSS) of housekeeping and developmental regulator genes, 
and most of them are unmethylated. On the other hand, CpG sites that exist outside 
CpG islands are largely methylated [68]. Generally, the hypo-methylated DNA 
regions are involved in active transcription, while the hyper-methylated DNA 
regions are involved in gene silencing [67-69]. For example, CpG regions at the 
promoter regions of tissue-specific genes are usually highly unmethylated in their 
tissue of expression while they are highly methylated in other tissues where they 
are not expressed [69]. In accordance, housekeeping genes were found to have 
constitutively unmethylated CpG islands at their promoters regardless of tissue 
types [67]. 
DNA methylation is known to directly repress gene expression by interfering 
with the binding of transcription factors to their target sequences or by initiating 
the recruitment of corepressors. However, the effect of DNA methylation may be 
also mediated by affecting gene accessibility at the level of chromatin structure. 
Indeed, it has been described that methylated CpGs result in closely packed 
chromatin and unmethylated CpGs result in more open chromatin structure. For 
example, the presences of a methyl groups can promote the binding of methyl-
binding proteins, as MeCP2 and MBD2 [70], and/or impair the binding of other 
proteins, as the chromatin proteins CTCF and Cfp1 (fig. 8) [71]. Given its pivotal 
role in gene regulatory networks, DNA methylation represents a key epigenetic 
mechanism contributing to normal development, phenotypic variations as well as 
susceptibility to diseases.  
DNA methylation is mainly mediated by two types of DNA methyltransferases 
(DNMTs): i. DNMT1, responsible for maintaining DNA methylation pattern in the 
newly synthesized DNA strand, after cellular replication cycle; and, ii. DNMT3A 
and DNMT3B, responsible for de novo DNA methylation, essential during 
embryogenesis and other cell differentiation events [72]. 
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Figure 8. Mechanisms of DNA-methylation-mediated gene silencing. (a) DNA methylation of 
cytosine residues in DNA-binding sequences of some transcription factors (TF) may directly block 
activators from binding targets sites, inhibiting transcriptional activation. (b) Methyl-CpG-binding 
proteins (MBPs) directly recognize methylated DNA and recruit co-repressor factors to modify 
surrounding chromatin packaging and to silence transcription. (c) DNA methyltransferases may be 
functionally linked to histone deacetylase (HDAC) and histone methyltransferase (HMT) enzymes. 
In this case, the transcriptional repression initiated by the addition of methyl groups to DNA is 
coupled to chromatin modifications. (d) DNA methylation may also have a dampening effect on 
transcriptional elongation. MBPs may inhibitielongation, either directly or by their effects on the 
surrounding chromatin structure. Trends Biochem Sci. 2006; 31(2):89-97. 
 
Although the mechanism of DNA methylation is not fully elucidated, data in 
literature have shown that this modification is typically established during early 
developmental stages. In the gametes and pre-implantation embryo, almost all 
methylation modifications are erased, but imprinted regions maintain their 
methylation status on one allele (also throughout development). Post-implantation, 
pluripotency genes undergo de novo methylation to establish tissue specific DNA 
methylation patterns. The acquiring of two or more different epigenetic states at a 
specific genomic locus in different cells or tissues within the same organism is a 
biological event known as epigenetic mosaicism. This phenomenon adds a further 
complexity to the field of DNA methylation and contribute to individual 
phenotypic variation [73]. Global and/or local changes of methylation patterns may 
also arise in response to environmental exposures or as a function of aging [72,73]. 
Recent study has shown that methylation patterns at some genomic loci may be 
inherited through generations [74]. Two principal types of DNA methylation 
heritability have been identified: i. the genetic inheritance of DNA sequence 
variations within a CpG locus which disrupts the methylation site; and, ii. the 
epigenetic inheritance related to the sequence-independent transmission of 
epigenetic mark, that may happen through escaping the methylation 
reprogramming events during development [75]. Bell et al. [76] investigated the 
DNA methylation heritability in twin pairs, by methylation profiling of whole 
blood-DNA. Their data demonstrated that monozygotic twins shared a significant 
higher genome-wide methylation profile compared to dizygotic twins, estimating 
the DNA methylation heritability to be about 18%. Moreover, McRae et al. [75] 
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analyzed the heritability of DNA methylation in whole-blood DNA from 
multigenerational families, both within and across generations. This study showed 
that the DNA methylation heritability is mostly driven by the underlying genetic 
sequence (i.e., genetic inheritance). 
1.3.3 DNA Methylation and Obesity 
Several findings, mostly derived from animal studies, support the role of DNA 
methylation as one of the major epigenetic mechanisms responsible for the 
developmental programming of obesity. Robust data from mouse models have 
demonstrated that obesity development induced by environmental exposures, such 
as diet (e.g., the quantity and/or quality of the diet), exercise, epigenetic drugs, 
parental nutrition, intrauterine environment, is associated with DNA methylation 
changes at genes involved in the regulation of growth factors, adipogenesis, 
glucose metabolism, energy homeostasis, appetite and satiety pathways [77-81]. 
For instance, the administration of a high-fat diet increased DNA methylation of 
leptin promoter in retroperitoneal adipocytes from obese mice, and this was 
associated with lower circulating leptin levels, suggesting the DNA methylation 
impairs its gene expression [82]. 
Similarly, increasing evidence in humans indicates an association between 
environmental-induced changes in gene-specific and global DNA methylation and 
the development of or susceptibility toward obesity. The subtle differences 
between human and animal findings, may be partly attributed to certain factors, 
such as sampling tissue, period and duration of exposure and in the case of humans, 
lifestyle. However, likely animal studies, human data support a role of DNA 
methylation, either global, gene-specific or genome-wide levels, both in 
development of obesity and/or its related complications, and in risk of this disease 
[2,41,43]. Since the blood is easily accessible, peripheral blood cells (PBL) are the 
principal source of DNA used for epigenetic analyses. On the other hand, 
metabolically important tissues, as adipose tissue, are of high interest to understand 
the role of epigenetics in obesity. Adipose tissue includes functionally different 
cellular types and different depots with specific characteristics depending on their 
anatomical location. Metabolic alterations are linked to increased fat deposition in 
visceral depots, whereas storage in subcutaneous depots is considered less 
detrimental. As DNA methylation has a pivotal role in cell fate and adipocyte 
differentiation, studying DNA methylation profiles in distinct adipose tissue 
depots under different metabolic conditions could clarify how epigenetic 
regulation of adipose tissue is involved in the development of obesity and 
associated comorbidities, and how this could potentially be manipulated [83]. 
To date, gene-specific DNA methylation is the epigenetic mark most extensively 
investigated, in studies regarding the involvement of epigenetics in health 
outcomes, including obesity. Many of them are cross-sectional analysis, thus, 
DNA methylation levels and obesity-related traits are assessed at the same time 
point. A great number of these candidate gene methylation studies have focused 
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on a range of genes implicated in obesity, cell differentiation, appetite control 
and/or metabolism, insulin signaling, immunity, growth, circadian clock regulation 
and imprinted genes [83]. Altogether, these studies have showed the hypo-
methylation of TNFα in PBL, pyruvate dehydrogenase kinase 4 (PDK4) in muscle, 
and LEP in whole blood (WB), and hyper-methylation of POMC in WB, PPARγ 
coactivator 1 alpha (PGC1α) in muscle, and CLOCK and aryl hydrocarbon 
receptor nuclear translocator-like (BMAL1) genes in PBL in obese compared with 
lean individuals. Moreover, associations between BMI, adiposity, and waist 
circumference, with DNA methylation in PDK4 in muscle, melanin-concentrating 
hormone receptor 1 (MCHR1) in WB, and the serotonin transporter (SLC6A4), the 
androgen receptor (AR), and glucocorticoid receptor (GR) in PBL have also been 
reported. The strongest epigenetic association has been observed between DNA 
methylation status at the IGF2/H19 imprinting region in PBL with adiposity 
measures [83]. In addition, Kuehnen et al. [84] have analyzed DNA methylation 
status at the POMC locus, one of the identified monogenic obesity genes which 
encodes the anorexigenic alpha melanocyte stimulation hormone (α-MSH) 
produced in the hypothalamic arcuate nucleus, in blood leukocytes of obese 
children. This study has demonstrated the association between increased DNA 
methylation in the region adjacent to an intronic Alu element in the POMC locus 
and childhood obesity. Interestingly, the findings showed that the hyper-
methylation of this region impaired the binding activity of the histone 
acetyltransferase/transcriptional coactivator p300, inhibiting the expression of 
POMC gene [84]. Collectively, these studies provide evidence that obesity is 
associated with modification of DNA methylation status of several metabolically 
relevant genes.  
Additional studies have investigated the relationship of DNA methylation at birth 
to childhood metabolic outcomes and obesity, also in association with in utero 
exposures [83,85,86]. Godfrey at al. [85] have demonstrated that the methylation 
variation in the promoter of the retinoid X receptor alpha gene (RXRα), a nuclear 
receptor with a known role in adipogenesis, in umbilical cord tissue explain up to 
26% of the variation in childhood adiposity and is associated with the onset of 
obesity in pre-pubertal children. Furthermore, in the same cohort study, it has been 
demonstrated that this epigenetic mark is also associated with lower maternal 
carbohydrate intake in the first trimester of pregnancy [85]. IGF2 is another 
example of a gene showing loci-specific variation in methylation at birth, and also 
at childhood, that is associated with obesity in later life. Differences in the DNA 
methylation levels near IGF2 locus has been correlated to exposure to a suboptimal 
environment in utero [86]. These findings suggest a critical role of DNA 
methylation as potential mark to predict the individual’ s obesity risk, before the 
phenotype  
The development of high-throughput sequencing technologies and genome-wide 
array-based methods has opened a new window for identifying a large number of 
differentially methylated genes and CpGs. Overall, obesity-associated 
differentially methylated sites were enriched both in obesity candidate genes and 
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in genes regulating adipose tissue functioning, cell differentiation, immune 
response, and transcription. The majority of EWASs has been performed on blood 
samples, but adipose tissue, muscle and placenta have also been studied; many of 
these used BMI and/or body fat percentage to classify obesity [83]. Recently, Dick 
et al. [87] have provided a systematic analysis of the association between variation 
in DNA methylation and BMI. In particular, it has been used DNA of 479 
European individuals and two replication cohorts for a total of 2128 participants to 
analyze whole blood specific-CpG DNA in relation to BMI. The authors have 
demonstrated that increased BMI in adults is associated with specific hyper-
methylation at the hypoxia-inducible factor 3 alpha (HIF-3α) locus in blood cells 
and adipose tissue [87]. The association between HIF-3α methylation levels in 
blood and adiposity has been replicated in independent populations, highlighting 
the importance of its epigenetic regulation in energy expenditure and obesity 
[2,43,87]. Another EWAS, using whole-blood DNA from 2377 white adults, CD4+ 
T-cell DNA from 991 white individuals and adipose tissue DNA from 648 white 
women, has reported the association between the methylation level at 18 CpG sites 
located in/near the Carnitine Palmitoyltransferase 1A (CPT1A), ATP-Binding 
Cassette, Sub-Family GMember 1 (ABCG1), LYS6GE, Lysine (K)-Specific 
Demethylase 2B (KDM2B), RALB, PRRL5, Lectin, Galactoside-Binding, Soluble, 
3 Binding Protein (LGALS3BP), Chromosome 7 Open Reading Frame 50 
(C7orf50), Pre-B-Cell Leukaemia Homeobox 1 (PBX1), erythrocyte membrane 
protein band 4.9 (EPB49) and BBS2 genes with BMI in blood and adipose tissue 
cells [43]. Recently, Ronn et al., by analyzing the whole-genomic DNA 
methylation and gene expression in human adipose tissue from European 
individuals (96 males and 94 females), have demonstrated a correlation between 
age, BMI and/or HbA1c levels and DNA methylation and expression in many 
genes, that include also the Ankyrin repeat domain 26 (ANKRD26) [88]. In order 
to provide for the first time new and valuable DNA methylation biomarkers of 
VAT pathogenesis associated with insulin resistance, Crujeiras et al. [28] have 
performed EWAS in VAT from morbidly obese patients, classified based on the 
insulin sensitivity, evaluated by the clamp technique. This study has identified in 
982 CpG sites the specific methylome map associated with insulin-resistant (IR) 
in VAT. These identified sites represente 538 unique genes, 10% of which are 
diabetes-associated genes. However, it has been also revealed new IR-related 
genes, epigenetically regulated in VAT, such as COL9A1, COL11A2, CD44, 
MUC4, ADAM2, IGF2BP1, GATA4, TET1, ZNF714, ADCY9, TBX5, and HDACM. 
These data indicate that alteration of epigenetic regulation is involved in the 
dysregulation of VAT that could predispose patients to insulin resistance and 
future T2D in morbid obesity, and provide a potential therapeutic target and 
biomarkers for counteracting obesity-associated diseases [28]. Another study has 
examined the DNA methylation patterns in adipose tissues from obese women, 
before and after weight-loss surgery, showing a significant global hyper-
methylation in subcutaneous and omental adipose tissue, before weight loss 
through gastric bypass [89]. In particular, relative to promoter regions, this higher 
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methylation has been discovered in the 3’  untranslated region, especially in genes 
associated with obesity, epigenetic regulation and development, such as, fork head 
box P2 (FOXP2), DNMT3B and the HOX clusters [89]. Very recently, Macartney-
Coxson et al. [38], by using novel combinatorial algorithms, have analyzed DNA 
methylation data previously obtained from obese individuals, before and after 
gastric bypass [89] to identify specific CpG loci that differentiate between 
subcutaneous and omental adipose tissue. Significant differential methylation has 
been observed for 3239 and 7722 CpG sites, between adipose tissue types before 
and after significant weight loss, respectively. The vast majority of these extended 
differentially methylated regions are consistent across both time points and 
enriched for genes with a role in transcriptional regulation and/or development 
(e.g., SORBS2, HOXC cluster, CLD1), reflecting epigenetic differences critical to 
the function of these two tissues. Other differentially methylated loci have been 
observed at one-time point after weight loss (e.g., WTAPP1), thus they potentially 
highlight genes important to adipose tissue dysfunction observed in obesity and/or 
weight loss. Strong correlations between changes in DNA methylation 
(subcutaneous adipose vs omentum) and changes in clinical trait, have been 
particularli identified for CpGs within PITX2 and fasting glucose and four CpGs 
within ISL2 and HDL cholesterol. Only one CpG locus in ATP2C2 is useful to 
distinguish between the two tissues in this study cohort, both in lean and obese 
individuals [38]. The data obtained in the current study illustrate the extreme 
potential power and the overall utility of DNA methylation as a biomarker, 
together with other previously reported data in adipose tissue. However, it should 
be necessary to elucidate the molecular mechanisms involved in adipose tissue 
dysfunction associated with obesity in an easily accessible biological material, i.e., 
blood. Consistently with this issue, a study assessing the whole-genomic DNA 
methylation in PBL from individuals who went from being obese to normal weight 
on methylation patterns, have reported that peripheral blood mononuclear cell 
methylation is associated with BMI [90]. Moreover, Crujeiras et al., by using DNA 
samples isolated from subcutaneous adipose tissue and circulating leukocytes from 
obese and non-obese patients, have recently identified new DNA methylation 
biomarkers of obesity-related adipose tissue dysfunction in blood sample, an easily 
accessible and minimally invasive biological material instead of adipose tissue 
[91].   
Overall, significant progress has been made in the field of epigenetics and 
obesity, but there is still much to be learned before we fully understand the (causal) 
role of the epigenetic processes in development of complex diseases such as 
obesity, and assessing the epigenome at the right time in life and in the relevant 
tissues is a major barrier for studies in humans. 
1.4 ANKRD26 gene 
The Ankyrin repeat domain 26 (ANKRD26) gene maps on human chromosome 
10p12.1, in a genetic locus that may influence susceptibility to obesity when it is 
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maternally transmitted, and on chromosome 6 (qF1) in the mouse [92,93]. The 
gene encodes a ~190 kDa protein that contains ankyrin repeats and spectrin helices. 
EST database analysis of both the human and mouse genomes shows that 
ANKRD26 RNA is present in many normal tissues [92]. The protein is highly 
expressed in neuronal cell bodies and their processes, and in glial cells in feeding 
centers of the hypothalamus as well as both in areas of the brain that project to 
these centers and in the ependyma and circumventricular organs, that act as 
interface between peripheral and central circulation [92-94]. Moreover, it has been 
identified in other tissues and organs, including liver, skeletal muscle and WAT 
[93]. The ANKRD26 protein is located in the cytosol close to the inner aspect of 
the cell membrane, where it could act as scaffold protein regulating the function of 
signaling proteins and effectors. Indeed, it contains two conserved domains: 
ankyrin repeats (located from amino acids 74–199) and spectrin regions (743–
1538), that are known to mediate protein-protein interactions [95].    
Liu et al. [95], by two-hybrid screening, have identified 13 independent 
interacting partners of ANKRD26. The screening data have showed that only one 
protein (ANKRD17) interacted with the ankyrin repeat region at the N-terminus of 
ANKRD26; all the other 12 proteins, including the triple functional domain protein 
(TRIO), the G protein pathway suppressor 2 (GPS2), the delta-interacting protein 
A (DIPA) and the hyaluronan-mediated motility receptor (HMMR), bound to 
region 901–1702 of ANKRD26, containing the coiled-coil domain in the C-
terminus [95]. The positive interactions for the above protein was validated in 
mammalian cells, by immune-precipitation assays. Moreover, to establish the 
biological relevance of these interacting proteins and whether it may be carried out 
by their interaction with Ankrd26 protein, knock-down experiments were 
performed. The specific silencing of ANKRD26, TRIO, GPS2, DIPA or HMMR 
enhanced adipocyte differentiation upon induction in 3T3-L1 cells, suggesting that 
ANKRD26 may exert its pro-adipogenic function by modulating the localization 
and/or function of these interacting partners [95]. These findings indicate that C-
terminus domain of ANKRD26 is responsible for its protein-protein interactions 
and its biological functions, such as the adipogenesis regulation. 
In support of this concept, mutant mice in which Ankrd26 has been inactivated 
by removing the region encoding amino acids 1212–1710, encompassing all the 
C-terminus region, have marked hyperphagia, which results in extreme obesity, an 
increase body size, and insulin resistance and diabetes (fig. 9) [92,93]. In addition, 
it has been previously demonstrated that partial disruption of the Ankrd26 gene 
enhanced adipogenesis, both at level of pre-adipocyte commitment and at early 
and late differentiation steps, in mouse embryonic fibroblasts from Ankrd26 
mutant mice (MEFs Ankrd26-/-) [96]. 
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Figure 9. Photomicrograph of a homozygous Ankrd26 mutant (MT) and wild-type (WT) 
mice. Adapted from Proc. Natl. Acad. Sci. U S A. 2008; 105:270-275. 
1.4.1 ANKRD26 as a candidate (epi)gene for obesity 
Ankrd26 has been recently identified as a gene involved in the control of the 
feeding behavior and in the development of both obesity and T2D in mice [92-94]. 
Indeed, mice with partial inactivation of Ankrd26 (Ankrd26-/-) gene develop 
marked hyperphagia, without reduction in energy expenditure, severe obesity and 
diabetes, by impairing both insulin action and secretion, in obesity-dependent 
manner (tab. 1) [93].  
 
 
 
Table 1. Metabolic characteristics of 4-month-old Ankrd26 mutant mice (MT). *, p < 0.05 
versus wild-type (WT) mice of the same sex. Proc. Natl. Acad. Sci. U S A. 2008; 105:270-275. 
 
Recently, the phenotyping of the brain regions that control appetite and energy 
homeostasis from Ankrd26-/- mice has demonstrated that these mice exhibit central 
leptin resistance, the impairment of melanocortin pathway function, caused by 
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reduced expression of MC4R and resistance to α-MSH, and defects in the 
expression and subcellular localization of primary specific-cilium proteins [94]. It 
is known that mutations in genes that directly influence the expression of signaling 
or structural proteins of the primary cilia induce disturbances in energy 
homeostasis in both humans and mice, and are responsible for human obesity in 
Bardet–Biedl syndrome [43,45,94]. Interestingly, in vivo data indicate Ankrd26 as 
the first example of a non-cilium-specific protein that is necessary to prevent the 
development of a ciliopathy associated with morbid obesity [94]. This evidence 
provides a novel mechanism for genetic obesity, in which membrane and/or 
scaffold proteins are required for the proper primary ciliary function, and broader 
spectrum of targets, diagnostic and therapeutic approaches to human obesity than 
previously considered.  
Interestingly, earlier findings in humans have showed that individuals 
homozygous for SNPs in the coding region of the ANKRD26 gene (rs139049098), 
among other SNPs with a predicted damaging impact on the protein related to cilia 
function, develop rare forms of severe obesity [97].   
As cilia are relevant for the proper development and physiology of many cell 
types, tissues and organs, variations of cilia and ciliary genes may contribute to the 
obesity risk from a broad spectrum of processes, including adipogenesis, 
hypothalamic food intake regulation and olfactory perception. The evidence that 
those genes are players in various etiological processes makes them an interesting 
potential targets for obesity treatment. Indeed, the obesity phenotype in 
ciliopathies is a consequence of mutations that impair protein function, thus, 
overexpression of ciliary genes may provide a new way to prevent obesity [97]. 
However, more knowledge on regulation of cilia and ciliary gene expression and 
function should be provided to clarify their actual involvement in obesity. In this 
scenario, assuming that cilia monitor signals from the environment, it would be 
interesting to know how cilia and ciliary genes respond to changes in energy 
availability.  
Intriguingly, recent data in the literature have identified ANKRD26 among 
several genes, of which the changes in gene expression and/or DNA methylation 
is associate with modifications in calorie intake and body weight. Indeed, gene 
expression profiles of the hypothalamus and striatum from C57BL/6J mice treated 
with the anorectic drugs, subutramine, phenimetrazine and methamphetamine, 
have revealed that the induced reductions of food intake and weight loss were 
paralleled by the up-regulation of Ankrd26 gene expression in the above brain 
regions [98]. These findings not only suggest that Ankrd26 may account for 
biological effects of these drugs, but also that this gene may be a target and 
transcriptional outcome of specific environmental exposure.  
In support of this concept, emerging evidence points to alterations in 
environmental-induced ANKRD26 epigenetic regulation, in mouse as well as in 
human obesity. Indeed, the methylome analysis of murine eAT [78], representative 
VAT depot in rodents [23], has identified promoter hyper-methylation of Ankrd26 
gene in HFD-fed compared to age- and sex-matched chow diet-fed mice, 
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suggesting that Ankrd26 gene is amenable to nutritionally-induced epigenetic 
modifications. Additionally, computational data from the genome-wide analysis of 
DNA methylation in human adipose tissue have revealed that ANKRD26 is 
included in a list of 2825 genes, for which both DNA methylation and mRNA 
expression levels significantly correlate with age and BMI [88].  
Altogether, these observations paved the way to support the hypothesis that the 
adipose tissue abnormalities may be accompanied by epigenetic changes at the 
ANKRD26 gene, in mice as well as in humans, that may represent one of the 
molecular mechanisms by which environmental cues may generate adipose tissue 
dysfunction, contributing to development of obesity and associated comorbidities. 
Interestingly, pleiotropic meta-analyses of genetic variants, across multiple 
studies, have recently demonstrated that the ANKRD26 SNP rs7081476, located 
on 10p12.1, is associated with a variety of obesity- and age-related 
endophenotypes and diseases, as elevated BMI, systolic blood pressure, 
triglycerides and blood glucose, reduced HDL cholesterol and increased hazards 
of diabetes mellitus (DM), heart failure (HF), atrial fibrillation and coronary heart 
diseases (CHD) [99]. The effects of this ANKRD26 variant on DM, HF and CHD 
are mediated through several endophenotypes, among which BMI has the most 
significant indirect effect [99].  
As outlined above, in vitro and in vivo studies have clearly demonstrated the 
close relationship between the impairment of ANKRD26 expression and/or 
function and development of obesity and associated comorbidities. However, 
whether these alterations occurring in obese individuals are exclusively determined 
by genetic mechanisms, and/or non-genetic mechanisms may also contribute to the 
same, are issues that still remain to be established. Elucidating how the ANKRD26 
gene is regulated could generate further insight into the molecular bases of obesity 
as well as novel translational perspectives. 
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2. AIMS OF THE STUDY 
 
 
Obesity is a complex and multifactorial chronic disease, resulting from the 
complex interactions between genetic and environmental factors. It is a growing 
health problem worldwide and genetic models to explain its epidemic are 
inadequate because its increase has been too rapid to allow for the appearance of 
new mutant genes. In addition, increasing evidence show that environmental cues, 
such as fat-enriched diet, strongly contribute to development and progression of 
multifactorial disease, by altering gene expression through epigenetic 
modifications. 
Ankrd26 gene is widely expressed in metabolically relevant tissues and organs, 
as hypothalamus, WAT, liver and skeletal muscle. It has emerged as a new 
important player in the control of the feeding behavior and in the onset of both 
obesity and T2D.  Indeed, in vitro and in vivo studies, in mice as well as in humans, 
have clearly demonstrated the close relationship between the impairment of 
ANKRD26 expression and/or function and development of obesity and associated 
comorbidities. However, whether these alterations occurring in obese individuals 
are exclusively determined by genetic mechanisms, and/or non-genetic 
mechanisms may also contribute to the same, are issues that still remain to be 
established. 
Based on this knowledge, the aims of this work are: i. to clarify whether and how 
external stimuli, such as the administration of a high fat diet, could impact on 
Ankrd26 expression in different adipose tissue depots; and, ii. to evaluate whether 
chromatin remodeling and epigenetic modifications take part in the regulation of 
this candidate (epi)gene, driving the adipose tissue dysfunction that contributes the 
onset and progression of obesity. 
Since the knowledge about the molecular mechanisms linking specific 
environmental cues and metabolic disorders are still limited, addressing these 
issues will provide some insights into epigenetic mechanisms associated with 
obesity. 
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3. MATERIALS AND METHODS 
 
 
3.1 Animal study, diet protocols and metabolic test  
Six-week-old C57BL/6J male mice (n=48) from Charles River Laboratories 
International, Inc. (Wilmington, MA) were hosted at the common facility of the 
University of Naples Medical School. They were housed under the conditions of 
temperature-controlled (22°C), a light/dark cycle of 12 hours, with free access to 
food and water. Two weeks after arrival, mice were randomly divided into two 
groups of 12 mice each and were fed either a HFD (60 kcal% fat content; Research 
Diets formulas D12331; Research Diets, Inc., New Brunswick, NJ) or a standard 
chow diet (STD; 11 kcal% fat content; Research Diets formulas D12329; Research 
Diets, Inc.) for 8 and 22 weeks. The composition of these diets is reported in the 
Table 2. Body weight was recorded weekly throughout the study. 
The glucose tolerance test (GTT) was performed at the beginning and at the 8- 
and 22-week diet time points. Mice were fasted overnight and then injected with 
2g/kg body weight of glucose. Blood samples were obtained from mice tail and 
glycaemia was measured by using a glucose analyzer (LifeScan) at the following 
time points, after glucose injection: 0, 15, 30, 45, 60, 90, 120 min. 
Similarly, the insulin tolerance test (ITT) was performed at the beginning and at 
the 8- and 22-week diet time points. Insulin sensitivity was assessed on 5 hours 
starved mice and then injected with 0,75 U/kg body weight of insulin. Blood 
samples were obtained from mice tail and glycaemia was analyzed by using a 
glucose analyzer (LifeScan). Glucose levels were assessed at the following time 
points: 0, 15, 30, 45, 60, 90, 120 min after insulin injection. 
All the experiments performed on mice were conducted in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the National 
Institutes of Health (publication no. 85-23, revised 1996). Protocols were approved 
by the ethics committee of the “Federico II” University of Naples.  
3.2 Western blotting analysis 
Tissues were weighed and were homogenized in ice-cold T-PER tissue protein 
extraction reagent (ThermoFisher Scientific), supplemented with the Complete 
Protease Inhibitor Mixture Tablets (Roche Applied Science). Differently, the cells 
were homogenized in ice-cold RIPA buffer [25 mM Tris (pH 7.5), 10 mM EDTA, 
10 mM EGTA, 1% Nonidet P-40, 10 μg/ml leupeptin, 2 μg/ml aprotinin, 20 μg/ml 
PMSF, 100 μM NaF, 50 μM NaPPi, 10 μM Na3VO4]. The lysates were kept on ice 
for 15 min and then cleared by centrifugation at 15,000 × g for 20 min. After lysates 
clarification, protein concentration was determined using Bradford assay (Bio-
Rad). Protein extracts (50 µg) were resolved by SDS-PAGE and blotted on 
nitrocellulose membranes (Millipore, Billerica, MA). Non-specific binding was 
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blocked with 5% nonfat milk for 1 hour at the room temperature. Bands were 
revealed by chemio-luminescence (Amersham, Biosciences). The following 
antibodies were used: antibody against ANKRD26 (#SC-82505, Santa Cruz 
Biotechnology), and α-Tubulin (#MA1-19162, Sigma-Aldrich), as loading control. 
 
Table 2. Composition of diets, D12329 and D12331 
3.3 Real time PCR (qPCR) 
The cDNA synthesis was generated from 1 µg of total RNA by using Superscript 
III (Invitrogen, Life Technologies). After cDNA synthesis, Real time PCR was 
performed on CFX96 (Biorad) in a final volume of 10 µl containing 20 ng of 
cDNA, 5 µl of iTaq Universal SYBR Green Supermix (Biorad) and specific 
forward and reverse primers (Sigma). For in vivo study, the results of Real time 
analysis are expressed as the ratio between the copy number variation (CNV) of 
Ankrd26 and that of the reference gene. 
3.4 Methylated DNA Immuoprecipitation (MeDIP)  
DNA methylation enrichment was evaluated on genomic DNA isolated from 
eAT of STD- and HFD-fed mice and from 3T3-L1 adipocytes. MeDIP assay was 
performed as described by Weber et al. [100]. Sonicated pooled genomic DNA 
from WAT was immunoprecipitated using anti-5meCpG Q11 (#ab10805, Abcam) 
or mouse IgG with anti-mouse IgG beads (#10003D, Life Technologies). DNA 
methylation enrichment on recovered DNA was evaluated by qPCR. Samples were 
Formula  D12329 D12331 
  g% kcal% g% kcal% 
Protein  16.8 16.4 23 16.4 
Carbohydrate  74.3 73.1 35.5 25.5 
Fat  4.8 10.5 35.8 58 
 
Formula  D12329 D12331 
Ingredient  g kcal g kcal 
Casein, 30 Mesh  228 912 228 912 
DL-Methionine  2 0 2 0 
Maltodextrin 10  170 680 170 680 
Corn Starch  0 0 0 0 
Sucrose  835 3340 175 700 
Soybean Oil   25 225 25 225 
Coconut Oil, Hydrogenated  40 360 333.5 3001.5 
Mineral Mix S10001  40 0 40 0 
Sodium Bicarbonate  10.5 0 10.5 0 
Potassium Citrate, 1 H2O  4 0 4 0 
Choline Bitartrate  2 0 2 0 
FD&C Blue Dye   0.1 0 0.1 0 
Vitamin Mix V10001  10 40 10 40 
 Total 1366.6 5557 1000.1 5558.5 
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normalized to their respective input using the 2-ΔCT method.  
3.5 Bisulfite sequencing 
For bisulfite sequencing analysis, was used genomic DNA isolated from eAT of 
STD- and HFD-fed mice. Bisulfite conversion of DNA was performed with the EZ 
DNA Methylation Kit (Zymo Research), following manufacturer's instructions. 
Converted DNA was amplified by PCR and PCR products were cloned into the 
pGEM T-Easy vector (Promega). For sequencing analysis, 10 clones for each 
sample were sequenced on AB 3500 genetic analyzer (Life Technologies). DNA 
methylation percentage at the -436 and -431 bp CpGs for each mouse was 
calculated using the formula: DNA methylation % = [methylated 
CpGs/(methylated CpGs + unmethylated CpGs)]*100. 
3.6 Cloning strategy, site-direct mutagenesis and in vitro methylation  
The Ankrd26 promoter region encompassing -733 bp to -344 bp flanking TSS, 
was PCR amplified using murine genomic DNA with primers having restriction 
sites AvrII and BamHI at 5′ and 3′ ends respectively.   The purified PCR fragment 
was cloned into the firefly luciferase reporter pCpGfree-promoter-Lucia vector 
(Invivogen).  
The following site-specific mutated constructs were generated by PCR-based 
mutagenesis: pCpG-Ankrd26-436, pCpG-Ankrd26-431, pCpG-Ankrd26-391. The 
wilde type (Wt) pCpG-Ankrd26 vector, used as template, was removed from the 
PCR reaction by DpnI digestion (New England BioLabs). Wt and mutated (mut) 
vectors were amplified into E. coli GT115 cells (Invivogen). Site-specific 
mutagenesis of each construct was validated by sequencing.  
In vitro methylation was performed by using the CpG methyltransferase M.SsI 
(New England BioLabs). Plasmid DNA (10 µg) was incubated with M.SsI (2 
U/µg) in the presence of 640 µM S-Adenosylmethionine (SAM; New England 
Biolabs) at 37°C for 4 h, with subsequent inactivation of enzyme at 60°C for 20 
min. Un-methylated DNA was obtained in the absence of M.SsI (mock-
methylated). The methylation was confirmed by resistance to HpyCH4IV 
digestion (10 U/µg; New England BioLabs).   
3.7 Luciferase assay 
NIH-3T3 cells were transfected with methylated or un-methylated Wt or 
mutagenized pCpG-Ankrd26 vector and Renilla control vector (Promega) by 
lipofectamine (Life Technologies), following manufacturer’ s instructions. Where 
indicated, cells were co-transfected with pCl.p300 expression vector (Promega). 
Forty-eight hours after transfection, the culture media and the cell lysates were 
assayed for firefly and renilla luciferase activity. Firefly luciferase activity of each 
transfection was normalized for transfection efficiency against Renilla luciferase 
activity. 
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3.8 Chromatin Immunoprecipitation (ChIP) and Micrococcal Nuclease 
(MNase) assays 
ChIP and MNase assays were performed as described [101,102]. Briefly, 100 mg 
of eAT were cross-linked with 1% formaldehyde for 15 min at 37°C. The cross-
linking reaction was stopped by the addition of glycine 125mM. For ChIP assay, 
the cross-linked samples were lysed and sonicated to achieve chromatin fragments 
ranging between 500 and 1000 bp in size. The lysates were incubated at 4°C 
overnight with the following appropriated antibodies: anti-p300 (#SC-585, Santa 
Cruz Biotechnology), anti-Ac-H4-K16 (#07-329, Millipore, Temecula, CA), anti-
DNMT1 (#NB100-56519) and anti-DNMT3b (#NB300-516) from Novus 
Biologicals, anti-DNMT3a (#ab2850), anti-MBD2 (#ab38646), and anti-RNA Pol 
II (#ab5408) from Abcam. Normal anti-rabbit IgG (#I8140) and anti-mouse IgG 
(#I8765) from Sigma-Aldrich were used as negative control. Immunoprecipitates 
and INPUT controls were eluted by freshly prepared 1% SDS, 0.1M NaHCO3 
buffer. After reversion cross-linking, DNA was purified by the QIAquick PCR 
purification kit (Qiagen) followed by qPCR. Samples were normalized to their 
respective input using the 2-ΔCT method and corrected to negative control. 
For MNase assay, the nuclei were isolated from 100 mg of eAT, suspended in 
wash buffer [100 mmol/L Tris-HCl, 15 mmol/L NaCl, 60 mmol/L KCl, 1 mmol/L 
CaCl2] and treated with 200 U of MNase for 20 min at 37°C. Cross-link reversal 
was performed at 65°C for 16 hours, followed by an RNase treatment and 
proteinase K digestion. DNA was purified by phenol–chloroform. Samples were 
then run on 1% agarose gel and the resulting mononucleosomal DNA fragments 
(~ 150 bp) were gel purified. For both assays, relative protein binding and 
nucleosome occupancy to the Ankrd26 promoter region were evaluated on 
recovered DNA by qPCR. Samples were normalized to their respective input using 
the 2-ΔCT method. 
3.9 Electrophoretic mobility shift assay (EMSA) 
Nuclear proteins were extracted from NIH-3T3 cells by NE-PER Nuclear and 
Cytoplasmic Extraction Kit (ThermoFisher Scientific) according to the 
manufacturer’ s protocol. The Ankrd26 promoter region spanning from -455 bp to 
-425 bp and including the p300 response element, was used as probe to detect 
sequence-specific p300 binding in vitro. Protein-DNA complexes were detected 
using unlabeled or biotin end-labeled double-stranded DNA probes by annealing 
complementary oligonucleotides. Biotin 3’ -end oligonucleotides were from 
Sigma-Aldrich and where indicated were synthesized to incorporate methylated 
cytosines (meC).  The binding reaction was performed using the LightShift kit 
(ThermoFisher Scientific) as described below. Before the addition of labeled 
probe, 10 μg of nuclear extracts were incubated for 20 min on ice in 20 μl of 
reaction buffer, containing 5% glycerol, 1 mM MgCl2, 50 mM KCl, 0.5 mM 
EDTA, 50 ng of double-stranded poly (dI-dC). Biotin-labeled probe (20 fmol) was 
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added and the reaction was allowed to incubate for 20 min at room temperature. In 
the competition experiments, the nuclear extracts were preincubated with 200 
molar excess of unlabeled probes for 20 min on ice. In super-shift experiments, 2 
µg of p300 antibody (#SC-585, Santa Cruz Biotechnology) or 2 µg of rabbit IgG 
(#I8140, Sigma-Aldrich) were preincubated with nuclear extracts for 1 hour on ice. 
Protein-DNA complexes were separated on native polyacrylamide gel, transferred 
onto nylon membrane and detected by the LightShift Chemiluminescent EMSA kit 
(ThermoFisher Scientific) following the manufacturer’ s procedure. 
3.10 Primer Sequences  
The oligonucleotides used for PCR, qPCR, MeDIP, bisulfite sequencing, ChIP, 
MNase, EMSA are listed in the Table 3. 
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Table 3. Oligonucleotide sequences. Methylated CpGs are indicated as meC. Mutated cytosines 
(C → T) are indicated in bold. F, forward; R, reverse. 
 
3.11 Cell culture and transfection 
3T3-L1 preadipocytes were maintained as a subconfluent monolayer culture and 
differentiation was induced by placing cells in differentiation cocktail (DMEM 
with 10% FBS, 1 μg/ml bovine insulin, 1 μM dexamethasone and 0.5 mM IBMX) 
for 48 hours and then changing the medium every two days with DMEM with 10% 
FBS and 1 μg/ml insulin. The cells were fully differentiated 8 days after induction, 
as evidenced by observation of lipid droplet formation. The mature adipocytes 
were i. silenced with 25 nmol/l of scrambled-siRNA or Ankrd26-siRNA for 48 
hours, or ii. treated with palmitate (0.250 mM; Sigma-Aldrich), or oleate (0.250 
mM; Sigma-Aldrich) or corresponding vehicle (diluent solution with the same 
 
Technique Gene/Region Primer sequence 
qPCR 
Ankrd26 
F 5’ -CTTTGGACGCGAGAGTGCTA-3’  
R 5’ -AGCAGTCCTGTCCTTCTTGTC-3’  
β-Actin F 5’ -AAGATCAAGATCATTGCTCCTCCTG-3’  
R 5’ -AGCTCAGTAACAGTCCGCCT-3’  
ANKRD26 
F 5’ -GTATGCTAGTAGTGGTCCTGC-3’  
R 5’ -GTAGGCCTTCCTTCATCCTCAT-3’  
RPL13A 
F 5’ -CTTTCCGCTCGGCTGTTTTC-3’  
R 5’ -GCCTTACGTCTGCGGATCTT-3’  
MeDIP-qPCR 
Ankrd26 S1 
F 5’ -CTGCAAGGCTTCAACAGGAA-3’  
R 5’ -ACAAAATCTCTTCCCTTACTCTTCC-3’  
Ankrd26 S2 
F 5’ -TGGAAACAACACACTGCCCA-3’  
R 5’ -AACGCAGCTAGGGCACTTAT-3’  
Bisulfite sequencing 
Ankrd26 Region 1 
F 5'-TAAATTATTTAGTTTAATAAAATTTTTTTT-3' 
R 5'-TCTTTACTATTCAAAAAATCAAAAC-3' 
Ankrd26 Region 2 
F 5'-TTTTGATTTTTTGAATAGTAAAGAAGG-3'  
R 5'-CCTTATAAATCTTACCCATATCCTTATC-3' 
Cloning and mutagenesis 
Ankrd26 Wild Type 
F 5’ -GCCCTAGGCCTTTGAGGTGAGTTGTGGCT-3’   
R 5’ - GCGGATCCGGCAGTTAAACCTGTTGGGG-3’  
Ankrd26 Mut -436 
F 5’ -TCCCTTACTCTTCCATGCCACGATTCCATCC-3’   
R 5’ - GGATGGAATCGTGGCATGGAAGAGTAAGGGA-3’  
Ankrd26 Mut -431 
F 5’ -   ACTCTTCCACGCCATGATTCCATCCATGC-3’  
R 5’ - GCATGGATGGAATCATGGCGTGGAAGAGT-3’  
Ankrd26 Mut -391 
F 5’ - GTAGTTTACTTTTTGATTATTGCCTACCTAGAGTCCAATAG-3’   
R 5’ - CTATTGGACTCTAGGTAGGCAATAATCAAAAAGTAAACTAC-3’  
ChIP-qPCR and MNase 
p300/DNMTs/MBD2 
bs Ankrd26 
F 5’ -ACCTCCCATCAGCTTGTCTAAC-3’   
R 5’ -GCCTTGTGTTTCAGTGGCAG-3’  
-257/-198  
Nuc-2 Ankrd26 
F 5’ -TCCTGGAGTACTGGGTCTGG-3’   
R 5’ -AGGCTTCAACAGGAATGGGG-3’  
-84/-25  
Nuc-1 Ankrd26 
F 5’ -CCTGAACAGCAAAGAAGGCG-3’   
R 5’ -CAGCGACCAGTGCCCAG-3’  
+16/+159 
TSS Ankrd26 
F 5’ -GTTGCTAGTTTGCAGCTCGG-3’   
R 5’ -CAACGTTGGCTGACAACACA-3’  
EMSA 
Labeled  
Ankrd26 probe 
F 5’ - CTCTTCCCTTACTCTTCCACGCCACGATTCC-3’ [Btn] 
R 5’ - GGAATCGTGGCGTGGAAGAGTAAGGGAAGAG-3’ [Btn] 
Un-labeled  
Ankrd26 probe    
F 5’ - CTCTTCCCTTACTCTTCCACGCCACGATTCC -3’  
R 5’ - GGAATCGTGGCGTGGAAGAGTAAGGGAAGAG-3’  
Un-labeled Methy  
Ankrd26 probe 
F 5’ -   CTCTTCCCTTACTCTTCCAmeCGCCAmeCGATTCC-3’  
R 5’ -  GGAATmeCGTGGmeCGTGGAAGAGTAAGGGAAGAG  -3’  
Un-labeled Mut  
Ankrd26 probe 
F 5’ - CTCTTCCCTTACTCTTCCATGCCATGATTCC -3’  
R 5’ - GGAATCATGGCATGGAAGAGTAAGGGAAGAG -3’  
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concentrations of BSA and ethanol of the Fatty Acid/BSA complex solution) for 
96 hours, or iii. treated with leptin (100 nM; R&D Systems) or corresponding 
vehicle (20 mM Tris-HCl, pH 8.0) for 24 hours. Adipokines were assayed in media 
from silenced cells by Bio-Plex Pro Mouse Cytokine Immunoassay following the 
manufacturer's protocol (Bio-Rad). Ankrd26 promoter methylation and gene 
expression in cell cultures were analyzed as previously described in this section. 
3.12 Fatty Acid/BSA complex solution preparation  
Palmitate and oleate have been conjugated to fatty acid-free BSA (2:1 molar ratio 
Fatty Acid/BSA) as described by [103]. The stock solution of palmitate (100 nM) 
was dissolved at 70 °C in 50% ethanol in a shaking water bath. In parallel, the fatty 
acid-free BSA solution was prepared at 55 °C in NaCl in a shaking water bath. 
Finally, the palmitate and the fatty acid-free BSA solutions were complexed at 55 
°C in a shacking water bath, cooled to room temperature and sterile filtered. Oleate 
was complexed to the fatty acid-free BSA solution following the same protocol. 
For fatty acid cell treatment, control adipocytes were treated with diluent only, 
corresponding concentrations of BSA and ethanol.    
3.13 Patient enrollment and tests 
Abdominal VAT biopsies and serum samples were obtained from patients 
undergoing bariatric surgery. A cohort of 11 normal glucose tolerance (NGT) 
obese subjects was selected for in vivo human study. The baseline characteristics 
of the enrolled subjects are reported in the Table 4. Participants with metabolic and 
endocrine disorders, inflammatory diseases, previous or current malignancies, 
and/or treated with drugs able to interfere with the epigenome were excluded from 
the study. Secreted mediators were assayed in serum samples by Bioplex multiplex 
Human Cytokine, Chemokine and Growth factor kit (Bio-Rad) following 
manufacturer’ s protocol. ANKRD26 gene expression in VAT was analyzed as 
previously described in this section. This study adhered to the Declaration of 
Helsinki and has been reviewed and approved by the Ethics Committee of the 
“Federico II” University of Naples (Ethics Approval Number: No. 225_2013). 
Informed consent was obtained from all of enrolled individuals. 
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Table 4. Baseline characteristics of the obese subjects with normal glucose tolerance.  Data 
are means ± SD of determinations. For each variable, the lowest and the higher values are shown. 
BMI, Body Mass Index; OGTT, Oral Glucose Tolerance Test. 
3.14 Statistical analysis 
The area under the curve (AUC) was calculated using the trapezoidal rule. Data 
are expressed as mean ± SD. Statistical significance of the differences between 
groups was determined by two-tailed unpaired Student’ s t test or the one-way 
analysis of variance, as appropriate, using GraphPad Software (version 6.00 for 
Windows). Correlation between two variables was calculated using the parametric 
Pearson r-test. p˂0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Subjects, n=11(5M/6F) 
 Mean ± SD Range 
General variables   
Age (years) 27.4 ± 5.6 19.0 - 46.0 
BMI (Kg/m2) 43.6 ± 9.3 32.6 - 61.0 
Fasting glucose (mmol/l) 4.8 ± 0.4 4.3 - 5.8 
Fasting insulin (pmol/l) 105.9 ± 31.5 63.2 -154.9 
HOMA-IR 3.0 ± 1.2 1.3 - 5.1 
OGTT plasma glucose (mmol/l) 6.4 ± 0.8 5.0 - 7.0 
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4. RESULTS 
 
 
4.1 Animal study design 
It has been well demonstrated the link between obesity, diet and epigenetic 
mechanisms both in animal models and in humans. The administration of high fat 
diet to several animal species leads to obesity and induces disease signs that model 
human T2D. Moreover, diet-induced obesity (DIO) in the mouse, in the absence 
of mutation of selected genes, provide a powerful tool for identifying epigenetic 
and environmental mechanisms potentially involved. 
C57BL6/J is a well-established model for studies of metabolic diseases and the 
most commonly used mouse strain for diet-induced obesity. Indeed, this strain 
develops severe obesity, hyperglycemia and insulin resistance if weaned onto 
HFD, and therefore it was used for this study. 
Animals were acclimated for 2 weeks before experiments and diet protocol 
started when mice were 8 week-old. To avoid sex hormone influences, exclusively 
male mice were used in this study.  They were randomly divided into two groups 
of 12 mice each and were fed either a HFD or a STD. After each time point of diet 
protocol, mice were sacrificed and tissues collected for further analysis (fig. 10). 
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Figure 10. Experimental study design for diet-induced obesity. In the current study, two 
different diet regimens were used to investigate the potential pathophysiologic effect of egigenetic 
regulation of Ankrd26 gene in obesity-related adipose tissue dysfunction.  
4.2 Metabolic characteristics of standard and high fat diet mice 
Body weight and food intake were weekly evaluated during each diet protocol 
duration. Table 5 reports the difference in body weight of STD- and HFD-fed mice 
at 8 and 22 weeks of diet protocol. HFD mice significantly increased their body 
weight after 8 and 22 weeks of feeding (16-week-old HFD 34.4 ± 3.2 g vs 16-
week-old STD 24.7 ± 2.1 g, p-value<0.001; 30-week-old HFD 38.8 ± 3.3 g vs 30-
week-old STD 26.4 ± 2.8 g, p-value<0.001). Concomitantly, these obese mice also 
exhibited an impairment of glucose metabolism (tab. 5). The glucose homeostasis 
of these mice, was assessed by measuring the blood glucose levels and the glucose 
tolerance. Fasting blood glucose was significantly increased in HFD group 
compared to STD mice (16-week-old HFD 7.7 ± 1.7 mmol/l vs 16-week-old STD 
5.9 ± 0.9 mmol/l, p-value<0.001; 30-week-old HFD 9.1 ± 1.8 mmol/l vs 30-week-
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old STD 5.8 ± 1.2 mmol/l, p-value<0.001). Additionally, during GTT, glucose 
loading rendered HFD-fed mice significantly more hyperglycemic than control 
mice during the following 120 min, revealing a strong impairment of glucose 
tolerance after 8 and 22 weeks of diet regimens. Furthermore, as showed in the 
Table 5, after intraperitoneal insulin injection HFD mice displayed reduced insulin 
sensitivity compared to the control mice. Therefore, upon 8 and 22 weeks of high 
fat diet treatment, mice become both glucose intolerant and insulin resistant. 
 
Variable 
16 week-old  30 week-old  
STD (n=12) HFD (n=12) STD (n=12) HFD (n=12) 
Body weight (g) 24.7 ± 2.1 34.4 ± 3.2a 26.4 ± 2.8 38.8 ± 3.3b,c 
Fasting glucose (mmol/l) 5.9 ± 0.9 7.7 ± 1.7a 5.8 ± 1.2 9.1 ± 1.8b 
GTT AUC (mmol/l 120 min-1) 725.7 ± 103.3 1290.7 ± 162.4a 653.6 ± 150.0 1344.2 ± 172.2b 
ITT AUCi (mmol/l 120 min-1) 741.6 ± 127.0  355.7 ± 132.2a 681.0 ± 128.9  312.9 ± 117.6b 
Table 5. Effect of HFD on Body weight, fasting blood glucose, glucose tolerance and insulin 
sensitivity. 8-week-old male C57BL/6J mice were fed a high-fat diet (HFD) or a standard chow 
diet (STD) for 8 and 22 weeks. Body weight, fasting blood glucose, glucose tolerance test (GTT) 
Area Under the Curve (AUC) and insulin tolerance test (ITT) AUCi were reported. Data are mean 
± SD of determinations. ap<0.001, 16-week-old HFD vs 16-week-old STD; bp<0.001, 30-week-old 
HFD vs 30-week-old STD; and cp<0.001, 30-week-old HFD vs 16-week-old HFD. 
4.3 Effect of HFD on Ankrd26 gene expression in visceral adipose tissue 
As mentioned before, Ankrd26 gene is widely expressed in metabolically 
relevant tissues including WAT, and, both in vitro and in vivo studies have clearly 
demonstrated the close relationship between the impairment of Ankrd26 
expression and/or function and development of obesity and associated 
comorbidities, in mice as well as in humans. In this context, it has been investigated 
whether Ankrd26 expression could be affected by external cues, in particular by a 
high fat diet administration. 
Therefore, by immunoblotting analysis it has been compared the Ankrd26 
protein levels in visceral adipose tissues of mice fed with standard or high fat diet 
for 8 and 22 weeks. The results show that obese mice have higher Ankrd26 protein 
levels than lean control mice in eAT after 22 weeks of HFD regimen, but not after 
8 weeks of the same obesogenic treatment (fig. 11). 
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Figure 11. Ankrd26 protein expression in eAT. Western blot analysis of Ankrd26: total protein 
extracts obtained from eAT (50µg) of C57BL/6J mice fed a standard diet (STD) or high fat diet 
(HFD) for 8 and 22 weeks were separated by SDS-PAGE followed by immunoblotting with 
Ankrd26 antibody; alpha-tubulin was used as a loading control. (a) Representative western blot for 
Ankrd26 and α-Tubulin and densitometric analyses of the data from mice upon 8 weeks of STD or 
HFD treatments. (b) Representative western blot for Ankrd26 and α-Tubulin and densitometric 
analyses of the data from mice upon 22 weeks of STD or HFD treatments. (a-b) Bars represent 
mean ± SD from three independent experiments. (b) Asterisks denote statistically significant 
differences (**p<0.01 vs STD). 
 
Consequently, to further investigate whether the increased Ankrd26 expression, 
induced by long-term HFD treatment, is linked to a transcriptional regulation of 
Ankrd26 gene, its mRNA expression has been evaluated in eAT by performing 
qPCR (fig. 12). The obtained results confirmed western blot analysis. Indeed, 
Ankrd26 mRNA showed no differences between HFD- and STD-fed mice after 8 
weeks of diet regimens (fig. 12a). On the other hand, the treatment with HFD for 
22 weeks led to a significant decrease in Ankrd26 mRNA levels (p<0.001) in obese 
mice compared to lean controls (fig. 12b).  
Interestingly, HFD treatment for 4 additional weeks did not elicit any further 
decrease in Ankrd26 mRNA expression in the eAT of HFD-fed mice (34 week-old 
STD, Ankrd26 mRNA: 2.29 x 10-3 ± 0.11 x 10-3 AU; 34 week-old HFD, Ankrd26 
mRNA: 1.36 x 10-3 ± 0.19 x 10-3 AU; p<0.001), suggesting that the aging does not 
have a role in mediating the transcriptional regulatory response of Ankrd26 gene 
to prolonged obesogenic diet. 
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Figure 12. Ankrd26 mRNA expression levels in eAT. Ankrd26 mRNA levels were measured 
performing absolute cDNA quantification by qPCR analysis. Data are shown as copy number 
variation (CNV) of Ankrd26 normalized on CNV of a reference gene, and are expressed in absolute 
units (AU).  Ankrd26 mRNA for standard diet (STD)- (n=12) and high fat diet (HFD)-fed (n=12) 
mice, upon 8 weeks (a) and 22 weeks (b) of diet regimens. (b) Asterisks denote statistically 
significant differences (***p<0.001 vs STD). 
 
To determine whether the down-regulation of Ankrd26 expression in the eAT 
during obesity is a depot-specific phenomenon or is feature of VAT dysfunction, 
the transcript levels of Ankrd26 gene have been determined in another VAT depot: 
the mesenteric adipose tissue (mAT). As shown in Figure 13, Ankrd26 mRNA 
expression was significantly lowered by long-term HFD treatment also in the mAT 
of obese mice (p<0.01).  
 
 
 
Figure 13. Ankrd26 mRNA expression levels in mAT. Ankrd26 mRNA levels were measured 
performing absolute cDNA quantification by qPCR analysis. Data are shown as copy number 
variation (CNV) of Ankrd26 normalized on CNV of a reference gene, and are expressed in absolute 
units (AU).  Ankrd26 mRNA for standard diet (STD)- (n=6) and high fat diet (HFD)-fed (n=6) mice 
upon 22 weeks of diet regimens. (b) Asterisks denote statistically significant differences (*p<0.05 
vs STD). 
 
Moreover, real time analysis suggest that Ankrd26 mRNA levels are higher in 
the eAT than in the mAT, however the data indicate that high fat diet affects 
Ankrd26 expression at transcriptional levels and this regulation seems to be a 
specific response of VAT depots. 
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Therefore, for the first time it has been demonstrated that Ankrd26 can be 
modulated by environmental cues. 
4.4 Effect of HFD on DNA methylation at Ankrd26 promoter 
Among various biological processes, DNA methylation is one of the key 
transcriptional regulatory mechanisms governing the accessibility of transcription 
machinery to target sites, through modulation of chromatin structure. Furthermore, 
recent findings have shown that DNA methylation is an active regulatory 
mechanism responding to the changes in nutrient cues, with multiple impacts on 
the regulation of systemic energy homeostasis. 
To gain insight into the involvement of DNA methylation in the obesity-induced 
decrease of Ankrd26 expression, Methylated DNA Immunoprecipitation (MeDIP) 
assay has been adopted to investigate the DNA methylation levels of the Ankrd26 
promoter and 5’ -untraslated regions (5’ UTR) in eAT of STD- and HFD-fed mice, 
upon 22 weeks of diet regimens. The degree of DNA methylation of Ankrd26 
promoter was examined in a region positioned 500 bp upstream of Ankrd26 TSS, 
that has been arbitrarily subdivided in two segments: S1 (from -462 to -193 base 
pairs) and S2 (from -158 to +140 base pairs) (fig.14).  The results obtained showed 
a 2-fold enrichment in DNA methylation in the promoter region encompassing the 
positions -462 to -193 base pairs in obese mice compared to lean controls. 
Conversely, no DNA methylation enrichment was observed in the region located 
around the TSS, ranging from -158 to +140 base pairs. 
 
 
Figure 14. Methylation analysis of the Ankrd26 gene by MeDIP assay. Relative quantification 
of Ankrd26 promoter region DNA immunoprecipitated with anti-5meCpG in eAT of standard diet 
(STD) and high fat diet (HFD) mice. DNA immunoprecipitation was followed by qPCR 
amplification with primers spanning the 500 bp upstream the Ankrd26 TSS. Results are expressed 
as enrichment relative to input (%) and corrected for IgG control levels both at segment 1 (S1; -462 
bp/-193 bp) and segment 2 (S2; -158 bp/+140 bp) of Ankrd26 promoter region. Data are means ± 
SD from three independent experiments. Asterisks denote statistically significant differences 
(*p<0.05 vs STD).  
 
To further validate the HFD-induced DNA methylation changes occurring at the 
Ankrd26 gene and determine the specific methylation profile of 9 CpGs located in 
the promoter region that showed a more enrichment in the MeDIP signal, the 
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Ankrd26-associated differentially methylated region (DMR) has been subjected to 
bisulphite treatment and then directly sequenced. As shown in Figure 15a, this 
procedure revealed an average 10% increased DNA methylation of this region 
from HFD compared with STD-exposed mice, validating the MeDIP data. In 
particular, the DMR featured a significantly higher DNA methylation density in 2 
close cytosine residues at -436 and -431 base pairs from the Ankrd26 TSS in obese 
mice compared to lean controls (fig. 15b). In addition, plotting the combined 
percentage of the DNA methylation at these specific cytosine residues versus the 
amount of Ankrd26 mRNA revealed a strong inverse correlation (n=8, r=0.952, 
p<0.001).  
 
 
 
Figure 15. Ankrd26 promoter is specifically hyper-methylated in obese mice after 22 weeks of 
high fat diet. Graphic representation and results of the bisulphite-sequenced portion of the DMR 
relative to the Ankrd26 locus. (a) Bisulfite sequencing of Ankrd26 promoter region (-462 bp/-193 
bp) in standard diet (STD)- (n=4) and high fat diet (HFD)-fed (n=4) mice. Each horizontal row 
represents a single independent clone; the methylation percentages of 10 individual clones are 
indicated, with un-methylated (○) and methylated (●) CpG sites. CpG position relative to Ankrd26 
TSS is shown above each column. (b) Bars are means ± SD of 4 animals/group. Asterisks denote 
statistically significant differences (*p<0.05 vs STD; **p<0.01 vs STD). 
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These data indicate that HFD-induced Ankrd26 silencing in eAT of obese mice 
is accompanied by a specific increase of DNA methylation at its promoter region, 
suggesting a functional relevance of these epigenetic changes in Ankrd26 
transcriptional regulation in VAT during obesity. To clarify this point, DNA 
methylation profile of Ankrd26-associated DMR has been also analyzed in eAT of 
STD and HFD mice upon 8 weeks of diet regimens. As shown in Figure 16, not 
statistically differences were observed between STD- and HFD-fed mice, as 
expected, supporting the functional relevance of specific CpG methylation in the 
epigenetic regulation of Ankrd26 gene in murine VAT. 
 
Figure 15. Methylation analysis of Ankrd26 promoter by bisulfite sequencing in mice upon 8 
weeks of diet regimens. Graphic representation of bisulfite sequencing of Ankrd26 promoter 
region (-462 bp/-193 bp) in standard diet (STD)- (n=3) and high fat diet (HFD)-fed (n=3) mice. 
Each horizontal row represents a single independent clone; the methylation percentages of 10 
individual clones are indicated, with un-methylated (○) and methylated (●) CpG sites. CpG position 
relative to Ankrd26 TSS is shown above each column. 
4.5 Role of free fatty acids in epigenetic regulation of Ankrd26 gene 
It has well known that alterations in the extracellular milieu, including elevated 
free fatty acids and hyperleptinemia, are features of DIO mice, when they are 
weaned onto HFD [104]. To investigate whether diet-induced obesity or specific 
fats is responsible for the changes in Ankrd26 expression and methylation 
associated to HFD exposure, cultured 3T3-L1 mature adipocytes have been used 
and screened for putative factors involved in Ankrd26 methylation. 
Supplementation of the culture medium with 0.25 mM palmitate, a major 
component of the HFD, decreased Ankrd26 expression (fig. 17a) and increased its 
promoter methylation (fig. 17c) to a similar extent as that observed in eAT from 
HFD-treated mice. Medium supplementation with 0.25 mM oleate or 100 nM 
leptin did not elicit any significant effect (fig. 17a-d). These results provide further 
evidence of high CpG methylation in murine adipocyte fraction and, collectively, 
demonstrate that the transcriptional repression accompanying the epigenetic 
dysregulation of Ankrd26 may have been, at least in part, caused by the saturated 
fat enrichment of the diet rather than representing a consequence of obesity.  
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Figure 17. Ankrd26 expression and DNA methylation changes in mature adipocytes upon 
treatment with palmitate or oleate for 96 h, or leptin for 24 h. 3T3-L1 mature adipocytes were 
treated with palmitate (0.250 mM; Palm), or oleate (0.250 mM; Ole) or corresponding vehicle 
(diluent solution with the same concentrations of BSA and ethanol of the Fatty Acid/BSA complex 
solution; Vehicle) for 96 h, or treated with leptin (100 nM; Lep) or corresponding vehicle (20 mM 
Tris-HCl, pH 8.0; Vehicle) for 24 h. (a-b) Ankrd26 mRNA levels were measured performing 
relative cDNA quantification by qPCR. (c-d) Relative quantification of Ankrd26 promoter region 
DNA immunoprecipitated with anti-5meCpG in treated mature adipocytes. DNA 
immunoprecipitation was followed by qPCR amplification with primers spanning the 500 bp 
upstream the Ankrd26 TSS. Results are expressed as enrichment relative to input (%) and corrected 
for IgG control levels at segment 1 (S1; -462 bp/-193 bp) of Ankrd26 promoter region. (a-d) Data 
are means ± SD from three independent experiments. Asterisks denote statistically significant 
differences (***p<0.001 vs Vehicle).  
4.6 Methylation of specific CpG sites controls Ankrd26 gene expression 
Given that DNA methylation located within or close to the 5’  region of genes has 
been associated with regulation of gene expression [104], the effect of specific 
DNA methylation on Ankrd26 gene activity has been further investigated by using 
a CpG-free gene reporter assay. The luciferase assay has been performed in NIH-
3T3 cells transfected with in vitro methylated (me) or un-methylated (unme) 
pCpG-Ankrd26 luciferase reporter vectors, in which the selected region of the 
Ankrd26 promoter, spanning the -436, -431 and -391 CpG site, was cloned. The 
un-methylated portion of Ankrd26 promoter induced a 2.5-fold increase of 
luciferase activity compared to the empty vector (fig. 18a) demonstrating, for the 
first time, that the region from -733 to -344 is sufficient to mediate maximal 
Ankrd26 promoter activity. In addition, in vitro-methylated portion of Ankrd26 
promoter caused a 35% decrease of luciferase activity compared to the same un-
methylated construct (fig. 18a) implying the causal relationship between promoter 
DNA methylation and transcription of Ankrd26 gene. 
Next, to define whether the -436 or -431 CpG site or both is/are responsible for 
the regulation of the Ankrd26 gene activity, C→T mutations have been introduced 
at -436, -431 or -391 CpG sites into the pCpG-Ankrd26 luciferase reporter vector 
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by site-specific mutagenesis. The obtained un-methylated mutagenized constructs 
have been further used to perform luciferase assays in NIH-3T3 cells. The un-
methylated Ankrd26 construct mutagenized at the -436 CpG site (Ankrd26-
436unme), similarly to in vitro-methylated wild type (Wt) Ankrd26 construct, 
showed a 40% reduction of the luciferase activity when compared to un-
methylated Wt Ankrd26 construct (fig. 18b). The same data have been obtained by 
using un-methylated Ankrd26 construct mutagenized at the -431 CpG site 
(Ankrd26-431unme) (fig. 18b). Conversely, the un-methylated Ankrd26 construct 
mutagenized at the -391 CpG site (Ankrd26-391unme) did not elicit any significant 
difference in luciferase activity in comparison to un-methylated Wt 
Ankrd26construct (fig. 18b).  
Therefore, it has been demonstrated, for the first time, that DNA methylation 
influences Ankrd26 gene activity and that the transcriptional silencing effect of 
DNA methylation is mediated, at least in part, through the CpG sites located at -
436 and -431 base pairs in the promoter region. 
 
 
 
Figure 18. Suppression of the Ankrd26 promoter activity by specific CpG methylation. (a) 
Luciferase activity of un-methylated (unme) or in vitro methylated (me) or pCpG-Ankrd26 
constructs and of pCpG empty vector. Firefly luciferase activity was normalized to Renilla 
luciferase activity. Luciferase activity was measured in relative light units (RLU). Data are means 
± SD from three independent experiments. Asterisks denote statistically significant differences 
***p<0.001 vs pCpG; ###p<0.001 vs pCpG-Ankrd26unme. (b) Luciferase activity of un-
methylated mutagenized vectors: pCpG-Ankrd26-436, pCpG-Ankrd26-431 and pCpG-Ankrd26-
391. Firefly luciferase activity was normalized to Renilla luciferase activity. Luciferase activity 
was measured in relative light units (RLU). Data are means ± SD from three independent 
experiments. Asterisks denote statistically significant differences ***p<0.001 vs Wt unme. 
4.7 DNA methylation suppresses Ankrd26 promoter activity by impairing 
the binding of co-activator/acetyltransferase p300 
Despite an ongoing debate to what extent CpG methylation is a driver of gene 
silencing or the consequence thereof, the general view is that methylation has a 
repressive effect on transcription factor (TF) binding, thus, endogenous methylated 
motifs containing a CpG at specific sites provide mechanism underlying the 
epigenetic control of TF binding and gene expression [105]. 
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To test whether methylated -436 and -431 CpG sites impair the binding of 
transcription factors, TFBIND tools has been used to analyze TF binding motifs in 
the Ankrd26 promoter, focusing on nucleotide sequence including these two 
cytosine residues. The bioinformatics analysis identified a putative binding site for 
p300, a transcriptional co-activator that acts as histone acetyltransferase and 
regulates chromatin remodeling [106]. The Ankrd26 promoter region containing 
this site spanned nucleotides −442 to −429 upstream the TSS. To examine whether 
HFD-induced DNA methylation of Ankrd26 promoter could affect p-300 binding 
affinity, quantitative Chromatin Immunoprecipitation (ChIP) assayhas been 
performed in eAT of STD- and HFD-fed mice, using p300 antibody. ChIP analysis 
showed a 40% decrease in p300 binding at Ankrd26 promoter in obese mice 
compared to lean controls (fig. 19), indicating that decreasing levels of Ankrd26 
gene in eAT are also accompanied by a lower binding affinity of p300 for the 
Ankrd26 promoter. 
 
 
 
Figure 19. High fat diet impairs the binding of transcriptional co-activator p300 at Ankrd26 
promoter. Relative quantification of Ankrd26 promoter region DNA immunoprecipitated with 
anti-p300, in eAT of standard diet (STD) and high fat diet (HFD) mice, upon 22 weeks of diet 
regimens. Chromatin immunoprecipitation was followed by PCR amplification with primers 
spanning the Ankrd26 promoter region containing the putative p300 binding site. Results are 
expressed as enrichment relative to input (%) and corrected for IgG control levels. Data are means 
± SD of 3 animals/group. Asterisks denote statistically significant differences (***p<0.001 vs 
STD). 
 
To determine whether p300 directly binds its putative binding site in the Ankrd26 
promoter and the methylation of -436 and -431 CpG sites affects p300-binding 
affinity, Electrophoretic Mobility Shift Assays (EMSAs) have been performed. For 
these experiments, it has been necessary to synthesize double-stranded biotinylated 
probes containing the consensus sequence for p300, with un-methylated, 
methylated or C→T mutated -436 and -431 CpG sites. Super shift EMSAs with 
p300 antibody showed that p300 had a strong binding to un-methylated Wt probe, 
as indicated by the super-shift of one of the complexes formed by the interaction 
of the probe with the nuclear extract (NE) from NIH-3T3 cells (fig. 20a, lane 3).  
Moreover, the presence of an un-methylated competitor to the probe/NE mix 
effectively displaced p300 binding to the probe (fig. 20b, lane 3), while the 
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probe/p300 complex was not affected by the addition of both a methylated (fig. 
19b, lane 4) or a mutagenized competitor (fig. 20b, lane 5). These results indicate 
that: i. p300 binds to its consensus sequence in the Ankrd26 promoter; and, -436 
and -431 cytosine residues have functional significance in p300-binding affinity. 
 
 
 
 
 
Figure 20. Methylation of -436 and -431 CpG site affects p300-binding affinity to Ankrd26 
promoter. Representative Electrophoretic Mobility Shift Assays (EMSA) for double-stranded 
biotinylated Ankrd26 probe with Nuclear Extract (NE) from NIH-3T3 cells. (a) Super-shift EMSA 
with p300 antibody (lane 3) or a rabbit IgG (lane 4). (b) Competition EMSAs with 200-fold molar 
excess of un-labeled un-methylated (unme; lane 3), methylated (me; lane 4) or mutagenized (mut; 
lane 5) competitor. 
 
To examine whether p300-binding site is crucial for Ankrd26 promoter 
activation, a p300 expression vector has been co-transfected into NIH-3T3 cells 
along with un-methylated or methylated pCpG-Ankrd26 luciferase reporter 
vectors. The promoter activity of un-methylated Ankrd26 construct was increased 
3-fold in the presence of p300 (fig. 21). At variance, when p300 was over-
expressed, the luciferase activity of the methylated Ankrd26 construct was 60% 
lower compared to the un-methylated Ankrd26 construct (fig. 21).  
All together, these data indicate, for the first time, that p300 regulates Ankrd26 
promoter activation and its binding is dependent on the methylation state of the -
436 and -431 cytosine residues. 
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Figure 21. Methylation inhibits Ankrd26 promoter activity by impairing binding of p300.  
Luciferase activity of un-methylated (unme) or in vitro methylated (me) pCpG-Ankrd26 construct, 
in NIH-3T3 cells co-transfected with pCl.p300 vector. Firefly luciferase activity was normalized to 
Renilla luciferase activity. Luciferase activity was measured in relative light units (RLU). Data are 
means ± SD from three independent experiments. Asterisks denote statistically significant 
differences (***p<0.001 vs pCpG-Ankrd26 unme; ###p<0.001 vs pCpG-Ankrd26 unme+pCl.p300; 
§§§p<0.001 vs pCpG-Ankrd26 me). 
4.8 HFD-induced differential recruitment of DNMTs and MBD2 initiates 
the repression and silencing of Ankrd26 gene  
DNA methylation of Ankrd26 promoter influences binding of p300 to DNA, both 
in vitro and in vivo, potentially leading changes in the occupancy and activity of 
TFs and/or epigenetic modifying enzymes based on methylation of their 
recognition motifs. Thus, ChIP assays have been performed to analyze the 
molecular events upstream the methylation-induced displacement of p300 binding 
to Ankrd26 promoter.  
First, it has been verified which DNMTs among the three isoforms in mammals, 
DNMT1, DNMT3a and DNMT3b [72], were responsible for the HFD-induced 
hyper-methylation of Ankrd26 promoter. ChIP analysis showed that the levels of 
DNMT3a and DNMT3b binding observed at the Ankrd26 promoter was 
significantly increased in eAT from the obese mice compared to lean controls 
(p<0.001), whereas no changes were observed in the levels of DNMT1 binding (fig. 22a). 
Then, to get further insight into the functional role of the HFD-induced hyper-
methylation on TF occupancy at Ankrd26 promoter, ChIP assay has been 
performed to identify the enrichment of methylation-dependent transcriptional 
repressor MBD2 [70]. Interestingly, as shown in Figure 22b, significantly 
increased levels of MBD2 binding were detected in obese mice compared to 
control diet group (p<0.01) at the same specific region of Ankrd26 promoter.  
These results imply that the HFD-induced hyper-methylation of Ankrd26 
promoter is mediated, at least in part, by epigenetic targets, such as de novo 
DNMTs and MBD2.     
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Figure 22. Changes in DNMTs and MBD2 binding at Ankrd26 promoter in DIO mice. Relative 
quantification of Ankrd26 promoter region immunoprecipitated with anti -DNMT1, -DNMT3a, -
DNMT3b and -MBD22 antibodies, in eAT of standard diet (STD) and high fat diet (HFD) mice, 
after 22 weeks of feeding. Chromatin immunoprecipitation was followed by PCR amplification 
with primers spanning the Ankrd26 promoter region from -553 to -348 base pairs relative the TSS. 
Results are expressed as enrichment relative to input (%) and corrected for IgG control levels. Data 
are means ± SD of 3 animals/group. Asterisks denote statistically significant differences 
(***p<0.001 vs STD; **p<0.01 vs STD). 
4.9 HFD increases nucleosome occupancy at the Ankrd26 promoter 
It is well demonstrated, also here, that methylated CpG dinucleotides can be 
recognized by methyl-CpG domain–binding proteins, some of which can recruit 
histone deacetylases and are thought to promote local chromatin condensation 
[105]. To analyze the dynamics of chromatin organization at Ankrd26 promoter in 
eAT, upon HFD administration, Micrococcal Nuclease (MNase) assays have been 
performed on 300 base pairs upstream Ankrd26 TSS.   
Many studies indicated that nucleosome organization is somewhat non-random 
and some regions of the genome are more likely to contain nucleosomes than 
others. Thus, to predict nucleosome occupancy at Ankrd26 promoter, a further 
bioinformatics analysis of its nucleotide sequence has been performed, by using 
the NuPoP software. This tool predicted 2 nucleosomes (Nuc), Nuc-2 (-288 bp/-
132 bp) and Nuc-1 (-105 bp/+41 bp), positioned between the p300 consensus 
sequence and the Ankrd26 TSS, that were analyzed. 
After nuclei isolation and MNase digestion, nucleosome-protected DNA was 
evaluated by qPCR and the data are represented as the percentage of the loss of 
amplification following MNase digestion. As shown in Figure 23, in eAT of the 
HFD-fed mice, the Ankrd26 promoter region upstream of the TSS showed a 
reduced MNase sensitivity, reported as a higher nucleosome-bound DNA in the 
analyzed Nuc-2 and Nuc-1 fragments, thus suggesting a more condensed 
chromatin conformation compared to their control mice.    
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Figure 23. MNase assays upon HFD administration. Micrococcal Nuclease (MNase) analysis 
was performed in eAT of standard diet (STD) and high fat diet (HFD) mice, after 22 weeks of 
feeding. After MNase digestion, nucleosome-bound DNA was analyzed by qPCR and normalized 
to not digested DNA. Nuc-2: from -257 to – 198; Nuc-2: from -84 to -25; (distance is relative to 
Ankrd26 transcription start site). Data are means ± SD of 3 animals/group. Asterisks denote 
statistically significant differences (**p<0.01 vs STD).  
4.10 HFD changes histone acetylation and RNA Pol II binding at the 
Ankrd26 promoter  
Transcriptional repression and gene silencing are dynamic processes involving 
the conversion of the transcription factor-accessible euchromatin into the closed   
chromatin [105]. A key role in these processes is played by histone modifications.  
Their presence or absence may create or disrupt chromatin contacts. Among the 
modifications of different histones, those on histones H3 and H4 are the most 
studied and involved in the regulation of gene expression [66,82]. Moreover, 
regulation of histone modifications has been shown to be influenced by nutrients 
[82]. 
Therefore, this evidence suggests that decreased Ankrd26 expression in eAT of 
mice exposed to long-term HFD may be the result of specific histone 
modifications, occurring at its promoter, associated to reduced gene transcription. 
To test this hypothesis, ChIP assays have been performed to evaluate both the 
levels of histone 4 acetylation of lysine 16 (AcH4K16) on the regions of Ankrd26 
promoter with reduced MNase sensitivity (Nuc-2 and Nuc-1), and the RNA Pol II 
binding at the region encompassing the Ankrd26 TSS (fig. 24). Consistently, ChIP 
analysis showed that HFD feeding significantly lowered histone H4 acetylation at 
both nucleosomes (p<0.001; fig. 24a) and RNA Pol II binding to the Ankrd26 TSS 
(p<0.001; fig. 24b) in the obese mice compared to lean controls, upon 22 weeks of 
feeding. Thus, all together these data suggest that, with development of obesity, 
DNA methylation, through complicated mechanism involving multiple 
modifications, as the recruitment of HDAC by the bound of MBD2, reduces the 
acetylation of histone H4 and RNA Pol II binding at the Ankrd26 promoter and 
tightly compacts the nucleosomes, leading to a transcriptionally repressed state. 
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Figure 24. Changes in histone H4 acetylation and RNA Pol II binding at the Ankrd26 
promoter in DIO mice. Relative quantification of Ankrd26 promoter region immunoprecipitated 
with anti -AcH4K16 and -RNA Pol II antibodies, in eAT of standard diet (STD) and high fat diet 
(HFD) mice, after 22 weeks of feeding. (a) Chromatin immunoprecipitation with anti-AcH4K16 
antibody was followed by PCR amplification with primers spanning the Nuc-2 (-257 bp/-198 bp) 
and Nuc-1 (-84 bp/-25 bp) fragments. (b) Chromatin immunoprecipitation with anti-RNA Pol II 
antibody was followed by PCR amplification with primers spanning the Ankrd26 promoter region 
from +16 to +159 base pairs relative the TSS. (a-b) Results are expressed as enrichment relative to 
input (%) and corrected for IgG control levels. Data are means ± SD of 3 animals/group. Asterisks 
denote statistically significant differences (***p<0.001 vs STD). 
4.11 Ankrd26 silencing induces a pro-inflammatory cytokine profile in 
cultured adipocytes 
Chronic inflammation is a common feature of obesity, and, it has been well 
demonstrated that inflammatory signals may originate within VAT as this fat depot 
expands in response to chronic positive energy balance. Both adipocytes and 
macrophages within fat secrete numerous hormones and cytokines that contribute 
to local inflammation within adipose tissue and may be the sentinel event that 
causes systemic insulin resistance and systemic inflammation [107]. A growing 
body of evidence shows that the inciting event that causes adipose tissue to become 
inflamed as it expands has a significant epigenetic component, potentially 
accounting for some of the variance in metabolic risk between equivalently obese 
individuals. 
To examine whether the Ankrd26 hyper-methylation induced by caloric overload 
is involved in the obesity-related adipocyte pro-inflammatory response, Ankrd26 
gene has been specifically knockdown in mature adipocytes. In particular, in order 
to mimick the HFD-induced epigenetic silencing of Ankrd26 in vitro, its 
expression has been reduced by 35% in the siRNA transfected 3T3-L1 adipocytes. 
The efficacy of transfection was analyzed by qRT-PC and the data presented in 
Figure 25a.  
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Figure 25. Effect of Ankrd26 gene silencing on pro-inflammatory mediators mature 
adipocytes. 3T3-L1 mature adipocytes were silenced with 25 nmol/l of scrambled-siRNA or 
Ankrd26-siRNA for 48 h. Un-transfected cells were used to exclude transfection interference on 
gene expression. Ankrd26 (a), Eotaxin (b), Mcp1 (c), Kc/Il-8 (d) and Rantes (e) mRNA levels were 
evaluated at the end of the experiment and expressed in Relative Expression Units (REU). Data are 
mean ± SD of determinations from three independent experiments. ***p<0.001, vs Un-trasfected; 
###p<0.001, vs Scrambled-siRNA.   
 
Table 6 also shows the effect of Ankrd26 knockdown on secretion of pro-
inflammatory mediators. When compared to Scrambled-siRNA cells, Ankrd26-
siRNA adipocytes showed significant increase of secretion of pro-inflammatory 
chemokines, Keratinocyte-derived Cytokine/Interleukine 8 (KC/IL-8), Eotaxin, 
MCP1 and Rantes. Similarly, mRNA levels of Eotaxin and Mcp1 were also 
significantly increased in Ankrd26-deficient cells; however, the increase of Kc/Il-
8 and Rantes mRNA expression just failed to reach significance (fig. 25b-e). These 
results strongly support the physiopathological role of Ankrd26 in regulating 
adipocyte pro-inflammatory secretion profile through effects occurring at different 
levels. 
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Variable 
3T3-L1 Adipocytes 
Un-transfected Scrambled-siRNA Ankrd26-siRNA 
Eotaxin (pg/ml) 514.34 ± 73.25 521.16 ± 82.90 705.92 ± 98.99b,d 
G-CSF (pg/ml) 6.45 ± 0.96 7.11 ± 0.22 7.14 ± 0.90 
IL-4 (pg/ml) 3.41 ± 0.32 3.21 ± 0.44 3.81 ± 0.51 
IL-5 (pg/ml) 0.88 ± 0.14 0.79 ± 0.16 0.83 ± 0.33 
KC/IL-8 (pg/ml) 565.39 ± 15.32 588.67 ± 30.86 702.58 ± 34.08a,c 
IL-17 (pg/ml) 1.44 ± 0.62 1.72 ± 0.51 1.56 ± 0.42 
MCP1 (pg/ml) 1758.04 ± 72.31  1718.77 ± 248.29  2500.31 ± 225.38b,d 
MIP1β (pg/ml) 1.32 ± 0.75 1.14 ± 0.52 1.17 ± 0.37 
Rantes (pg/ml) 27.95 ± 2.74 33.31 ± 8.88 53.45 ± 2.35b,d 
TNFα (pg/ml) 4.98 ± 1.46 5.29 ± 1.31 5.57 ± 1.81 
 
Table 6. Effect of Ankrd26 gene silencing on adipocyte-released chemokines/cytokines. 3T3-
L1 mature adipocytes were silenced with 25 nmol/l of Scrambled-siRNA or Ankrd26-siRNA for 
48 h. Conditioned media were collected for 24 h in Dulbecco's modified Eagle's medium without 
serum and with 0.5% BSA. Secreted adipokines were then assayed using the Bio-Plex Pro Mouse 
Cytokine Immunoassay. Un-transfected cells were also used to exclude transfection interference 
on adipokine secretion. Detectable adipokines are reported. Data are mean ± SD of determinations 
from three independent experiments. ap<0.001 and bp<0.01, vs Un-transfected; cp<0.001 and 
dp<0.01, vs Scrambled-siRNA.  Granulocyte-colony stimulating factor, G-CSF; Interleukin, IL; 
Keratinocyte-derived Cytokine/Interleukine 8, KC/IL-8; Monocyte chemotactic protein 1, MCP1; 
Macrophage inflammatory protein 1 beta, MIP1β; Tumor necrosis factor alpha, TNFα. 
4.12 ANKRD26 expression negatively correlates with BMI and 
inflammatory markers in obese subjects 
Together, these data along with findings emerging from other studies [88,97,99], 
led to speculate the possibility of potential role of ANKRD26 gene for human 
obesity.  To address this hypothesis, the correlation between mRNA expression of 
ANKRD26 in VAT and BMI or inflammatory parameters has been examined in 
normal glucose tolerant (NGT) obese subjects (tab. 4). Interestingly, in human 
VAT, ANKRD26 expression was not only negatively correlated with BMI (fig. 
26a), but also negatively associated with serum levels of pro-inflammatory 
chemokines IL-8 and RANTES, as well as of inflammatory markers IL-6 and C-
reactive protein (CRP) (fig. 6b-e), findings that further support the potential role 
of reduced ANKRD26 gene expression in VAT to mediate the obesity-related 
inflammatory status. 
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Figure 26. Correlation between VAT ANKRD26 mRNA expression and BMI or systemic 
inflammatory markers in obese subjects. Correlations between VAT ANKRD26 mRNA 
expression and BMI (a) or serum levels of IL-8 (b), RANTES (c), IL-6 (d) or CRP (e) in normal 
glucose tolerant obese individuals (n=11; 5M/6F). r, Pearson’ s coefficient; p˂0.05 was considered 
statistically significant. 
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5. DISCUSSION 
 
 
Epigenetic modifications are responsible for chromatin structure and stability as 
well as the modulation of tissue-specific gene expression, thus, epigenetics may be 
an important contributor to many chronic diseases including obesity [39-41,82]. 
The relationship between obesity and the epigenetic regulation of gene expression 
has been widely reported, and DNA methylation of promoter regions of several 
genes has been demonstrated to change upon the development of obesity in animal 
models and humans [58]. Notably, DNA methylation is the only known epigenetic 
modification that targets DNA itself and is usually associated with gene silencing 
[82] and appears to be dynamically regulated responding to changes in nutrients 
cues, such as fat and high-calorie diets, affecting systemic energy homeostasis both 
in humans and rodents [108].   
Interestingly, in this current study, a negative functional relationship has been 
demonstrated between DNA methylation of the Ankrd26 promoter and Ankrd26 
gene transcription, in the visceral adipose tissue of DIO mice. Indeed, in eAT of 
obese mice, the methylation percentage at specific CpG sites at the Ankrd26 
promoter and the binding of de novo DNMT3a and DNMT3b to this same 
promoter region were increased together with an increase of MBD2 binding and a 
decrease in bound RNA Pol II. All these changes were followed by down-
regulation of Ankrd26 expression in the eAT, demonstrating that the long-term 
HFD exposure simultaneously changes DNA methylation and expression of 
Ankrd26 genes. The transcriptional repression accompanying the epigenetic 
dysregulation of Ankrd26 may have been, at least in part, caused by the saturated 
fat enrichment of the diet rather than representing a consequence of obesity, as it 
can be mimicked by exposing 3T3-L1 adipocytes to palmitate. It remains possible, 
however, that obesity per se or specific obesity-associated traits further contribute 
to Ankrd26 dysregulation. 
The evidence that the specific cytosine hyper-methylation at the Ankrd26 
promoter appeared in eAT of obese mice after a prolonged HFD feeding, but not 
at earliest time-point, emphasize the role of chronic exposure to HFD in the 
epigenetic regulation of Ankrd26 gene. This time-dependent effect may contribute 
to the adipose tissue functional changes and remodeling that accompany weight 
gain determined by HFD exposure. Indeed, eAT, along with other VAT depots, 
contributes to the inflammatory and metabolic complications in murine obesity 
[109], and responds to HFD through specific time-dependent changes [30,110]. 
Upon early HFD exposure (8-12 weeks), eAT expansion is accompanied by a 
major increase in adipocyte size. Instead, after more prolonged HFD exposure (20 
weeks), eAT expansion is mainly sustained by increased adipogenesis and is 
accompanied by enhanced secretion of inflammatory mediators, including TNFα, 
IL-6, MCP1 and Rantes [30,31,110]. The mechanisms triggering this 
compensatory response of eAT have not been clarified yet. However, the present 
work shows, for the first time, that they may include the HFD-induced Ankrd26 
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down-regulation.  
Along with its role in the control of feeding behavior and body fat accumulation 
[92-94], Ankrd26 has been identified as a regulator of adipogenesis in vitro 
[95,96]. Firstly, adipogenesis of 3T3-L1 cells is enhanced by selective silencing of 
the Ankrd26 gene with an Ankrd26-specific shRNA [95]. Secondly, Mouse 
Embryonic Fibroblasts from Ankrd26 mutant mice (MEFs Ankrd26-/-) have a 
higher rate of adipocyte differentiation. The expression of the master regulator 
genes of differentiation process, CCAAT enhancer-binding protein α (C/ebpα), 
and Peroxisome proliferator-activated receptor γ (Pparγ), are up-regulated in 
MEFs Ankrd26-/-, indicating that this gene is involved in regulating both the pre-
adipocyte commitment and differentiation [96]. In addition, in this work, the 
enhanced expression and/or secretion of the pro-inflammatory mediators Eotaxin, 
MCP1, KC/IL-8, and Rantes by 3T3-L1 adipocytes, whose Ankrd26 expression 
was silenced to levels similar to those occurring in response to HFD, has been 
further demonstrated.  Since secretion of Eotaxin, MCP1, KC/IL-8, and Rantes by 
eAT increases upon prolonged exposure to HFD [30,110], these findings suggest 
the involvement of Ankrd26 down-regulation in raising and/or sustaining the low-
grade inflammatory response, that occurs in the eAT after long-term HFD feeding 
and is implicated in the development of insulin resistance and T2D [30,110,111]. 
The epigenetic regulation of Ankrd26 gene in VAT might represent a mechanism 
by which environmental cues are integrated at specific genomic loci, contributing 
to the metabolic disorder.  
The relevance of these observations to humans is supported by further findings 
in normal glucose tolerant obese subjects, revealing that the reduction of 
ANKRD26 expression in VAT is associated with increased serum concentrations 
of inflammatory markers and pro-inflammatory chemokines, which are related to 
obesity development in humans [112] and predict occurrence of T2D [111,113-
116]. It is still unclear which is the mechanism accounting for the Ankrd26-
mediated pro-inflammatory response of VAT, upon metabolic alterations. 
However, Cardamone et al. [117] have recently shown the relevance of cytosolic 
function of the GPS2 (G protein pathway suppressor 2), an interactor of Ankrd26 
protein [95], to the prevention of uncontrolled activation of inflammatory 
programs in human adipose tissue [117]. Thus, even though this issue deserves 
further mechanistic investigation, an intriguing hypothesis is that Ankrd26 might 
work as intracellular regulator of pro-inflammatory signaling pathways, at least in 
part, by facilitating the cytoplasmic localization of its interacting partner GPS2 
[95,117]. Therefore, ANKRD26 down-regulation might represent an early event 
triggering chronic low-grade inflammation in human adipose tissue.  
Detailed mechanistic analysis of specific methylation of -436 and -431 CpG 
dinucleotides at the Ankrd26 promoter, both in vitro and in vivo, have provided 
evidence that these two cytosine residues play a functional role in the HFD-induced 
epigenetic repression of Ankrd26 gene. Current findings support a role for 
epigenetic changes in the regulation of metabolic diseases, and, in some cases, as 
in this study, it has been well demonstrated that small DNA methylation changes 
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are associated with gene expression variability and significant effects on the 
phenotype [104,118,119]. For instance, in support of this concept, Barrès et al. 
[104] have shown that hyper-methylation of the Peroxisome proliferator-activated 
receptor γ coativator 1 α (PGC1α) promoter modulates PGC1α expression, 
implying a mechanism for decreased mitochondrial content in skeletal muscle 
from T2D patients. Also, using a gene reporter assay, these authors have 
demonstrated that the in vitro methylation of a single cytosine residue at the 
PGC1α promoter is responsible for the reduction of gene activity [104]. DNA 
methylation generally affects transcription directly, by blocking the binding of 
transcriptional activators [120,121], or indirectly, by recruiting DNA-binding 
proteins and co-repressor complexes that occupy the methylated promoters and 
facilitate the formation of heterochromatin [122]. In this study, it has been further 
demonstrated that i., in vitro, the histone acetyltransferase/transcriptional co-
activator p300 directly binds the consensus sequence at the Ankrd26 promoter, 
containing the methylation sensitive-436 and -431 cytosine residues; ii., the hyper-
methylation of these two GpG dinucleotides affects p300 binding and activity both 
in vivo and in vitro.  
p300 regulates gene expression by acetylating both histones and transcriptional 
factors and plays a key role in modulating chromatin structure and function 
[41,106]. This work has provided evidence that prolonged HFD exposure reduces 
histone H4 acetylation and increases nucleosome occupancy at the Ankrd26 
promoter, and impairs RNA Pol II binding at the Ankrd26 TSS, suggesting that the 
HFD-dependent p300 displacement from the Ankrd26 promoter initiates the 
epigenetic silencing Ankrd26 gene. These findings are consistent with recent 
studies demonstrating that CpG methylation suppresses transcription of several 
genes by direct inhibition of p300 binding to their promoter sequences [123]. In 
conjunction with the inhibition of p300 binding, HFD induced the binding of 
MBD2 to the Ankrd26 promoter in mice. MBD2 is a methyl-CpG binding protein 
that induces the silencing of target genes by recruiting histone deacetylase at their 
methylated promoters [122,124]. Accordingly, all these observations suggest that 
the specific CpG methylation at the Ankrd26 promoter lead to HFD-induced 
epigenetic silencing of Ankrd26 by triggering a cascade of events which involves 
DNA-associated regulatory proteins, such as p300 and MBD2, and that changes in 
chromatin structure.  
The relevance of the presented findings to humans is supported by very recent 
computational data from a genome-wide DNA methylation analysis of human 
adipose tissue, revealing that ANKRD26 mRNA expression is negatively 
correlated with DNA methylation at its promoter and with BMI [88]. This evidence 
supports the hypothesis that epigenetic regulation of ANKRD26 gene may occur in 
humans as well.  
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6. CONCLUSION 
 
 
This work has identified the impact of the environment on the regulation of 
Ankrd26 gene. The results have revealed that the chronic administration of a high 
fat diet in mice is able to affect Ankrd26 expression in eAT, through epigenetic 
repression of transcriptional gene activity. A schematic model of the epigenetic 
mechanisms underlying Ankrd26 gene expression is shown in Figure 27.  The 
degree of methylation of specific CpG dinucleotides at Ankrd26 promoter changes 
with development of obesity and regulates the gene expression. The promoter 
methylation by de novo DNMTs is increased together with MBD2 binding. 
Furthermore, the acetylation of histone H4 and RNA Pol II at Ankrd26 promoter 
is concomitantly reduced.   
Furthermore, this study provides new insight regarding the physio-pathological 
role of epigenetic silencing of Ankrd26 gene in pro-inflammatory response of 
visceral adipose tissue, following unhealthy dieting. Since evidence linking 
specific environmental cues and metabolic disorders are still limited, elucidating 
the mechanisms through which environmental factors can alter metabolic 
homeostasis remain a challenge. 
Therefore, highlighting how environmental cues impact on Ankrd26 expression 
and function may provide a good-model to understand more general epigenetic 
mechanisms by which nutrition interacts with the genome thereby influencing 
metabolic health. 
 
 
 
Figure 27. A schematic model of the epigenetic mechanisms underlying Ankrd26 gene 
expression in obesity.  
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Speciic CpG hyper-methylation 
leads to Ankrd26 gene down-
regulation in white adipose tissue 
of a mouse model of diet-induced 
obesity
Gregory A. Raciti1,2,*, Rosa Spinelli1,2,*, Antonella Desiderio1,2, Michele Longo1,2, 
Luca Parrillo1,2, Cecilia Nigro1,2, Vittoria D’Esposito1,2, Paola Mirra1,2, Francesca Fiory1,2, 
Vincenzo Pilone3, Pietro Forestieri4, Pietro Formisano1,2, Ira Pastan5, Claudia Miele1,2 & 
Francesco Beguinot1,2
Epigenetic modiications alter transcriptional activity and contribute to the efects of environment on 
the individual risk of obesity and Type 2 Diabetes (T2D). Here, we have estimated the in vivo efect of a 
fat-enriched diet (HFD) on the expression and the epigenetic regulation of the Ankyrin repeat domain 
26 (Ankrd26) gene, which is associated with the onset of these disorders. In visceral adipose tissue 
(VAT), HFD exposure determined a speciic hyper-methylation of Ankrd26 promoter at the −436 and 
−431 bp CpG sites (CpGs) and impaired its expression. Methylation of these 2 CpGs impaired binding 
of the histone acetyltransferase/transcriptional coactivator p300 to this same region, causing hypo-
acetylation of histone H4 at the Ankrd26 promoter and loss of binding of RNA Pol II at the Ankrd26 
Transcription Start Site (TSS). In addition, HFD increased binding of DNA methyl-transferases 
(DNMTs) 3a and 3b and methyl-CpG-binding domain protein 2 (MBD2) to the Ankrd26 promoter. More 
importantly, Ankrd26 down-regulation enhanced secretion of pro-inlammatory mediators by 3T3-L1 
adipocytes as well as in human sera. Thus, in mice, the exposure to HFD induces epigenetic silencing of 
the Ankrd26 gene, which contributes to the adipose tissue inlammatory secretion proile induced by 
high-fat regimens.
Obesity and T2D are two common non-communicable diseases, which are now reaching epidemic proportions 
globally1–3. Epigenetic processes may contribute to the development of these disorders and mediate the efects 
of environmental exposure on risk of both diseases. Indeed, studies in humans and animal models support the 
association between changes in the nutritional status, epigenetic modiications and predisposition to obesity and 
T2D4–7.
White adipose tissue (WAT) is a major endocrine tissue actively involved in the maintenance of the meta-
bolic homeostasis in response to nutrition and other environmental clues through changes in fat storage, tissue 
expansion and adipokine secretion8. In disease states, the failure of compensatory response results in an impaired 
endocrine function which leads to insulin resistance and metabolic derangement9. In particular, fat stored in 
VAT strongly correlates with metabolic alterations and has been shown to be an independent risk factor for 
obesity-associated comorbidities10–12.
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Ankrd26 was recently identiied as a gene involved in the regulation of the feeding behavior and in the devel-
opment of both obesity and T2D in mice13–15. ANKRD26 maps at chromosome 10p12 in humans, a region 
associated with certain forms of hereditary obesity16. In mice, Ankrd26 gene is highly expressed in both the 
hypothalamus and WAT and its partial inactivation induces marked hyperphagia, severe obesity and diabetes 
in vivo13,14. In addition, in vitro evidence indicates Ankrd26 as a regulator of adipogenesis17,18. A methylome anal-
ysis of mouse epididymal WAT (eAT)19, the largest and easy accessible VAT depots in rodents20,21, has identiied 
promoter hyper-methylation of Ankrd26 gene in HFD-fed compared to age- and sex-matched chow diet-fed 
mice, suggesting that Ankrd26 gene is amenable to nutritionally-induced epigenetic modiications. In this study, 
we aimed at establishing whether and how HFD modulates Ankrd26 gene expression in VAT in vivo through 
epigenetic processes.
Results
HFD afects body weight, glucose homeostasis and insulin sensitivity in mice. HFD-fed mice 
were heavier than standard chow diet (STD)-fed mice and reached a 50% increase of body weight compared 
with controls ater 22 weeks of diet regimens (Table 1). hese mice also exhibited increased fasting blood glucose 
levels, impaired glucose tolerance upon glucose loading and reduced insulin sensitivity ater insulin injection 
compared with control mice (Supplementary Fig. S1).
HFD impairs Ankrd26 expression in mice. To establish whether HFD modulates in vivo Ankrd26 expres-
sion, mRNA and protein levels were measured in eAT. Treatment with HFD for 22 weeks led to a signiicant 
decrease in both Ankrd26 mRNA (p < 0.001) and protein (p < 0.01) levels in obese mice compared with con-
trols (Fig. 1a and b). Similarly, HFD lowered Ankrd26 mRNA levels in mesenteric VAT (Supplementary Fig. S2). 
HFD treatment for 4 additional weeks did not elicit any further decrease in Ankrd26 mRNA expression in the 
HFD-fed mice (34 week-old STD, Ankrd26 mRNA: 2.29 × 10−3 ± 0.11 × 10−3 AU; 34 week-old HFD, Ankrd26 
mRNA: 1.36 × 10−3 ± 0.19 × 10−3 AU; p < 0.001). Differently from the long-term treatment, both Ankrd26 
mRNA and protein levels showed no diferences between HFD- and STD-fed mice upon 8 weeks of diet regimens 
(Supplementary Fig. S3a and b). Next, the Ankrd26 gene expression was assessed in vitro by exposing 3T3-L1 
adipocytes to either palmitate or oleate, representing saturated and unsaturated fatty acid species, which are 
abundant in the HFD, or alternatively to leptin, whose levels raise through obesity development22. Quantitative 
real-time PCR (qPCR) analysis showed that palmitate, but not oleate or leptin, reduced Ankrd26 expression by 
about 25% (Supplementary Fig. S4a and b), suggesting that, at least in part, excess of saturated fats accounts for 
HFD-induced Ankrd26 gene repression.
HFD induces DNA methylation at the Ankrd26 promoter in mice. To discover whether HFD induces 
DNA methylation changes at the Ankrd26 promoter and 5′ -untraslated region (5′ UTR), we performed Methylated 
DNA Immunoprecipitation (MeDIP) assay on pooled eAT genomic DNA from STD- and HFD-fed mice. his 
analysis revealed a 2-fold increase in DNA methylation at a segment of the promoter region (S1; − 462 bp/− 193 
bp) in HFD-fed mice, while no DNA methylation enrichment was observed in a second segment (S2; − 158 bp/ 
+ 140 bp; Fig. 1c). Consistently, palmitate but not oleate or leptin, enhanced S1 DNA methylation at the Ankrd26 
promoter in 3T3-L1 adipocytes (Supplementary Fig. S4c and d), as showed by MeDIP assay. To further deter-
mine the speciic HFD-induced DNA methylation proile occurring at 9 CpGs located at − 436 and − 221 bp 
from the Ankrd26 TSS, we adopted bisulite sequencing analysis. High CpG methylation density was detected 
in obese mice compared with controls in 2 close cytosine residues at − 436 and − 431 bp from the Ankrd26 
TSS (Fig. 1d). he combined percentage of methylation at these sites was inversely related to the amount of 
Ankrd26 mRNA (Fig. 1e). In parallel with mRNA expression, mice fed HFD or STD for 8 weeks showed no 
diference in the Ankrd26 DNA methylation state (Supplementary Fig. S3c). In addition, in 16 week-old and 
30 week-old STD-fed mice, no diference in both Ankrd26 mRNA levels (16 week-old STD, Ankrd26 mRNA: 
2.10 × 10−3 ± 0.20 × 10−3 AU; 30 week-old STD, Ankrd26 mRNA: 1.96 × 10−3 ± 0.23 × 10−3 AU; p = 0.126) and 
DNA methylation (16 week-old STD, DNA methylation: 51.7 ± 2.9%; 30 week-old STD, DNA methylation: 
51.3 ± 4.8%; p = 0.900) were observed. All together, these data indicate that the long-term exposure to calorie 
overload, rather than aging, afects eAT Ankrd26 expression and DNA methylation in mice.
Variable
16 week-old 30 week-old
STD (n = 12) HFD (n = 12) STD (n = 12) HFD (n = 12)
Body weight (g) 24.7 ± 2.1 34.4 ± 3.2a 26.4 ± 2.8 38.8 ± 3.3b,c
Fasting glucose (mmol/l) 5.9 ± 0.9 7.7 ± 1.7a 5.8 ± 1.2 9.1 ± 1.8b
GTT AUC (mmol/l 120 min−1) 725.7 ± 103.3 1290.7 ± 162.4a 653.6 ± 150.0 1344.2 ± 172.2b
ITT AUCi (mmol/l 120 min−1) 741.6 ± 127.0 355.7 ± 132.2a 681.0 ± 128.9 312.9 ± 117.6b
Table 1. Metabolic characteristics of HFD- and STD-fed mice. 8-week-old male C57BL/6 J mice were fed 
a high-fat diet (HFD) or a standard chow diet (STD) for 8 and 22 weeks. Body weight, fasting blood glucose, 
glucose tolerance test (GTT) Area Under the Curve (AUC) and insulin tolerance test (ITT) AUCi were 
reported. Data are mean ± SD of determinations. ap < 0.001, 16-week-old HFD vs 16-week-old STD; bp < 0.001, 
30-week-old HFD vs 30-week-old STD; and cp < 0.001, 30-week-old HFD vs 16-week-old HFD.
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Methylation at the CpGs −436 and −431 bp modulates Ankrd26 promoter activity. To evalu-
ate the causal relationship between the promoter DNA methylation and transcription of Ankrd26 gene, a lucif-
erase assay was performed in NIH-3T3 cells transfected with in vitro methylated (me) or un-methylated (unme) 
pCpG-Ankrd26 luciferase reporter vectors, in which a selected region of the Ankrd26 promoter was cloned, 
Figure 1. Ankrd26 expression and DNA methylation in eAT from mice upon 22 weeks of HFD or STD 
treatments. (a) qPCR of Ankrd26 mRNA for HFD- (n = 12) and STD-fed (n = 12) mice. mRNA levels are 
expressed in absolute units (AU). (b) Representative western blot for ANKRD26 and α -Tubulin. Uncut western 
blot images are in the Supplementary Fig. S5. (c) MeDIP-qPCR of segment 1 (S1; − 462 bp/− 193 bp) and 
segment 2 (S2; − 158 bp/+ 140 bp) of Ankrd26 promoter region. (d) Bisulite sequencing of Ankrd26 promoter 
region (− 436 bp/− 221 bp) in HFD- (n = 4) and STD-fed (n = 4) mice. Each row indicates sequencing results 
of ten independent clones. White circles, un-methylated CpGs; black circles, methylated CpGs. CpG position 
relative to Ankrd26 TSS is shown above each column. (e) Correlation between DNA methylation percentage 
at CpGs − 436 and − 431 bp and Ankrd26 mRNA levels. r and p values are indicated on graph. (b,c) Results are 
mean ± SD from three independent experiments. (a–c), *p < 0.05, **p < 0.01, and ***p < 0.001 vs STD.
www.nature.com/scientificreports/
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containing the CpGs − 436, − 431 and − 391 bp. he un-methylated Ankrd26 promoter induced a 2.5-fold increase 
in the luciferase activity compared with the empty vector (Fig. 2a), indicating that this selected fragment is sui-
cient to mediate promoter activity. In addition, methylation of the Ankrd26 promoter caused a 35% decrease of 
luciferase activity compared with the un-methylated Ankrd26 promoter (Fig. 2a), indicating that methylation of 
this region has a negative impact on Ankrd26 gene expression. Next, to deine whether the CpGs − 436 or − 431 
bp or both is/are responsible for the regulation of the Ankrd26 promoter activity, luciferase assays were performed 
in NIH-3T3 cells transfected with un-methylated site-speciic mutagenized vectors. he un-methylated Ankrd26 
promoter mutagenized at the − 436 bp CpG site (Ankrd26− 436unme), similarly to the wild type (Wt) methylated 
Ankrd26 promoter, showed a 40% reduction of the luciferase activity compared with the un-methylated Ankrd26 
Wt fragment (Fig. 2b). Similar data were obtained when the Ankrd26 promoter was mutagenized at the − 431 bp 
CpG site (Fig. 2b). Conversely, when the Ankrd26 promoter was mutagenized at the − 391 bp CpG site, the lucif-
erase activity of the un-methylated Ankrd26− 391 promoter was comparable to the un-methylated Wt promoter 
(Fig. 2b). hus, speciic methylation at the − 436 and − 431 bp CpGs in the Ankrd26 promoter modulates Ankrd26 
gene expression in vitro.
Figure 2. Ankrd26 promoter activity in NIH-3T3 cells. (a) Luciferase activity of pCpG-Ankrd26 constructs 
in vitro methylated (me) or un-methylated (unme) and of pCpG empty vector. Firely luciferase activity 
was normalized to Renilla luciferase activity. Luciferase activity was measured in relative light units (RLU). 
***p < 0.001 vs pCpG; ###p < 0.001 vs pCpG-Ankrd26unme. (b) Luciferase activity of unme mutagenized 
vectors, pCpG-Ankrd26-436, pCpG-Ankrd26-431 and pCpG-Ankrd26-391. Firely luciferase activity was 
normalized to Renilla luciferase activity. Luciferase activity was measured in relative light units (RLU). 
***p < 0.001 vs Wt unme. (a,b) results are mean ± SD from three independent experiments.
www.nature.com/scientificreports/
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Methylation at the CpGs −436 and −431 bp impairs p300 binding to the Ankrd26 promoter. 
DNA methylation oten induces gene silencing by inhibiting transcriptional activator binding to promoters23. 
TFBIND analysis of the Ankrd26 promoter region spanning the CpGs − 436 and − 431 bp, predicted a consensus 
sequence (− 442 bp/− 429 bp) for the histone acetyltransferase/transcriptional coactivator p30024,25. he recruit-
ment of p300 to this putative binding site and its relevance to the regulation of the Ankrd26 gene expression 
was therefore investigated. Chromatin Immunoprecipitation (ChIP) analysis showed a 40% decrease in p300 
binding to the Ankrd26 promoter in eAT of obese compared with lean mice (Fig. 3a). In addition, Electrophoretic 
Mobility Shit Assay (EMSA) with a double-stranded labeled probe containing the p300 consensus sequence 
on the Ankrd26 promoter revealed that the addition of p300 antibody to the probe/Nuclear Extract (NE) mix 
super-shited one of the complexes formed by interaction of the probe with the NE proteins (Fig. 3b). Also, the 
presence of an un-methylated competitor to the probe/NE mix efectively displaced p300 binding to the probe, 
while the probe/p300 complex was not afected by the addition of both a methylated or a mutagenized competitor 
(Fig. 3c). he in vitro over-expression of p300 in NIH-3T3 cells caused a 3-fold increase of the un-methylated 
Ankrd26 promoter activity (Fig. 3d). At variance, when p300 was over-expressed, the luciferase activity of the 
methylated Ankrd26 promoter was 60% lower compared with the un-methylated Ankrd26 promoter (Fig. 3d). All 
together, these data indicate that p300 binding to Ankrd26 promoter regulates Ankrd26 gene expression and is 
dependent on the methylation state of the CpGs − 436 and − 431 bp.
HFD induces hyper-methylation of the Ankrd26 promoter through DNMT3a and DNMT3b in 
mice. he molecular events upstream and downstream methylation-induced displacement of p300 binding 
to the Ankrd26 promoter were subsequently analyzed. ChIP analysis revealed that binding of DNMT3a and 
DNMT3b, but not of DNMT1, to the Ankrd26 promoter was increased in HFD-fed mice compared to controls 
Figure 3. p300 binding and activity on Ankrd26 promoter. (a) ChIP of p300 binding on Ankrd26 promoter in 
eAT from HFD- (n = 3) and STD-fed (n = 3) mice, upon 22 weeks of diet regimens. ChIP enrichment is relative 
to Input chromatin. ***p < 0.001 vs STD. (b,c) Representative EMSA for double-stranded biotinylated Ankrd26 
probe with Nuclear Extract (NE) from NIH-3T3 cells. Uncut gel images are in the Supplementary Fig. S5.  
(b) EMSA super-shit assay with an anti-p300 antibody (lane 3) or a rabbit IgG (lane 4). (c) EMSA competition 
assay with 200-fold molar excess of un-labeled un-methylated (unme; lane 3), methylated (me; lane 4) or 
mutagenized (mut; lane 5) competitor. (d) Luciferase activity of in vitro methylated (me) or un-methylated 
(unme) pCpG-Ankrd26 vector in NIH-3T3 cells co-transfected with pCl.p300 vector. Firely luciferase activity 
was normalized to Renilla luciferase activity. Luciferase activity was measured in relative light units (RLU). 
***p < 0.001 vs pCpG-Ankrd26 unme; ###p < 0.001 vs pCpG-Ankrd26 unme + pCl.p300; §§§p < 0.001 vs pCpG-
Ankrd26 me. (a and d), results are mean ± SD from three independent experiments.
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(Fig. 4a). Interestingly, HFD increased the binding of methylation-dependent transcriptional repressor MBD2 as 
well (Fig. 4b)23.
HFD afects histone acetylation, nucleosome positioning and RNA Pol II binding at the Ankrd26 
promoter in mice. Further analysis of the Ankrd26 promoter using the NuPoP sotware predicted 2 nucle-
osomes (Nuc), Nuc-2 (− 288 bp/− 132 bp) and Nuc-1 (− 105 bp/ + 41 bp), positioned between the p300 consensus 
sequence and the Ankrd26 TSS. Micrococcal Nuclease (MNase) treatment of eAT chromatin from HFD- and 
STD-fed mice followed by qPCR revealed that HFD rendered the Ankrd26 promoter less sensitive to nuclease 
digestion, increasing Nuc-2 and Nuc-1 positioning (Fig. 4c). Consistently, ChIP analysis showed that HFD feed-
ing signiicantly lowered histone H4 acetylation at both nucleosomes in the HFD- compared to STD-fed mice 
(p < 0.001; Fig. 4d). he RNA Pol II binding to the Ankrd26 TSS was also signiicantly lower in HFD-fed mice 
(p < 0.001; Fig. 4e). All together, these data indicate that methylation at the CpGs − 436 and − 431 bp and the 
subsequent p300 displacement from this region silenced Ankrd26 expression through nucleosome remodeling at 
the Ankrd26 promoter.
Figure 4. Epigenetic changes and protein binding at Ankrd26 promoter in eAT from mice upon 22 weeks  
of HFD. ChIP of DNMT1, DNMT3a, DNMT3b (a) and MBD2 (b) binding at Ankrd26 promoter region  
(− 553 bp/− 348 bp). (c) MNase for Nuc-2 (− 257 bp/− 198 bp) and Nuc-1 (− 84 bp/− 25 bp) occupancy at 
Ankrd26 promoter. (d) ChIP for acetyl-H4 enrichment at Nuc-2 and Nuc-1. (e) ChIP of RNA Pol II binding at 
Ankrd26 TSS (+ 16 bp/+ 159 bp). (a,b) and (d,e), ChIP enrichment is relative to Input chromatin. (a–e), results 
are mean ± SD from three independent experiments. **p < 0.01 and ***p < 0.001 vs STD.
www.nature.com/scientificreports/
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Ankrd26 silencing promotes secretion of pro-inlammatory chemokines by cultured adipo-
cytes. To assess the functional consequences of the HFD-induced epigenetic silencing of the Ankrd26 
gene, Ankrd26 mRNA was reduced by about 35% by transfecting Ankrd26-specific siRNA in 3T3-L1 adi-
pocytes (Fig. 5a). Silenced adipocytes showed enhanced secretion of the pro-inflammatory chemokines, 
Keratinocyte-derived Cytokine/Interleukine 8 (KC/IL-8), Eotaxin, Monocyte chemotactic protein 1 (MCP1) and 
Rantes (Table 2). hese changes were accompanied by increased mRNA levels of Eotaxin and Mcp1 with no 
change in Kc/Il-8 and Rantes mRNAs (Fig. 5b,c,d and e). It appeared therefore that Ankrd26 physiologically con-
trols the adipocyte pro-inlammatory secretion proile through efects occurring at diferent levels.
ANKRD26 expression negatively correlates with Body Mass Index (BMI) and inlammation 
markers in humans. mRNA expression of ANKRD26 in VAT was further examined in human obese sub-
jects (Supplementary Table S1) in relation to BMI and inlammatory parameters. Interestingly, in obese subjects 
with normal glucose tolerance (NGT), ANKRD26 expression in VAT was found to negatively correlate with BMI 
(Fig. 6a), with serum levels of the pro-inlammatory chemokines, IL-8 and RANTES and with serum levels of the 
inlammatory markers, IL-6 and C-reactive protein (CRP) (Fig. 6b,c,d and e). Altogether, these data indicate that, 
in obese humans, the reduction of ANKRD26 gene expression is associated with increased body weight and with 
a pro-inlammatory status.
Figure 5. Ankrd26 mRNA expression in Ankrd26-silenced mature adipocytes. 3T3-L1 mature adipocytes 
were silenced with 25 nmol/l of scrambled-siRNA or Ankrd26-siRNA for 48 h. Un-transfected cells were used 
to exclude transfection interference on mRNA expression. Ankrd26 (a), Eotaxin (b), Mcp1 (c), Kc/Il-8 (d) and 
Rantes (e) mRNA levels were evaluated at the end of the experiment and expressed in Relative Expression Units 
(REU). Data are mean ± SD of determinations from three independent experiments. ***p < 0.001, vs  
Un-trasfected; ###p < 0.001, vs Scrambled-siRNA.
www.nature.com/scientificreports/
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Variable
3T3-L1 Adipocytes
Un-transfected Scrambled-siRNA Ankrd26-siRNA
Eotaxin (pg/ml) 514.34 ± 73.25 521.16 ± 82.90 705.92 ± 98.99b,d
G-CSF (pg/ml) 6.45 ± 0.96 7.11 ± 0.22 7.14 ± 0.90
IL-4 (pg/ml) 3.41 ± 0.32 3.21 ± 0.44 3.81 ± 0.51
IL-5 (pg/ml) 0.88 ± 0.14 0.79 ± 0.16 0.83 ± 0.33
KC/IL-8 (pg/ml) 565.39 ± 15.32 588.67 ± 30.86 702.58 ± 34.08a,c
IL-17 (pg/ml) 1.44 ± 0.62 1.72 ± 0.51 1.56 ± 0.42
MCP1 (pg/ml) 1758.04 ± 72.31 1718.77 ± 248.29 2500.31 ± 225.38b,d
MIP1β (pg/ml) 1.32 ± 0.75 1.14 ± 0.52 1.17 ± 0.37
Rantes (pg/ml) 27.95 ± 2.74 33.31 ± 8.88 53.45 ± 2.35b,d
TNFα (pg/ml) 4.98 ± 1.46 5.29 ± 1.31 5.57 ± 1.81
Table 2. Efect of Ankrd26 gene silencing on adipocyte-released chemokines/cytokines. 3T3-L1 mature 
adipocytes were silenced with 25 nmol/l of scrambled-siRNA or Ankrd26-siRNA for 48 h. Conditioned media 
were collected for 24 h in Dulbecco’s modiied Eagle’s medium without serum and with 0.5% BSA. Adipokines 
were then assayed using the Bio-Plex Pro Mouse Cytokine Immunoassay. Un-transfected cells were also used 
to exclude transfection interference on adipokine secretion. Detectable adipokines are reported. Data are 
mean ± SD of determinations from three independent experiments. ap < 0.001 and bp < 0.01, vs Un-transfected; 
cp < 0.001 and dp < 0.01, vs Scrambled-siRNA. Granulocyte-colony stimulating factor, G-CSF; Interleukin, IL; 
Keratinocyte-derived Cytokine/Interleukine 8, KC/IL-8; Monocyte chemotactic protein 1, MCP1; Macrophage 
inlammatory protein 1 beta, MIP1β ; Tumor necrosis factor alpha, TNFα .
Figure 6. Associations between VAT ANKRD26 mRNA expression, BMI and systemic inlammatory 
parameters in humans. Correlations of the human VAT ANKRD26 mRNA expression with BMI (a) and with 
serum inlammatory markers, IL-8 (b), RANTES (c), IL-6 (d) and CRP (e) in normal glucose tolerant obese 
individuals (n = 11; 5 M/6 F). r, Pearson’s coeicient; p < 0.05 were considered statistically signiicant.
www.nature.com/scientificreports/
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Discussion
Epigenetic modiications represent a common mechanism through which both genetic and environmental expo-
sures impact on the susceptibility to obesity and T2D26–28. Recent evidence has underlined the potential impor-
tance of epigenetic regulation of gene expression and function in obesity26. Methylation changes at the promoter 
of several genes have been identiied in both human and rodent obesity29. Additionally, the exposure to high 
calorie diets, which promotes DNMT expression and enzymatic activities, impacts on DNA methylation proiles 
both at speciic genes and at genome-wide level22,30, suggesting that DNA methylation changes play a role in the 
responses to fat and high-calorie diets31.
Our study revealed HFD-induced methylation of the Ankrd26 promoter. We have no clue at the moment 
on the detailed mechanisms causing the increased methylation of Ankrd26 in HFD-fed mice, but our results 
indicate that the HFD-induced hyper-methylation at Ankrd26 promoter was concomitant with enhanced bind-
ing of de novo DNMT3a and DNMT3b to the same Ankrd26 promoter region. hese changes were followed by 
down-regulation of Ankrd26 expression in the eAT. he epigenetic silencing of Ankrd26 gene in eAT appear to 
depend, at least in part, on saturated fats, abundant in the HFD. Indeed, we found increased promoter DNA 
methylation and down-regulation of Ankrd26 in 3T3-L1 adipocytes upon exposure to palmitate, a major compo-
nent of the HFD, but not to oleate. At the variance with palmitate, cell exposure to leptin, whose serum concen-
tration increases in relation to obesity22, showed no efect on Ankrd26 expression and methylation. hese indings 
suggest that speciic nutritional components of the HFD may contribute to the epigenetic silencing of Ankrd26 
gene.
The HFD-induced changes in DNA methylation at Ankrd26 promoter and gene expression result from 
a long-term diet exposure. Indeed, cytosine hyper-methylation at the Ankrd26 promoter and gene silencing 
appeared in eAT from obese mice ater a prolonged HFD feeding, while no evident diference was observed at 
earliest time-point. his time efect was associated with the eAT compensatory remodeling occurring in response 
to HFD. Indeed, eAT, along with other VAT depots, contributes to the inlammatory and metabolic compli-
cations in murine obesity32, and responds to HFD through diferent time-dependent changes33,34. Early upon 
HFD exposure (8–12 weeks), eAT expansion is accompanied by a major increase in adipocyte size. Upon more 
prolonged HFD exposure (20 weeks), however, eAT expansion is mainly sustained by increased adipogenesis 
and accompanied by enhanced secretion of inlammatory mediators, including Tumor necrosis factor alpha 
(TNF-α), IL-6, MCP1 and Rantes33–35. he mechanisms triggering this compensatory response in eAT have not 
been clariied yet but the present work now shows that they may involve HFD-induced Ankrd26 down-regulation. 
Along with its role in feeding behavior and body fat accumulation13–15, Ankrd26 has been identiied as a regu-
lator of adipogenesis in vitro17,18. Firstly, adipogenesis of 3T3-L1 cells is enhanced by selective silencing of the 
Ankrd26 gene with an Ankrd26-speciic shRNA18. Secondly, Mouse Embryonic Fibroblasts from Ankrd26 mutant 
mice (MEFs Ankrd26−/−) have a higher rate of adipocyte diferentiation. Indeed, the mRNA expression of the 
master regulator genes of diferentiation process, CCAAT enhancer-binding protein α (C/ebpα), and Peroxisome 
proliferator-activated receptor γ (Pparγ), are up-regulated in MEFs Ankrd26−/−, indicating that this gene is 
involved in regulating both the pre-adipocyte commitment and diferentiation17.
In this work, we further demonstrated enhanced expression and/or secretion of the pro-inflammatory 
chemokines Eotaxin, MCP1, KC/IL-8, and Rantes by 3T3-L1 adipocytes whose Ankrd26 expression was silenced 
to levels similar to those occurring in response to HFD. hese cytokines have been reported to contribute to adi-
pose tissue inlammation36,37. Since secretion of Eotaxin, MCP1, KC/IL-8, and Rantes by the eAT also increases 
upon prolonged exposure to HFD33,34, our indings suggest the involvement of Ankrd26 down-regulation in rais-
ing and/or sustaining the low-grade inlammatory response which occursin the eAT ater long-termHFD feeding 
and is implicated in the development of insulin resistance and T2D33–35. his might represent a mechanism by 
which environmental cues are integrated at speciic genomic loci, contributing to the metabolic disorder. he 
relevance of these observations to humans is supported by our further indings in obese individuals with nor-
mal glucose tolerance, revealing that the reduction of ANKRD26 expression in VAT negatively correlates with 
the serum concentrations of inlammatory markers and pro-inlammatory chemokines, which are associated to 
obesity in humans38,39 and whose increased levels predict occurrence of T2D38–43. Cardamone et al. have recently 
shown in the adipose tissue the relevance of the cytosolic function of the Ankrd26 partner GPS2 (G protein path-
way suppressor 2) to the prevention of uncontrolled activation of inlammatory programs44. Even though this 
issue deserves further mechanistic investigation, we suggest that Ankrd26 might work as a molecular regulator 
of inlammatory signaling pathways, at least in part, by facilitating the cytoplasmic localization of its interact-
ing partner GPS218. herefore, ANKRD26 down-regulation might represent an early event triggering chronic 
low-grade inlammatory response in human adipose tissue.
Detailed methylation analysis of the Ankrd26 promoter showed that HFD induced speciic methylations at 
− 436 and − 431 bp CpGs, thereby exerting a suppressive efect on Ankrd26 promoter activity. Similar to DNA 
methylation, mutagenesis at the Ankrd26 promoter showed that introduction of C → T mutation at − 436 or − 431 
bp CpGs signiicantly reduces Ankrd26 promoter activity. hese results provide evidence that i., these cytosine 
residues have functional signiicance to the Ankrd26 gene expression; and ii., the DNA methylation at these spe-
ciic CpGs plays a functional role in the epigenetic repression of Ankrd26 gene.
Current evidence supports a role for epigenetic changes in the regulation of metabolic diseases and in some 
cases, as in our study, it has been demonstrated that small methylation changes are associated with gene expres-
sion variability with signiicant efects on the phenotype45–48. In support of this concept, Barrès et al.46 have 
recently shown that hyper-methylation of the Peroxisome proliferator-activated receptor γ coativator 1 α (PGC1α) 
promoter modulates PGC1α expression, implying a mechanism for decreased mitochondrial content in skeletal 
muscle from T2D patients. Also, using a gene reporter assay, these same authors have demonstrated that the 
in vitro methylation of a single cytosine residue at the PGC1α promoter is responsible for the reduction of gene 
activity46.
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CpG methylation generally afects transcription directly, by blocking the binding of transcriptional activators24,49, 
or indirectly, by recruiting DNA-binding proteins and co-repressor complexes that occupy the methylated pro-
moters and facilitate the formation of heterochromatin50. In this study, we have further demonstrated that i., 
in vitro, the histone acetyltransferase/transcriptional coactivator p300 directly binds the consensus sequence at 
the Ankrd26 promoter, containing the methylation sensitive cytosines − 436 and − 431 bp; ii., hyper-methylation 
of these sites afects p300 binding and activity in vivo and in vitro. p300 regulates gene expression by acetylating 
both histones and transcriptional factors and plays a key role in modulating chromatin structure and function25,26. 
In this paper, we have also reported that HFD reduces histone H4 acetylation, increases nucleosome occupancy at 
the Ankrd26 promoter, and impairs RNA Pol II binding to the Ankrd26 TSS, suggesting that the HFD-dependent 
p300 displacement from the Ankrd26 promoter silences Ankrd26 gene. hese indings are consistent with recent 
studies demonstrating that CpG methylation suppresses transcription of several genes by direct inhibition of 
p300 binding to their promoter sequences51–53. In conjunction with the inhibition of p300 binding, HFD induced 
the binding of MBD2 to the Ankrd26 promoter in mice. MBD2 is a methyl-CpG binding protein and causes 
gene silencing by recruiting histone deacetylase at the methylated promoter regions31,50. Accordingly, we propose 
that the speciic CpG methylation at the Ankrd26 promoter leads to HFD-induced epigenetic gene silencing by 
triggering a cascade of events which involves DNA-associated regulatory proteins, such as p300 and MBD2, and 
changes in chromatin structure.
he potential relevance to humans of the indings reported in the present work is supported by our further 
evidence that VAT ANKRD26 mRNA levels were negatively correlated with BMI in humans. Consistent with our 
results, very recent computational data from a genome-wide DNA methylation analysis in human adipose tissue 
have revealed that ANKRD26 DNA methylation and mRNA expression correlate with BMI53. hus, epigenetic 
regulation of ANKRD26 gene may occur in humans as well.
In conclusion, our work reveals that the methylation of speciic CpGs at the Ankrd26 promoter occurs in mice 
during HFD treatment and causes the down-regulation of Ankrd26 expression, at least in part, by impairing p300 
binding to its promoter. We propose that the epigenetic silencing of the Ankrd26 gene contributes to VAT inlam-
mation following unhealthy dieting.
Methods
Animals, diets and tests. Animal experiments were performed in accordance with the Guide for the Care 
and Use of Laboratory Animals published by the National Institutes of Health (publication no. 85–23, revised 
1996). Protocols were approved by the ethics committee of the “Federico II” University of Naples. Six-week-
old C57BL/6 J male mice (n = 48) from Charles River Laboratories International, Inc. (Wilmington, MA) were 
housed in a temperature-controlled (22 °C) room with a 12 h light/dark cycle. Two weeks ater arrival, mice were 
randomly divided into two groups of 12 mice each and were fed either a HFD (60 kcal% fat content; Research 
Diets formulas D12331; Research Diets, Inc., New Brunswick, NJ) or a standard chow diet (STD; 11 kcal% fat 
content; Research Diets formulas D12329; Research Diets, Inc.) for 8 and 22 weeks. he composition of these 
diets is reported in Supplementary Table S2. Body weight was recorded weekly throughout the study. he glucose 
tolerance test (GTT) and insulin tolerance test (ITT) were performed as described14,16. Blood glucose levels were 
measured using a glucometer (One Touch Lifescan, Milan, Italy). Mice were killed by cervical dislocation. eAT 
was collected from each mouse, snap frozen in liquid nitrogen and stored at − 80 °C.
Quantitative real-time PCR (qPCR) and western blot analysis. Tissues were homogenized by 
TissueLyser LT (Qiagen, Hilden, Germany) following manufacturer’s protocol. RNA and DNA were isolated 
using AllPrep DNA/RNA/miRNA Universal kit (Qiagen). cDNA synthesis and qPCR were performed as 
described19,54. Immunoblotting was carried out as indicated14. Antibodies against ANKRD26 (#SC-82505, Santa 
Cruz Biotechnology, Inc., Dallas, TX), and α -Tubulin (#MA1-19162, Sigma-Aldrich, St. Louis, MO) were used 
for protein detection.
Methylated DNA Immuoprecipitation (MeDIP). MeDIP assay was performed as described19. DNA 
methylation enrichment was evaluated on genomic DNA isolated from eAT of STD- and HFD-fed mice and 
from 3T3-L1 adipocytes. Sonicated pooled genomic DNA from eAT or cells was immuno-precipitated using 
anti-5meCpG (#ab10805, Abcam, Cambridge, MA) or mouse IgG (#I8765, Sigma-Aldrich) with anti-mouse IgG 
beads (Life Technologies, Carlsbad, CA). DNA methylation enrichment on recovered DNA was evaluated by 
qPCR. Samples were normalized to their respective input using the 2−∆CT method.
Bisulfite sequencing. For bisulfite sequencing analysis, we used genomic DNA isolated from eAT of 
STD- and HFD-fed mice. Bisulite conversion of DNA was performed with the EZ DNA Methylation Kit (Zymo 
Research, Orange, CA), following manufacturer’s instructions. Converted DNA was ampliied by PCR. PCR 
products were cloned into the pGEM T-Easy vector (Promega, Madison, WI) and 10 clones for sample were 
sequenced on AB 3500 genetic analyzer (Life Technologies). DNA methylation percentage at the − 436 and − 431 
bp CpGs for each mouse was calculated using the formula: DNA methylation % = [methylated CpGs/(methylated 
CpGs + unmethylated CpGs)]*100.
Cloning strategy, site-direct mutagenesis and in vitro methylation. Ankrd26 promoter (− 733 
bp/− 344 bp) was ampliied by PCR. he puriied PCR fragment was cloned into the irely luciferase reporter 
pCpGfree-promoter-Lucia vector (Invivogen, Toulouse, France). he following site-speciic mutated constructs 
were generated by PCR-based mutagenesis: pCpG-Ankrd26-436, pCpG-Ankrd26-431, pCpG-Ankrd26-391. he 
wilde type (Wt) pCpG-Ankrd26 vector, used as template, was removed from the PCR reaction by DpnI diges-
tion (New England BioLabs, Ipswich, MA). Wt and mutated (mut) vectors were ampliied into E. coli GT115 
cells (Invivogen). Site-speciic mutagenesis of each construct was validated by sequencing. In vitro methylation 
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was performed using the M.SsI CpG methyltransferase following manufacturer’s protocol (New England 
BioLabs). Un-methylated DNA was obtained in the absence of M.SsI. Methylation was conirmed by resistance to 
HpyCH4IV digestion (New England BioLabs).
Luciferase assay. NIH-3T3 cells were transfected with methylated or un-methylated Wt or mutagenized 
pCpG-Ankrd26 vector and Renilla control vector (Promega) by lipofectamine (Life Technologies), following man-
ufacturer’s instructions. Where indicated, cells were co-transfected with pCl.p300 expression vector (Promega). 
Firely luciferase activity of each transfection was normalized for transfection eiciency against Renilla luciferase 
activity.
Chromatin Immunoprecipitation (ChIP) and Micrococcal Nuclease (MNase) assays. ChIP and 
MNase assays were performed as described55,56. Briely, 100 mg of eAT were cross-linked with 1% formalde-
hyde for 15 min at 37 °C. For ChIP assay, sonicated chromatin was immuno-precipitated with the following 
antibodies: anti-p300 (#SC-585, Santa Cruz Biotechnology), anti-Ac-H4-K16 (#07-329, Millipore, Temecula, 
CA), anti-DNMT1 (#NB100-56519) and anti-DNMT3b (#NB300-516) from Novus Biologicals (Littleton, CO), 
anti-DNMT3a (#ab2850), anti-MBD2 (#ab38646), and anti-RNA Pol II (#ab5408) from Abcam and anti-rabbit 
IgG (#I8140) and anti-mouse IgG (#I8765) from Sigma-Aldrich. For MNase assay, nuclei were isolated from 
100 mg of eAT, suspended in wash bufer (100 mmol/L Tris-HCl, 15 mmol/L NaCl, 60 mmol/L KCl, 1 mmol/L 
CaCl2) and treated with 200 U of MNase for 20 min at 37 °C. Cross-link reversal was performed at 65 °C for at 
least 16 h followed by an RNase and subsequent proteinase K digestion. DNA was puriied by phenol–chloroform. 
Samples were then run on 1% agarose gel and the resulting mononucleosomal DNA fragments (~150 bp) were gel 
puriied. For both assays, relative protein binding and nucleosome occupancy to the Ankrd26 gene were evaluated 
on recovered DNA by qPCR. Samples were normalized to their respective input using the 2−∆CT method.
Electrophoretic mobility shift assay (EMSA). Protein-DNA complexes were detected using unlabe-
led or biotin end-labeled double-stranded DNA probes by annealing complementary oligonucleotides. Biotin 
3′ -end oligonucleotides, spanning the Ankrd26 promoter sequence from − 455 bp to − 425 bp relative to the 
Ankrd26 TSS, were from Sigma-Aldrich and, where indicated, were synthesized to incorporate methylated cyto-
sines (meC). Binding reactions, consisting of biotin-labeled probe and NE, were performed using the LightShit 
kit (Thermo Fisher Scientific, Waltham, MA) following manufacturer’s instructions. Biotin-labeled probe 
(20 fmol) was added and the reaction was allowed to incubate for 20 min at room temperature. In the competi-
tion experiments, the nuclear extracts were preincubated with 200 molar excess of unlabeled probes for 20 min 
on ice. In super-shit experiments, 2 µ g of p300 antibody (#SC-585, Santa Cruz Biotechnology) or 2 µ g of rabbit 
IgG (#I8140, Sigma-Aldrich) was preincubated with nuclear extracts for 60 min on ice. Protein-DNA complexes 
were separated on native polyacrylamide gel, transferred onto nylon membrane and detected by the LightShit 
Chemiluminescent EMSA kit (hermo Fisher Scientiic) following manufacturer’s procedure.
Primer Sequences. he list of oligonucleotides used for PCR, qPCR, MeDIP, bisulite sequencing, ChIP, 
MNase, EMSA can be found as Supplementary Table S3.
Fatty Acid/BSA complex solution preparation. Palmitate and oleate have been conjugated to fatty 
acid-free BSA (2:1 molar ratio Fatty Acid/BSA) as described in ref. 57. Briely, a stock solution of palmitate 
(100 nM) was dissolved at 70 °C in 50% ethanol in a shaking water bath. In parallel, a fatty acid-free BSA solution 
was prepared at 55 °C in NaCl in a shaking water bath. Finally, the palmitate and the fatty acid-free BSA solutions 
were complexed at 55 °C in a shacking water bath, cooled to room temperature and sterile iltered. Oleate was 
complexed to the fatty acid-free BSA solutions following the same protocol. For fatty acid cell treatment, control 
adipocytes were treated with diluent only, corresponding concentrations of BSA and ethanol.
Cell culture and transfection. 3T3-L1 cells were grown and allowed to diferentiate in mature adipocytes 
as described19. Mature adipocytes were i. silenced with 25 nmol/l of scrambled-siRNA or Ankrd26-siRNA for 48 h, 
or ii. treated with palmitate (0.250 mM; Sigma-Aldrich), or oleate (0.250 mM; Sigma-Aldrich) or corresponding 
vehicle (diluent solution with the same concentrations of BSA and ethanol of the Fatty Acid/BSA complex solu-
tion) for 96 h, or iii. treated with leptin (100 nM; R&D Systems, Minneapolis, CDN) or corresponding vehicle 
(20 mM Tris-HCl, pH 8.0) for 24 h. Adipokines were assayed in media from silenced cells by Bio-Plex Pro Mouse 
Cytokine Immunoassay following the manufacturer’s protocol (Bio-Rad, Hercules, CA). Ankrd26 promoter 
methylation and gene expression were analyzed as previously described in this section.
Patient enrollment and tests. Abdominal VAT biopsies and serum samples were from patients under-
going bariatric surgery. Eleven normal glucose tolerance (NGT) obese subjects were selected. Population char-
acteristics are in Supplementary Table S1. Participants with metabolic and endocrine disorders, inlammatory 
diseases, previous or current malignancies, and/or treated with drugs able to interfere with the epigenome were 
excluded. Secreted mediators were assayed in serum samples by Bioplex multiplex Human Cytokine, Chemokine 
and Growth factor kit (Bio-Rad) following manufacturer’s protocol. ANKRD26 gene expression was analyzed in 
VAT as previously described in this section.
Ethics statement. his study adhered to the Declaration of Helsinki and has been reviewed and approved 
by the Ethics Committee of the “Federico II” University of Naples (Ethics Approval Number: No. 225_2013). 
Informed consent was obtained from all of enrolled individuals.
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Statistical procedures. he area under the curve (AUC) was calculated using the trapezoidal rule. Data are 
expressed as mean ± SD. Comparison between groups were performed using Student’s t-test or the one-way anal-
ysis of variance, as appropriate, using GraphPad Sotware (version 6.00 for Windows, La Jolla, CA). Correlation 
between two variables was calculated using the parametric Pearson r-test. p < 0.05 was considered statistically 
signiicant.
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defined epigenetics as “the branch of biology which stud-
ies the causal interactions between genes and their products 
which bring the phenotype into being” [3]. However, the 
meaning of the word has gradually changed over the following 
years, and epigenetics is known today as “the study of changes 
in gene function that are mitotically and/or meiotically herita-
ble and that do not entail a change in DNA sequence” [4]. Dif-
ferently from traditional genetics, based on cell lineages and 
clonal inheritance, epigenetic changes often occur in groups 
of cells while some epigenetic events are clonal. In addition, 
genetic changes are, almost by definition, stable, whereas epi-
genetic changes are plastic events [2]. An example of the lat-
ter concept is provided by genomic imprinting, where DNA 
methylation may be lost during development, or when persist-
ing, it is erased and re-setted during gametogenesis [5]. Epige-
netic mechanisms are plastic genomic processes that change 
genome function under endogenous and exogenous influences 
[6, 7], and may propagate modifications of gene activity from 
one cell generation to the next [8]. These mechanisms imply 
chemical modification of DNA, such as DNA methylation, 
post-traslational changes in histone proteins altering chroma-
tin conformation, and transcriptional gene silencing mediated 
by non-coding RNAs (ncRNAs) [9] (Fig. 1). Abnormalities 
in one or more of these mechanisms can lead to inappropriate 
expression or silencing of genes, resulting in imbalance of the 
epigenetic network and may result in metabolic disorders such 
as T2D and obesity [10, 11].
Epigenetic mechanisms and gene function
DNA methylation
DNA methylation is a covalent modification of DNA that 
occurs at position 5 of the cytosine pyrimidine ring [12]. 
Abstract Type 2 diabetes (T2D) and obesity are the major 
public health problems. Substantial efforts have been made 
to define loci and variants contributing to the individual risk 
of these disorders. However, the overall risk explained by 
genetic variation is very modest. Epigenetics is one of the 
fastest growing research areas in biomedicine as changes in 
the epigenome are involved in many biological processes, 
impact on the risk for several complex diseases including 
diabetes and may explain susceptibility. In this review, we 
focus on the role of DNA methylation in contributing to the 
risk of T2D and obesity.
Keywords Epigenetics · DNA methylation · Type 2 
diabetes · Obesity
Epigenetics: current status of knowledge
It is now well recognized that environmental factors including 
diet, physical activity, drugs and smoking, affect the pheno-
type and provide a major contribution to susceptibility to most 
chronic non communicable diseases [1]. Epigenetics acts at 
the interface between the genome and environmental factors, 
and might be broadly defined as the sum of all the mechanisms 
necessary to unfold the genetic program into development 
[2]. In the early 1940 s, Conrad Waddington linked genetics 
and developmental biology coining the term epigenetics. He 
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Nearly four decades ago, DNA methylation was identified 
as hotspot for spontaneous base substitutions [13]. Indeed, 
while spontaneous deamination of cytosine produces ura-
cil, a nitrogenous base that does not belong to DNA and 
that is immediately recognized and corrected by the sys-
tem of DNA repair; deamination of 5-methyl cytosine pro-
duces thymine, causes C:G to T:A transitions, and creates 
a mismatch that the system of DNA repair does not always 
preserve [10, 14]. DNA methylation is the better character-
ized epigenetic mark. In mammals, it is essential during 
development and is involved in a variety of biological pro-
cesses, including genomic imprinting and X chromosome 
inactivation [15]. DNA methylation is established during 
embryogenesis by de-methylation and de novo methyla-
tion events that can be inherited and maintained clonally 
by the action of specific enzymes termed DNA methyl-
transferases (DNMTs) [15, 16]. DNMT1 faithfully and 
symmetrically propagates cytosine methylation through 
recognition of methylated cytosines from an existing DNA 
strand to its novel partner upon replication and is primar-
ily responsible for the maintenance of DNA methylation 
in cells. DNMT3A and DNMT3B are mainly involved in 
de novo methylation and establish new methylation pat-
terns [4]. DNA methylation has long been recognized as an 
epigenetic silencing mechanism [17] which preferentially 
occurs at CpG di-nucleotides that are usually clustered in 
the CpG islands (CGIs) [18]. Quite often, un-methylated 
CpG sites at gene promoters create a transcriptionally per-
missive chromatin state by destabilizing nucleosomes and 
facilitating the recruitment of transcription factors [19]. 
On the other hand, dense DNA methylation of CpGs medi-
ates stable long-term gene silencing by direct inhibition of 
transcription factors binding or by a combination of events 
mediated by methyl-CpG binding domain proteins (MBDs) 
which recruit methylated DNA mediators of chromatin 
remodeling, such as histone deacetylases (HDACs), or 
other repressors of gene expression (Table 1) [17, 20, 21].
Histone modifications
In eukaryotic cells, nucleosomes are the repeating and 
functional structural units of chromatin. They are com-
posed of DNA wrapped around eight histone proteins, two 
homo-dimers histones H3 and H4, and two hetero-dimers 
histones H2A/H2B. Nucleosomes are mutually connected 
among themselves by the stretches of variable length of 
DNA linker conveyed by histone H1 [22, 23]. Histone 
modifications, such as acetylation, methylation, phospho-
rylation, ubiquitination, sumoylation and ADP ribosylation, 
are reversible epigenetic modifications, occurring at the 
histone tails. These modifications regulate gene expression 
by dynamically altering chromatin conformation causing 
electrostatic change and/or modulating binding proteins to 
chromatin [22, 24]. Even more extensively than other types 
of modifications, acetylation and methylation mediate for-
mation of the condensed transcriptionally silent hetero-
chromatin and of the transcriptionally active euchromatin. 
In mammalian cells, heterochromatin prevails and is gener-
ally characterized by high levels of DNA methylation and 
histone de-acetylation, and is enriched in tri-methylation of 
H3-Lys9, H3-Lys27, and H4-Lys20 [25, 26]. On the other 
hand, euchromatin exhibits lower levels of DNA methyla-
tion, and is typically enriched in acetylation of lysine resi-
dues at histones H3 and H4 and in mono- and tri-methyla-
tion of H3-Lys4 (Table 1) [27, 28].
NcRNAs
Findings over the past ten years have progressively revealed 
the relevance of ncRNAs in most epigenetically controlled 
events including modulation of gene transcription, trans-
poson activity and silencing, X-chromosome inactivation 
and paramutation [29]. NcRNAs include multiple classes 
of RNA transcripts that do not encode proteins but rather 
regulate gene expression at the post-transcriptional level 
Fig. 1  Schematic representation of epigenetic modifications. Epi-
genetic modifications include DNA methylation, histone modifica-
tions and miRNAs. DNA methylation preferentially occurs at CpG 
di-nucleotides and is generally recognized as an epigenetic silencing 
mechanism. Histone modifications, instead, influence gene expression 
by directly altering the chromatin conformation through the passage 
from a condensed transcriptionally silent heterochromatin to tran-
scriptionally active euchromatin and vice versa. Different types of 
modifications are known and include acetylation (Ac), methylation 
(Me), and phosphorylation (P) of histones tails. Finally, miRNAs act 
at post-transcriptional level by suppressing target gene expression or, 
through a non-perfect complementarity between miRNA and target 
mRNA that causes translation inhibition of the target or through near-
perfect complementarity which results in the degradation of the target 
mRNA
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[30]. The most extensively studied ncRNAs are the miR-
NAs, small RNA molecules (21–25 nucleotides in length) 
often implicated in cell- and tissue-specific differentia-
tion and development and associated to different disorders 
[31]. In the human genome, the exact number of reported 
sequences coding for these regulatory molecules contin-
ues to rise. In 2015, an analysis of 13 human cell types has 
revealed the existence of 3707 novel miRNA sequences, in 
addition to the 1900 sequences previously described [32]. 
miRNAs in the human genome are transcribed from both 
introns and exons of non-coding genes and from introns of 
protein coding genes as well [33]. In addition, some mam-
malian miRNAs derived from various transposons and pro-
cessed pseudogenes [34]. miRNAs are critical regulators 
of post-transcriptional gene expression. In particular, sup-
pression of the target gene expression mediated by miR-
NAs occurs based on the degree of complementarity of 
the miRNA with the 3’ Untranslated Region (3’UTR) of 
the target mRNA. Non-perfect complementarity between 
miRNA and target RNA, generally due to a pairing of only 
six to eight nucleotides, causes translation inhibition of the 
target mRNA, while near-perfect complementarity results 
in the degradation of the target mRNA by the RNA-induced 
silencing complex (Table 1) [35]. Interestingly, miRNAs 
are also susceptible to epigenetic modulation. Aberrant 
DNA methylation of miRNA gene promoters frequently 
occurs in human cancer and results in miRNAs expres-
sion down-regulation [36]. On the other hand, miRNAs are 
able to regulate both DNA methylation and histone modi-
fications. Indeed, miRNAs may control the expression of 
important epigenetic regulators including DNMTs and 
HDACs thereby impacting on the entire gene expression 
profile [37].
Epigenetics in T2D and obesity
T2D and obesity are common metabolic disorders, which 
have reached epidemic proportions globally [38, 39]. Popu-
lation and family (including twins) studies have extensively 
documented the familial aggregation of these diseases [40–
45] with more than 175 genetic loci conclusively associ-
ated [46, 47]. Nevertheless, the impact of these loci, even 
in combination, on risk is very modest (5–10 % for T2D 
and ~2% for body mass index, BMI), leaving the heritabil-
ity issue unsolved [48]. Technical limitations might, in part, 
account for this situation [49]. More likely, inheritance 
may be explained by epigenetics. Indeed, familial aggrega-
tion may reflect not only genetic influences, but also rep-
resent the effects of a shared family environment and thus 
of common environmentally induced epigenetic modifica-
tions [48]. In addition, while not been proved in humans 
yet, in rodents, certain environmentally induced epigenetic 
modifications can be trans-generationally transmitted to 
the offspring [50–52]. Environmentally induced epigenetic 
modifications may further explain the global epidemics of 
Table 1  Epigenetic modifications
Overview of the epigenetic modifications and of the different classes of enzymes involved in these processes
DNMTs DNA methyltransferases, TET ten–eleven translocation enzymes family, HATs histone acetyltransferases, HDACs histone deacetylases, 
HMTs histone N-methyl transferases, HDMs histone demethylases, MSK1 mitogen-and-stress activated protein kinase-1, H3 histone 3, H4 his-
tone 4, K lysine residue, S serine residue, Me2 di-methylation, Me3 tri-methylation
Epigenetic modifications Enzymes Type of modification Effect on gene expression References
DNA Methylation DNMT1
DNMT3A, DNMT3B
Methylation maintenance
de novo methylation
Suppression
Suppression
[17]
TET family De-methylation Activation [16]
Histone modifications HATs Acetylation Activation
e.g., H3K9, H3K14, H3K18, H3K56, H4K5, 
H4K8, H4K12, H4K16.
[25–28]
HDACs De-Acetylation Repression [25–28]
HMTs Methylation Activation
e.g., H3K4me2, H3K4me3, H3K36me3, 
H3K79me2
Repression
e.g., H3K9me3, H3K27me3, H4K20me3.
[25–28]
HDMs De-methylation Activation or repression based on the lysine 
residue
[25–28]
MSK1 Phosphorilation Activation
e.g., H3S28
[26]
miRNAs Non-perfect complementarity Inhibition of the mRNA target translation [35]
Perfect complementarity Degradation of the mRNA target [35]
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T2D and obesity, whose exponential rise in the past dec-
ades have been related to rapid cultural and social changes, 
such as socio-economic status, dietary changes, physical 
inactivity and unhealthy behaviors, all of which tend to 
cluster in family groups [38, 53]. Finally, epigenetics may 
help to understand the identical twin discordance for obe-
sity and T2D [54, 55]. For example, the concordance rates 
for T2D among monozygotic twins are only ~ 70 % [56]. 
In these metabolic disorders, the incomplete concordance 
may be in part due to stochastic or environmentally deter-
mined epigenetic modifications that change over the life-
time and is responsible for the phenotypic differences and 
susceptibility to disease. Epigenetic processes may, there-
fore, contribute to the development of T2D and obesity and 
mediate the effects of environmental exposure on risk [9, 
57]. In the following paragraphs, examples from our own 
as well as other investigators will be presented supporting 
the evidence linking epigenetic modifications, in particular 
DNA methylation, to T2D and obesity in both humans and 
rodents.
T2D and DNA methylation
T2D is a metabolic abnormality characterized by elevated 
plasma glucose levels. T2D typically occurs when insulin 
secretion fails to keep pace with reduced sensitivity to the 
action of circulating insulin [38]. There is now substantial 
evidence indicating that environmentally induced epige-
netic changes contribute to diabetes prevalence (Table 2). 
Ling et al. have recently demonstrated that the promoter 
of the transcriptional co-activator Peroxisome proliferator 
activated receptor gamma coactivator-1 alpha (PGC1-α) 
gene, mainly involved in mitochondrial function, is highly 
methylated in pancreatic islets obtained from diabetic 
patients compared with non-diabetic controls [58]. Addi-
tionally, Barrès et al. have shown that the hyper-meth-
ylation of the PGC-1α promoter occurs even in the skel-
etal muscle from type 2 diabetic subjects compared with 
normal glucose-tolerant (NGT) individuals. Hyper-meth-
ylation negatively correlates with PGC-1α mRNA expres-
sion in these subjects [59]. In addition, the exposure of pri-
mary human skeletal muscle cells from NGT individuals to 
external factors, such as free fatty acids and tumor necrosis 
factor-alpha (TNF-α) directly and acutely alters the methyl-
ation status of PGC-1α promoter. These findings illustrate 
how alterations in the extracellular milieu may predispose 
to T2D by inducing DNA methylation changes [59]. Also, a 
genome-wide DNA methylation analysis of skeletal muscle 
from obese subjects before and after bariatric surgery pro-
vides evidence that the promoter methylation of PGC-1α 
is altered by obesity and restored after weight loss. DNA 
methylation inversely correlates to BMI, leptin, triglyceride 
and insulin levels in these subjects, which supports the role 
of DNA methylation in the physiological control of PGC-
1α gene transcription [60]. The Pancreatic duodenal home-
obox 1 (PDX-1) promoter is also methylated. PDX-1 is a 
homeodomain-containing transcription factor that plays a 
key role in pancreas development and function. In humans, 
mutations of PDX-1 cause maturity onset diabetes of the 
young 4 (MODY4) [61], while Pdx-1 silencing in pancre-
atic β-cells causes diabetes in mice [62]. In humans pan-
creatic islets, Yang et al. have shown that 10 CpG sites in 
the PDX-1 promoter and enhancer regions are hyper-meth-
ylated in type 2 diabetics compared with healthy individu-
als and that glycosylated hemoglobin (HbA1c) negatively 
correlates with mRNA expression of PDX-1 and positively 
correlates with DNA methylation, suggesting a role of 
chronic hyperglycemia in the modulation of PDX-1 expres-
sion through epigenetic events [63]. In support of this con-
cept, these authors also found an increased DNA methyla-
tion of the Pdx-1 gene in clonal rat β-cells exposed to high 
levels of glucose associated to increased mRNA expres-
sion and binding of the Dnmt1 on Pdx-1 promoter [63]. 
More recently, a genome-wide analysis of differentially 
methylated sites in genomic regions associated to T2D has 
recently revealed that the Fat mass and Obesity-associated 
Table 2  DNA methylation in T2D and Obesity
Examples of epigenetically modulated genes in T2D and obesity
T2D type 2 diabetes, PBLs peripheral blood lymphocytes, PGC1α peroxisome proliferator activated receptor gamma coactivator-1 alpha, PDX-1 
pancreatic duodenal homeobox1, FTO fat mass and obesity-associated, POMC pre-proopiomelanocortin, RXRA retinoid X receptor-alpha
Genes Regions Epigenetic modification Phenotypes Tissues/cells References
PGC1α Promoter ↑ DNA Methylation T2D Pancreatic islets, Skeletal muscle [58]
[59]
PDX-1 Promoter ↑ DNA Methylation T2D Pancreatic islets [63]
FTO Intron 1 ↓ DNA Methylation T2D PBLs [64]
POMC Intron 2-Exon 3 ↑ DNA Methylation Obesity PBLs [72]
RXRA Promoter ↑ DNA Methylation Obesity Umbilical cord [74]
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(FTO) gene is hypo-methylated in a CpG site within the 
first intron in type 2 diabetics compared with control sub-
jects in human peripheral blood. The T2D predictive power 
of this mark is significantly greater than all genetic vari-
ants so far described [64]. In the same investigation Top-
eroff et al. have also prospectively established, that, in an 
independent cohort hypo-methylation at the FTO intron is 
observed in young subjects that later progress to T2D. This 
further finding provides evidence that methylation changes 
predispose to T2D and deserve to be considered further 
investigated as T2D markers.
Obesity and DNA methylation
Obesity is a complex disorder resulting in an abnormal 
accumulation of fat in the organism due to alterations 
in energy homeostasis in terms of balance among energy 
intake, expenditure and storage [65]. It has been extensively 
documented in both humans and animal models that a rela-
tionship exists between obesity and the epigenetic regula-
tion of genes involved in the control of food intake (Table 2) 
[51, 66–70]. In this context, the epigenetic modulation of 
the Agouti gene is a paradigmatic example of this associa-
tion in mice. The Agouti gene encodes the paracrine-sign-
aling molecule “Agouti signalling peptide” (ASIP), which 
antagonizes the melanocortin 1 receptor (MC1R) and leads 
melanocytes to produce yellow rather than black coat pig-
ments. Additionally, ASIP acts as antagonist of the hypo-
thalamic MC4R, inhibiting the anorexigenic neuropeptide 
alpha-melanocyte-stimulating hormone (α-MSH) signaling, 
thereby promoting the activation of orexigenic pathways 
which make mice hyperphagic and prone to develop obe-
sity and diabetes [67]. It is now known that the Agouti gene 
is sensitive to cytosine methylation [69]. When its promoter 
is un-methylated, the Agouti gene is in an “ON” state, ASIP 
protein is abundant and mice show the typical agouti yel-
low coat and a tendency to develop obesity and diabetes 
[70]. On the contrary, when the promoter is heavily methyl-
ated, the Agouti gene is in an “OFF” state, ASIP levels are 
low resulting in mice that are lean and exhibit black coat. 
Interestingly, the Agouti gene is sensitive to environmental 
stimuli [51, 68, 71]. Nutrients and environmental pollutants 
impact on Agouti gene expression altering disease suscep-
tibility through epigenetic modifications. Agouti pregnant 
mice fed diets supplemented with the methyl donors folic 
acid, vitamin B12 or choline generate lean brown offspring 
which show increased DNA methylation on the Agouti 
gene promoter and decreased ASIP protein levels [71]. 
In addition, the effects on coat color induced by maternal 
methyl-donor supplemented diet are also inherited in the 
F2 generation, indicating a germline propagation of the 
epigenetic modifications [51]. On the other hand, maternal 
exposure to the environmental pollutant bisphenol A, which 
is commonly present in many items such as food and plas-
tic beverage containers and baby bottles, shifted the coat 
color of the offspring toward yellow by decreasing DNA 
methylation of CpG sites within the Agouti promoter [68]. 
Maternal supplementation with methyl donors abolished 
the bisphenol A-induced hypo-methylation of the Agouti 
gene in the offspring, demostrating the potential protec-
tive effect of simple dietary interventions against effect of 
an unhealthy environment effects on the fetal epigenome 
[68]. In humans, DNA methylation of the Pre-proopi-
omelanocortin (POMC) gene which encodes the anorexi-
genic hormone α-MSH produced by hypothalamic arcuate 
nucleus neurons has been associated with the individual 
risk of childhood obesity [72]. In particular, using periph-
eral blood cells, Kuenen et al. have found hyper-methyla-
tion at the Intron 2/Exon 3 boundary of the POMC gene in 
obese compared with normal weight children. In particular, 
in these obese children, the Alu elements, which are known 
to influence methylation in their genomic proximity at the 
Intron 2, trigger a default state methylation at the Intron 
2/Exon 3 boundary, interfering with binding of the his-
tone acetyltransferase/transcriptional coactivator p300 and 
reducing POMC expression [72]. In addition, several stud-
ies suggest a critical role of epigenetic marks also as pre-
dictors of susceptibility to obesity and metabolic disease 
in humans and animal models [73, 74]. A further example 
of this concept in humans has been provided by studies on 
the Retinoid X receptor-alpha (RXRA) gene. Godfrey et al., 
designed a perinatal epigenetic analysis of the methylation 
status of CpG sites at the promoters of 78 selected candi-
date genes in DNA from umbilical cord tissue of children 
who were assessed for adiposity at age 6 and 9 years. These 
authors have established that the variation of adiposity and 
the onset of obesity in pre-pubertal children were associ-
ated with the specific hyper-methylation of a CpG site at 
the RXRA chr9:1363558885+ at birth [74]. Furthermore, 
in the same population, it was demonstrated that this neo-
natal epigenetic mark was associated with lower maternal 
carbohydrate intake in pregnancy first trimester, providing 
a further example of how epigenetic processes may link 
the early prenatal life with the predisposition to obesity 
and other phenotypic outcomes [74]. In the future, perina-
tal identification of individuals that present DNA methyla-
tion changes at specific genes may help in preventing later 
obesity. In accordance to this concept, a recent bioinfor-
matic analysis, performed to search for epigenetic obesity 
biomarkers, has established potential regions of interest 
which have a high density of CGIs in the promoter of sev-
eral obesity-related genes (epiobesigenes), such as Leptin, 
Phosphatase and tensin homolog (PTEN), and Fibroblast 
growth factor 2 (FGF2) or genes implicated in adipogen-
esis, such as Peroxisome proliferator-activated receptor 
gamma (PPARG), in inflammation, such as Suppressors of 
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cytokine signaling 1 and 3 (SOCS1/SOCS3), and insulin 
signaling, like Lipoprotein lipase (LPL), Fatty acid binding 
protein 4 (FABP4), and Insulin-like growth factor binding 
protein-3 (IGFBP3) [75].
Epigenetics and nutrition: lessons from recent 
studies
Nutritional epigenetics has become an attractive field 
of study since it associates nutrients and bioactive food 
components with epigenetic modifications of gene func-
tion. As reported in this review, a variety of evidence, 
in both humans and animal models, supports the asso-
ciation between changes in nutritional status, epigenetic 
modifications and predisposition to T2D and obesity [76]. 
Shen et al. have demonstrated that high fat diet (HFD) 
feeding impacts on the Leptin gene by inducing pro-
moter CGI hyper-methylation in murine white adipose 
tissue (AT) [66]. Consistent with this observation, data 
obtained by our own group have further highlighted the 
role of over-nutrition in contributing to the gene function 
de-regulations occurring in obesity through epigenetic 
modification. By methylated DNA immuno-precipitation 
sequencing (MeDIP-seq), we have recently revealed that, 
HFD triggers a massive DNA methylation reprogramming 
in AT [77]. In particular, about 14.8 × 103 regions were 
found to be differentially methylated (DMRs) in mice 
fed a HFD. Interestingly, we have demonstrated that pro-
longed HFD regimen promotes a specific DMR distribu-
tion in mice [77]. DMR occurrence was increased in the 
gene-associated elements, particularly introns, and in the 
CGIs, while the number of DMRs identified in genomic 
repeat elements including long terminal repeats (LTRs) 
and long interspersed elements (LINEs) was decreased 
in obese compared with lean mice. Gene ontology analy-
sis indicates that HFD feeding promotes DMRs enrich-
ment in genes involved in developmental, metabolic and 
transcriptional processes in mice. In this same study, it 
has also been revealed that, among several differentially 
methylated pathways, the Hox family of transcription 
factors was highly enriched in differentially methylated 
genes in HFD-fed compared with STD-fed mice. In par-
ticular, the Hoxa5 gene, which is implicated in fat tis-
sue differentiation and remodeling [78, 79], was highly 
methylated at its 5′UTR and transcriptionally repressed 
in AT from obese compared with lean mice. In addition, 
the exposure of murine 3T3-L1 adipocytes to palmitate, 
a major component of the HFD, enhances methylation 
at the Hoxa5 5′UTR and causes Hoxa5 mRNA down-
regulation, suggesting that in AT the epigenetic silencing 
of Hoxa5 gene may be dependent, at least in part, on the 
effect of saturated fats rather than on obesity per se [79]. 
Interestingly, when obese mice exposed to chronic HFD 
treatment were returned to standard chow diet for two fur-
ther months, Hoxa5 DNA methylation and expression lev-
els returned to values similar to those of mice maintained 
under STD, emphasizing the plasticity of these epigenetic 
events [79] (Fig. 2).
This same MeDIP-seq approach has also identified the 
Ankyrin repeat domain 26 (Ankrd26) as a gene sensitive to 
nutrition-induced epigenetic changes. ANKRD26, a gene 
highly expressed in different areas of the hypothalamus, 
has been related to specific forms of hereditary obesity in 
humans [80] and was demonstrated to be involved in the 
regulation of feeding behavior and in the development 
of both obesity and diabetes in mice [81–83]. Mice with 
a partial inactivation of this gene show an obese pheno-
type which results from a marked hyperphagia rather than 
a reduction of the energy expenditure and activity [81]. 
When deleted at its C-terminus, Ankrd26 leads to exces-
sive food intake and obesity due to severe region-specific 
changes in primary cilia in the brain [83]. In addition to 
its function in appetite control, the Ankrd26 gene has a 
role in the regulation of adipocyte differentiation in mouse 
embryonic fibroblasts and in 3T3-L1 cells [84, 85]. We 
have demonstrated that hyper-methylation of the Ankrd26 
promoter occurs in obese mouse AT upon prolonged HFD 
feeding compared to age- and sex-matched STD-fed 
mice and directly interferes with the binding of the his-
tone acetyltransferase/transcriptional coactivator p300 to 
Fig. 2  High fat feeding: DNA methylation at the Hoxa5 gene in vivo. 
DNA methylation analysis performed on the AT from mice fed chow 
diet or high fat diet reveals the presence of a DMR relative to the 
Hoxa5 locus among high fat fed- and chow diet fed-mice. This event 
is associated with a strong reduction of the Hoxa5 mRNA expression 
levels in obese mice compared with lean mice. Interestingly, re-feed-
ing obese mice a chow diet for 2 further months reverted the Hoxa5 
DNA methylation and its expression to levels similar to those in lean 
control fed a standard chow diet
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this same region. These events result in the down regula-
tion of the Ankrd26 gene expression [unpublished obser-
vations]. We have further reveled that Ankrd26 silencing 
alters secretion of pro-inflammatory adipokines in vitro. 
These findings indicate that the epigenetic silencing of the 
Ankrd26 gene might be one of the mechanisms respon-
sible for AT inflammation in response to HFD [unpub-
lished observations]. In humans, computational data from 
a genome-wide DNA methylation analysis in subcutane-
ous white AT revealed that ANKRD26 gene is included 
in a list of 2825 genes where both DNA methylation and 
mRNA expression levels significantly correlate with BMI 
[86]. According to these findings, our preliminary data in 
human peripheral blood leukocytes underline a negative 
correlation between ANKRD26 mRNA expression levels 
and BMI, supporting the hypothesis that an epigenetic 
regulation of ANKRD26 gene may occur in humans, as 
well as in mice, and represent a pathogenic mechanism by 
which environmental exposures to nutrients contribute to 
disease susceptibility through epigenetic modifications.
Conclusions and future perspectives
The epigenome undergoes continuous transformations 
throughout our own lifetime leading to changes in genome 
function. The epigenetic hypothesis argues that, in addition 
to genetic variation, epigenetics provides an additional set 
of mechanisms mediating the relationship between geno-
type and the external environment and potentially contrib-
uting to the individual susceptibility to different disorders. 
During the past decades, the study of epigenetic modifica-
tions has been one of the most emerging and novel areas 
in fundamental as well as in clinical research and cur-
rently represents a very productive field of study, which has 
already provided a framework for the search of etiological 
factors in environment-associated diseases such as T2D and 
obesity. It is, indeed, clear that genetic variability only mar-
ginally contributes to the pathogenesis and family risk of 
these disorders. In this review, we have presented important 
acquisitions on the epigenetic network in T2D and obesity, 
mostly focusing on changes of the DNA methylation sta-
tus of specific genes. However, understanding of the epi-
genetics of these two complex diseases is still limited. Fur-
ther work is needed to clarify the molecular mechanisms 
responsible for the epigenetic control of gene activity and 
their interactions and alterations, and to establish the role 
of epigenetics in the risk stratification of these diseases. In 
the near future, further hints on how epigenetic changes are 
involved in the etiopathogenesis of T2D and obesity will 
be attained from studies accomplished on other epigenetic 
modifications, such as histone modifications and ncRNAs, 
which may selectively affect the expression of specific 
genes, and from epigenome-wide analysis extended to spe-
cific human cell types, e.g., stem, precursor and differenti-
ated cells, or to particular tissues, e.g., fat, skeletal muscle, 
liver and pancreatic islets. It is expected that these studies 
will pave the way to novel and more effective strategies 
aimed at diabetes and obesity prevention and at personal-
ized epigenetic treatment. Indeed, it becomes clear that 
getting a full picture of the epigenetic events involved in 
these two diseases will (1) represent a powerful tool for 
predicting and preventing future disease onset in the popu-
lation; (2) provide additional stimuli for the development of 
clinical epigenetic biomarkers, which will generate novel 
relevant information for diagnosis, prognosis and therapy 
optimization; and (3) drive advancement in epigenetic drug 
discovery with the generation of more effective epi-drugs, 
selective for specific epi-targets, which in the forthcom-
ing future might be used in combination with conventional 
therapeutics and/or might get the opportunity to develop 
epigenetic treatment personalized to the patient’s epige-
netic traits.
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ORIGINAL ARTICLE
Hoxa5 undergoes dynamic DNA methylation and
transcriptional repression in the adipose tissue of mice exposed
to high-fat diet
L Parrillo1,2, V Costa3,5, GA Raciti1,2,5, M Longo1,2, R Spinelli1,2, R Esposito3, C Nigro1,2, V Vastolo1,2, A Desiderio1,2, F Zatterale1,2,
A Ciccodicola3,4, P Formisano1,2, C Miele1,2 and F Beguinot1,2
BACKGROUND/OBJECTIVES: The genomic bases of the adipose tissue abnormalities induced by chronic positive calorie excess
have been only partially elucidated. We adopted a genome-wide approach to directly test whether long-term high-fat diet (HFD)
exposure affects the DNA methylation proﬁle of the mouse adipose tissue and to identify the functional consequences of these
changes.
SUBJECTS/METHODS: We have used epididymal fat of mice fed either high-fat (HFD) or regular chow (STD) diet for 5 months and
performed genome-wide DNA methylation analyses by methylated DNA immunoprecipitation sequencing (MeDIP-seq). Mouse
Homeobox (Hox) Gene DNA Methylation PCR, RT-qPCR and bisulphite sequencing analyses were then performed.
RESULTS:Mice fed the HFD progressively expanded their adipose mass accompanied by a signiﬁcant decrease in glucose tolerance
(Po0.001) and insulin sensitivity (Po0.05). MeDIP-seq data analysis revealed a uniform distribution of differentially methylated
regions (DMR) through the entire adipocyte genome, with a higher number of hypermethylated regions in HFD mice (Po0.005).
This different methylation proﬁle was accompanied by increased expression of the Dnmt3a DNA methyltransferase (Dnmt; Po0.05)
and the methyl-CpG-binding domain protein Mbd3 (Po0.05) genes in HFD mice. Gene ontology analysis revealed that, in the HFD-
treated mice, the Hox family of development genes was highly enriched in differentially methylated genes (P= 0.008). To validate
this ﬁnding, Hoxa5, which is implicated in fat tissue differentiation and remodeling, has been selected and analyzed by bisulphite
sequencing, conﬁrming hypermethylation in the adipose tissue from the HFD mice. Hoxa5 hypermethylation was associated with
downregulation of Hoxa5 mRNA and protein expression. Feeding animals previously exposed to the HFD with a standard chow diet
for two further months improved the metabolic phenotype of the animals, accompanied by return of Hoxa5 methylation and
expression levels (Po0.05) to values similar to those of the control mice maintained under standard chow.
CONCLUSIONS: HFD induces adipose tissue abnormalities accompanied by epigenetic changes at the Hoxa5 adipose tissue
remodeling gene.
International Journal of Obesity (2016) 40, 929–937; doi:10.1038/ijo.2016.36
INTRODUCTION
Through the second half of the past century, obesity established
as an increasingly prevalent response to the unhealthy environ-
ment and nutrition, both in the developed and in developing
countries.1 Obesity is associated with increased risk of a number of
different metabolic complications, and with increased mortality.2
In part, the excess morbidity accompanying obesity is determined
by dysfunctional adipose tissue.3
While most caloric excess is stored in the subcutaneous adipose
tissue, chronically positive caloric balance may induce ectopic
storage of lipids and involve intra-abdominal, pericardial, perivas-
cular and intramuscular adipose tissue (visceral adipose tissue).
Increased visceral adipose tissue is well recognized as an
independent risk factor for most obesity-associated comorbidities,
with the distribution of adipose tissue, their anatomical, cellular
and molecular features determining their occurrence.4 However, it
has been proposed that visceral adiposity represents a surrogate
marker for global body fat dysfunction. 3
Recent genome-wide association studies in humans led to the
identiﬁcation of 4100 common gene variants determining
individual propensity to adiposity. Most of them have an unknown
function at the present.5 In addition, the effect size of these
variants is small compared with the large effect of unhealthy
nutrition on the development of obesity.6 Even in the case of this
effect, however, the genomic bases of the visceral fat abnormal-
ities induced by chronically positive calorie excess have been only
partially elucidated.
It has become progressively clearer that environmental factors,
including the quality of nutrition, may affect individual pheno-
types by causing epigenetic modiﬁcations of the DNA.7,8 These
occur in the absence of DNA sequence alterations and include
variations in the methylation status at speciﬁc regions of the
genome, as well as posttranslational histone changes and
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differential miRNA expression.9,10 Studies in humans have also
revealed that speciﬁc epigenotypes have a very large effect on
adiposity variance. Godfrey and co-workers11 reported a positive
correlation between the degree of RXRα methylation at one
speciﬁc site in the promoter and childhood body adiposity at
age 6 and 9 years. These ﬁndings were replicated in both within-
cohort and between-cohort replicates. In contrast to the small
effect sizes typically seen with genetic polymorphisms associated
with metabolic disease risk, this single site epigenotype accounted
for at least 25% of the variance in childhood adiposity. However,
genes for which polymorphisms have strong associations with
disease risk might be anticipated to have epimutations.12 One
such gene is FTO, that acts as a nucleic acid demethylase,13
a co-substrate of which is α-ketoglutarate (a product of the Krebs
cycle), recently described as a biomarker of obesity-associated
non-alcoholic fatty liver disease.14 The FTO gene has been ﬁrst
identiﬁed by genome-wide association studies as being involved
in the risk of obesity. In a prospective study of nonsymptomatic
individuals of a mean age of 30 years, Toperoff et al.15 showed
that those who featured hypomethylation at an intronic CpG site
at FTO had an increased risk of developing impaired glucose
metabolism.
However, the majority of these studies have focused on
methylation at speciﬁc genes rather than adopting an unbiased
approach, although functionally relevant DNA methylation
changes may be located in different areas of the genome.16,17
Thus, a comprehensive analysis of the genome methylation proﬁle
in response to changes in the nutritional status is necessary to
interpret the epigenetic mechanisms accompanying diet-induced
obesity.
In this work, we have adopted methylated DNA immunopre-
cipitation sequencing (MeDIP-seq) to identify whole-genome
methylation changes occurring in the adipose tissue of
mice exposed to a long-term treatment with fat-enriched diet.
We have identiﬁed and cataloged several differentially methylated
genes (DMGs) whose function is modulated by this nutritional
regimen. We have further demonstrated that return of the animals
to a standard chow diet caused improvement of the metabolic
derangement, accompanied by rescue of both the epigenetic
modiﬁcations and the function of selected genes. Some of them
might therefore enable to quantify individual response to lifestyle
intervention in humans as well as in mice.
MATERIALS AND METHODS
Animals and diet
Male 5-week-old C57BL/6 J mice were obtained from Charles Rivers
(Deisenhofen, Germany) and housed in a temperature-controlled room
(22± 2 °C) with 12- h light-dark cycle. Mice were enabled ad libitum access
to food and water. Animals were randomly assigned to a standard chow
diet (STD about 10% energy as fat) or a high-fat diet (HFD about 60%
energy as fat) for 5 months. The composition of these diets is reported in
Supplementary Table S1. Body weight was recorded weekly. For insulin
tolerance testing, mice were fasted for 4 h and then subjected to
intraperitoneal injection with insulin (0.75 mIU g− 1 of body weight).
Venous blood was subsequently drawn by tail clipping at 0, 15, 30, 45,
60, 90 and 120 min as previously described.18 For intraperitoneal glucose
tolerance testing, mice were fasted overnight and then subjected to
intraperitoneal injection with glucose (2.0 g kg− 1 of body weight). Venous
blood was subsequently drawn by tail clipping at 0, 15, 30, 45, 60, 90 and
120 min as previously described.18 Blood glucose levels were measured
with Accu-Chek glucometers (Roche Applied Science, Penzberg, Germay).
The total area under the curve and the inverse area under the curve for
glucose response during glucose tolerance testing and insulin tolerance
testing were calculated as previously described.18 At the end of the
experiment, the animals were killed; the epididymal white adipose tissue
(WAT) was carefully dissected and stored at − 80 °C until analyzed. For
histology, epididymal WAT was ﬁxed in 10% neutral buffered formalin and
embedded in parafﬁn. Sections of 5 μm were obtained and stained with
hematoxylin and eosin. Images captured by an Olympus BX51 microscope
equipped with an Olympus (Shinjuku, Japan) DP-21 digital camera were
processed using the ImageJ software.
All the procedures performed were in agreement with the National and
Institutional Guidelines of the Animal Care and Use Committee at the
University of Naples Medical School.
Fractionation of adipose tissue
WAT was washed and minced in Dulbecco's modiﬁed Eagle's medium and
then incubated for 1 h at 37 °C with the same medium containing
collagenase (1 mg ml− 1; Sigma–Aldrich, St Louis, MO, USA). The mixture
was passed through a nylon ﬁlter (pore size, 250 μm) to remove
undigested material. The ﬁltrate was centrifuged for 5 min at 1500 g and
ﬂoating cells and the pellet were recovered as the mature adipocyte
fraction and the stromal vascular fraction, respectively, and were used for
RNA extraction.
DNA preparation and MeDIP-Seq
Genomic DNA was isolated from WAT of STD and HFD mice using the
AllPrep DNA/RNA Mini Kit (Qiagen, Hilden-Düsseldorf, Germany) according
to the manufacturer's instructions. The quality of each DNA sample was
analyzed for integrity, purity and concentration on a NanoDrop 2000c
Spectrophotometer (Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA).
Puriﬁed DNA (450 ng per sample) was then sent to Beijing Genomics
Institute (BGI at Shenzhen, China) for MeDIP-seq analysis by a Illumina
HiSeq 2000 (Illumina Inc., San Diego, CA, USA), and their detailed protocol
was published in the study by Li et al.19 DNA methylation data have been
deposited in GEO database under accession number GSE71476.
Reads alignment and pre-processing
Data ﬁltering was applied to remove adapter sequences, contamination
and low-quality reads from raw reads. About 73 million of ﬁltered
fragments—36.5 million 50 bp paired-end reads—were obtained for each
sample from MeDIP-seq experiments.
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was
used to assess the quality of sequenced reads. Raw reads were aligned to
the reference mouse genome (UCSC mm9) using BWA20 with default
parameters for paired-end mapping. Reads alignments in SAM format were
converted to BAM for further analyses using SAMtools.20 Statistics of
mapping quality was assessed by SAMStat on SAM/BAM input ﬁles.
Nucleotide composition, length distribution, base quality distribution,
mapping statistics, mismatches, insertions/deletions and error proﬁles
were reported in html5 format including unmapped, poorly and accurately
mapped reads. Only uniquely mapped reads were extracted from the.
sam ﬁle by a custom shell script and were used for further analyses.
BEDtools were used ﬁrst to convert mapped reads in BED format and then
to create ﬁles in Bedgraph format (.wiggle). These ﬁles were uploaded in
UCSC Genome Browser (http://genome.ucsc.edu) for visual inspection and
for gene-speciﬁc analysis.
Peak calling and identiﬁcation of differentially methylated regions
(DMRs)
The distribution of MeDIP-Seq reads on each mm9 chromosome was
analyzed. The genome was divided into windows of the arbitrary 10 kb
length, and read depth for each window was calculated. Read count within
each window was normalized using the following equation: RC*106/UMR
(RC= Read count in the 10 kb window; UMR=uniquely mapped reads).
Results are shown in Supplementary Figure S1. Reads coverage analysis
has been performed using BEDtools21 to test the number of CpGs covered
by sequenced reads, looking at the depth of coverage. The global
distribution of MeDIP-Seq-generated reads on speciﬁc genomic elements
of mouse genome (CGIs, shores and shelves, exons, introns, CDS, 5' and 3'
untranslated regions (UTRs), as well as repeat elements) has been
independently evaluated for both samples (Supplementary File S1).
Annotations of the genomic elements of interest were downloaded from
the Table Browser of UCSC Genome Browser for mm9 genome release.
Genomic coordinates of CGIs in mm9 genome release were obtained from
Smallwood et al.22 Shores and shelves genomic coordinates were
automatically computed from CGIs coordinates of.22 We annotated CpG
shores considering a range of ± 2 kb from the start and end positions of
each CGI, and CpG shelves in the range of ± 2 kb from start and end of
each CpG shore. MeDIP-Seq datasets from HFD and STD mice groups were
independently analyzed with model-based analysis of ChIP-Seq23 to ﬁnd
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signiﬁcant methylation peaks in both samples, and with the MEDIPS
package21 to identify DMRs. For both samples, the P-valueo10− 10 was
used to select signiﬁcant peaks computed by model-based analysis of
ChIP-Seq. Using MEDIPS package, uniquely mapped reads were extended
in the sequencing direction to a length of 300 nt. For the identiﬁcation of
DMRs, we used the MEDIPS option that enables to compute differential
methylation within ﬁxed genome-wide frames. Mean r.p.m. (reads per
million) values were computed for genome-wide 500 bp windows over-
lapping of 250 bp using MEDIPS ('frame_size = 500' and 'step = 250'
parameters were used). DMRs calculated by the MEDIPS software were
converted with custom scripts in BED format and loaded on Genome
Browser for immediate visualization. DMRs were mapped to known genes
or gene-associated elements (CGIs, shores and shelves, exons, introns, CDS,
5' and 3' UTRs, repeat elements) using SAMtools.20 BED ﬁles of each
annotated gene (or gene-associated elements) were downloaded from the
Table Browser of UCSC. ChipPeakAnno was used to assign each CGIs to
RefSeq genes based on the proximity of each gene transcription start site
to the nearest CGI. A similar approach was extended to associate all DMRs
to the above-mentioned gene-related elements. Protein Analysis THrough
Evolutionary Relationships (PANTHER) Classiﬁcation System (http://www.
pantherdb.org) was used to determine whether hypermethylated CGIs are
mostly associated with speciﬁc gene pathways and ontology terms. An
false discovery rateo0.05 was considered signiﬁcant.
Bisulphite sequencing analysis
Genomic DNA bisulphite modiﬁcation was performed using the EZ DNA
Methylation Kit (Zymo Research, Irvine, CA, USA) according to the
manufacturer’s instruction. The following primer pairs were designed by
Methprimer24 to amplify DMR-associated Hoxa5 locus: sense 5'-TTGGA
GTTGTTTAGGGAGTTTTTT-3'; antisense 5'-CCTCTAAAAATCATCAAACAA
AATTTAC-3'. PCR products were puriﬁed using Min Elute Gel Extraction Kit
(Qiagen) and cloned into the pGEM T-Easy vector (Promega, Fitchburg, WI,
USA). Individual clones were grown and plasmids puriﬁed using the
NucleoSpin Plasmid Kit (Macherey-Nagel, Düren, Germany). For each
condition, 10 clones were sequenced using SP6 promoter primer on AB
3500 genetic analyzer (Applied Biosystem, Waltham, MA, USA). The proportion
of methylation for each individual was calculated by dividing the total
number of methylated sites in all clones by the total number of CG sites.
Methylated DNA immunoprecipitation (MeDIP)
MeDIP assay was performed as described by Weber et al.25 Sonicated pooled
genomic DNA from WAT was immunoprecipitated using anti-5meCpG
(#ab10805, Abcam, Cambridge, MA, USA) or mouse IgG with anti-mouse
IgG beads (#10003D, Life Technologies, Waltham, MA, USA). DNA methylation
enrichment on recovered DNA was evaluated by qPCR. Samples were
normalized to their respective input using the 2-ΔCT method. The following
primer sequences were used: sense 5′-GTGCTTGATTTGTGGCTCGC-3′; anti-
sense 5′-TCCACCCAACTCCCCCATTA-3′.
RNA isolation, reverse transcription and quantitative RT-PCR
Analysis
Total RNA was isolated from WAT using AllPrep DNA/RNA Mini Kit (Qiagen).
cDNA was synthesized by reverse transcription using Superscript III Reverse
Transcriptase (Invitrogen, Waltham, MA, USA), according to the manufac-
turer’s protocol. Real-time RT-qPCR was performed on an iCycler IQ
multicolor Real Time PCR Detection System (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) using the comparative CT method (2-DDCT) with a
Platinum SYBR Green qPCR Super-UDG mix (Bio-Rad Laboratories, Inc.; 26).
All reactions were performed in triplicate, and the relative mRNA
expression levels of target genes were normalized to cyclophilin A. The
primer sequences used are shown in Supplementary Table S2.
Mouse Hox Genes DNA methylation PCR array
The Mouse Homeobox (Hox) Genes DNA Methylation PCR Array
(SABiosciences, Hilden-Düsseldorf, Germany) has been used to proﬁle
DNA methylation levels of Hox genes (n= 22). This novel restriction
enzyme-based technology was described by Kim et al.27 Brieﬂy, genomic
DNA is treated with a combination of methylation-sensitive and/or
methylation-dependent enzymes. Subsequent RT-qPCR enabled compar-
ison of Ct values between particular enzymatic reactions and thus
assessment of DNA methylation levels. PCR reactions were performed
using iCycler IQ multicolor Real Time PCR Detection System (Bio-Rad
Laboratories, Inc.). Detailed description of sample preparation and PCR
reaction conditions are provided in the manufacturer's protocol.
Western blot analyses
Adipose tissues were lysed in T-PER reagent (#78510, Thermo-Scientiﬁc,
Waltham, MA, USA) with a protease inhibitor cocktail (#05892791001,
Roche) and a phosphatase inhibitor (#04906837001, Roche). Twenty
micrograms of protein extracts were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred to polyvinyli-
dene diﬂuoride membranes (Millipore, Billerica, MA, USA). Upon incubation
with primary Hoxa5 (1:1000; #ab82645, Abcam), α-tubulin (1:1000;
#SC5546, Santa Cruz, Dallas, TX, USA) and secondary antibodies (Bio-Rad
Laboratories, Inc.), immunoreactive bands were detected by enhanced
chemiluminescence according to the manufacturer’s instructions (Pearce
ECL Western Blotting Substrate, # 32106, Thermo-Scientiﬁc).
Cell culture, treatments and transfection
3T3-L1 cells were grown and were allowed to differentiate into mature
adipocytes as described Bezy et al.28 Subsequently, adipocytes were
exposed to palmitate (0.25 mM; Sigma–Aldrich) and harvested 96 h later
for DNA and RNA extraction. For Hoxa5 silencing during adipogenesis,
3T3-L1 cells were transfected with 25 nmol l− 1 of Hoxa5 siRNA (OriGene,
Rockville, MD, USA), and subsequently induced to differentiate into mature
adipocytes. Transfection was repeated as on day − 2 every 48 h until day 8.
Then, lipid accumulation was assessed by Oil Red O staining as previously
described.29
Statistical analysis
Data are expressed as mean± s.e.m. Comparison between groups were
performed using Student's t-test or the one-way analysis of variance
followed by Tukey multiple comparison tests, as appropriate, using
GraphPad Software (version 6.00 for Windows, San Diego, CA, USA): a
P-value⩽ 0.05 was considered signiﬁcant. Statistical signiﬁcance of DMRs—
in HFD compared with STD mice—in genomic regions was performed with
chi-square test.
RESULTS
HFD changes the global DNA methylation proﬁle in adipose tissue
from C57BL/6 J mice
Five-week-old male mice were fed either standard chow (STD) or
fat-enriched diets (HFD) for 5 months followed by metabolic
phenotyping. Despite comparable food intake in the two groups,
mice exposed to the HFD exhibited a 37% increase in body weight
(Po0.001). Fasting glucose levels were increased in the HFD
treated mice (Po0.05). Glucose and insulin tolerance tests
revealed, respectively, decreased glucose tolerance (Po0.001)
and insulin sensitivity (Po0.05) in these animals (Table 1).
HFD treatment induced an increase in the individual adipose
cell size, accompanied by an elevated expression of macrophage
marker genes, including F4/80, Cd68 and Mcp-1. Moreover, HFD
exposure determined an upregulation of Fabp4 and Fas mRNA
Table 1. Metabolic phenotypes of high-fat- and standard chow
diet-exposed mice
STD (n=16) HFD (n= 16) P-value
Body weight 30.78± 0.9 42.18± 1.1 Po0.001
AUC GTT
(mg dl− 1*120 min)
11150± 1463 23686± 1783 Po0.001
AUC inv. ITT
(mg dl− 1*120 min)
10986± 920.12 6702.85± 1136.34 Po0.05
Glucose (mg dl− 1) 106± 12.7 163± 14.1 Po0.05
Abbreviations: AUC, area under the curve; GTT, glucose test tolerance; ITT,
insulin test tolerance; HFD, high-fat diet mice; STD, standard diet mice. All
values are means ± s.e.m.
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levels, together with a signiﬁcant reduction of adiponectin mRNA
levels, whereas Ppary2 expression showed no signiﬁcant variation
between HFD- and STD-fed mice, similar as described
previously29,30 (Supplementary Figure S1).
We have subsequently compared global methylation proﬁles in
epididymal fat from STD- and HFD-treated animals. By immuno-
precipitation of methylated DNA followed by massively parallel
sequencing (MeDIP-seq25,31), we generated 73 million reads in
each condition. Alignment to the mouse genome (mm9) revealed
that about 50% of the reads mapped in unique regions
(Supplementary Table S3). In addition, these reads were uniformly
distributed through the entire mouse genome, as indicated by the
detection of methylation events in most chromosomal regions
(Supplementary Figure S2), and were found to be mainly located
within introns and exons regions of the gene-associated elements
(Supplementary Table S4A).
About 17.6 × 104 and 16.7 × 104 methylation peaks were
identiﬁed, respectively, in HFD- and STD-maintained mice
(Bonferroni corrected Po0.01). Most of these peaks (52%)
were within the gene bodies, with 36% in intronic regions and
9% in CpG islands (Supplementary Table S4B). Analysis of different
repeat types revealed that methylation peaks were abundant in
LTR and LINE classes of the mouse genome (Supplementary Table
S4C).
About 14.8 × 103 DMRs were also identiﬁed in the genomes
from HFD- and STD-exposed mice (Po0.005), about 53% of which
were hypermethylated while 47% were hypomethylated in the
HFD compared with the STD mice. The highest frequency of DMR
occurrence was detected in gene bodies, particularly in the
intronic sequences where hypermethylation events were more
common (Figure 1a). Signiﬁcant DMR hypermethylation was also
noted in the CpG islands of HFD-fed mice, while no signiﬁcant
difference was observed in the CpG shores and shelves
(Figure 1b). At variance with the gene-associated elements, repeat
type analysis identiﬁed an increased number of hypomethylated
DMR in LTR and LINE classes of the HFD mouse genome
(Supplementary Figure S3).
Effect of HFD on expression of DNA-methylating enzymes in
adipose tissue
We then sought to explore whether the changes in DNA
methylation proﬁle observed in mice exposed to HFD could be
attributed to changes in the expression of DNA-methylating enzymes
and focused our attention on DNA methyltransferases32,33
and methyl-CpG-binding domain proteins (Mbd34). Interestingly,
quantitative real-time PCR analysis of mRNA from adipose tissue
revealed a speciﬁc twofold increase in the abundance of Dnmt3a
transcript in the HFD-fed mice (Po0.05; Figure 2a). The Mbd3, but
not the Mbd1, Mbd2 or Mbd4 genes was also signiﬁcantly
overexpressed in the adipose tissue of HFD-fed mice (Po0.05;
Figure 2b), suggesting a role Dnmt3a and Mbd3 genes in
mediating diet-induced hypermethylation events.
Diet-induced methylation changes affect developmental
processes
For the purpose of the present study, genes whose nearest CpG
island, shelf and/or shore overlap a DMR were termed differen-
tially methylated genes, which allowed us to identify 1.673 × 103
DMG. To initially address their functional signiﬁcance, we
performed gene set enrichment analysis both for the gene
ontology categories and the canonical pathways.
This analysis enabled us to identify the 'Ppar signaling pathway'
as the most signiﬁcantly enriched pathway among DMG (false
discovery rateo5%; Supplementary Table S5). DMG were also
enriched in the 'PI3k-Akt', 'Insulin resistance', 'Cytokine-cytokine
Figure 1. DMR distribution in mice subjected to HFD feeding.
Distribution of hypermethylated and hypomethylated DMRs (a) across
different gene elements (promoter, 5-UTR, exons, cds, introns, 3-UTR
and gene body) and (b) CpG-Island, -Shores and -Shelves. A CpG-Island
is deﬁned 200 bp (or larger) fragment of DNA with a C+G content of
450% and an observed CpG/expected CpG ratio4of 0.6. Shores: the
ﬂanking regions of the CpG-Islands, 0–2000 bp. Shelves: the regions
ﬂanking the island shores, i.e., covering 2000–4000 bp distant from the
CpG-Island. **Po0.005 and ***Po0.0005.
Figure 2. Expression of Dnmt and Mbd in WAT from HFD-exposed
mice. qRT-PCR analysis of mRNA expression levels of WAT Dnmt1,
Dnmt3a, Dnmt3b (a), and Mbd1, Mbd2, Mbd3 and Mbd4 (b). All data
are expressed as means± s.e.m. (n= 8 for STD; n= 8 for HFD).
*Po0.05, HFD vs STD.
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receptor interaction' and 'MAPK' pathways (false discovery
rateo5%; Supplementary Table S5A–D).
Gene ontology analysis indicated a strong enrichment in genes
involved in metabolic, transcription and developmental processes
in samples from HFD-exposed mice (Supplementary Figure S4).
Interestingly, a distinct set of genes belonging to the Hox family of
transcription factors was highly signiﬁcantly enriched among DMG
(P= 0.008). Aberrant methylation of transcription factor promoters
induce a wide array of downstream effects on gene expression. In
addition, increasing evidence indicate a role of Hox genes in
adipose tissue function and metabolic disorders.35 Therefore, we
focused on this cluster of genes for further investigation. We have
adopted a DNA methylation PCR array and systematically
examined the promoter methylation of 22 Hox genes. Whereas
most of these genes featured no signiﬁcant methylation
differences in DNA from HFD and STD-exposed mice, Hoxa5 and
Hoxa11 featured signiﬁcant promoter hypermethylation in DNA
from HFD compared with STD-fed mice (Figure 3a). At variance,
Hoxb1, Hoxb9, Hoxc6 and Hoxc8 showed reduced methylation in
the HFD-exposed animals.
Increased DNA methylation at the 5'-UTR promoter region is
often accompanied by transcriptional repression, whereas activa-
tion commonly follows hypomethylation.36 To directly test the
signiﬁcance of the observed methylation changes in Hox genes,
Figure 3. (a) DNA methylation and expression levels of Hox genes in WAT from HFD and STD-treated mice. A mouse Hox gene DNA
methylation array was used to proﬁle the indicated Hox methylation levels as described under Materials and methods. Un, unmethylated; Me,
methylated. RT-qPCR analysis of mRNA expression levels of WAT Hoxc8 (b) and Hoxa5 (c). All mRNA expression data are expressed as
means± s.e.m. (n= 8 for STD; n= 8 for HFD). (d) MeDIP-seq signals at Hoxa5 gene locus and bisulﬁte analysis of the Hoxa5-associated DMR.
Blue bar indicates hypermethylated DMR at Hoxa5 locus in HFD. CpG-Island (in green) overlapping Hoxa5 locus (in black). Start codon ATG
(gray) and transcription start (purple) sites are also indicated. Graphic representation and results of the bisulphite-sequenced portion of the
DMR (red arrows) relative to the Hoxa5 locus. Each horizontal row represents a single clone; the methylation percentages of 10 individual
clones are indicated, with unmethylated (○) and methylated (●) CpG sites. Representative image of n= 3 mice per group. (e) Immunoblot
analysis of Hoxa5 protein level (n= 2); α-tubulin was used as a loading control. ***Po0.001 and *Po0.05.
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we performed RT-qPCR assays. On the basis of this approach,
Hoxc8mRNA levels in adipose tissue from HFD-exposed mice were
found to be signiﬁcantly higher compared with control
mice (Figure 3b). At variance, Hoxa5 mRNA levels were decreased
in the adipose tissue of HFD-fed mice (Figure 3c). To further
validate the HFD-induced methylation changes occurring at the
Hoxa5 gene, we have subjected to bisulphite treatment and then
directly sequenced the Hoxa5-associated DMR, which encom-
passes a signiﬁcant portion of the 5'-UTR promoter region of the
Hoxa5 gene. As shown in Figure 3d, this procedure revealed an
average 25% increased methylation of the region from HFD
compared with STD-exposed mice (Po0.01), validating the
MeDIP-seq data. Furthermore, the amounts of the Hoxa5 protein
in WAT were decreased in the HFD-fed mice compared with
controls (Figure 3e).
To investigate whether diet-induced obesity or speciﬁc fats is
responsible for the changes in Hoxa5 methylation and expression
associated to exposure to HFD, we analyzed the effect of different
fat components on Hoxa5 in cultured 3T3-L1 cells. Supplementa-
tion of the culture medium with 0.25 mM palmitate, a major
component of the HFD, increased Hoxa5 promoter methylation
and decreased the expression of the gene to a similar extent as
that observed in WAT from HFD-treated mice (Supplementary
Figure S5A and B). Medium supplementation with 0.25 mM oleate
did not elicit any signiﬁcant effect.
Reversibility of HFD effect on Hoxa5 function
Current evidence indicates that, once established, epigenetic
modiﬁcations may be persistent.37 We therefore sought to assess
the stability of HFD-induced changes in promoter methylation and
expression of Hoxa5. To this end, we have prolonged the
nutritional intervention in animals exposed to HFD by returning
them to a STD for a further 2-month period, followed by
re-assessment of the metabolic phenotype. This diet change was
accompanied by a 50% reduction in the excess weight caused by
the previous HFD regimen (Po0.01; Figure 4a). Fasting plasma
glucose levels and IP glucose tolerance test were also signiﬁcantly
improved, indicative of improved glucose tolerance (Figures 4b and c).
Importantly, Hoxa5-associated DMR featured an almost twofold
decreased global methylation (Figure 5a). This effect was
accompanied by an almost complete rescue of Hoxa5 mRNA
expression in the adipose tissue (Figure 5b).
Expression of Hoxa5 is modulated during in vitro adipogenesis
In HFD-fed mice, Hoxa5 expression was downregulated in isolated
adipocytes but remained unchanged in stromal vascular fraction
cells (Supplementary Figure S6A). To investigate the role of Hoxa5
in WAT biology, we ﬁrst evaluated Hoxa5 expression during
adipogenesis, and found that Hoxa5 mRNA was induced in parallel
with differentiation in 3T3-L1 preadipocytes (Supplementary
Figure S6B). Consistently, the expression of Hoxa5 mRNA was
higher in the adipocyte fraction than in WAT stromal vascular
fraction from mice maintained under standard chow diet
(Supplementary Figure S6A).
3T3-L1 cells were subsequently transfected with Hoxa5-speciﬁc
siRNA and then induced to differentiate into mature adipocytes
(Supplementary Figure S6C). Oil Red O staining revealed a
decrease in lipid accumulation in the Hoxa5-siRNA treated
compared with control cells (Figure 5c). In parallel, the expression
of the adipogenic markers Ppary2 and C/ebpα was reduced in
Hoxa5-siRNA-treated cells (Figure 5d), suggesting that, at least
in the 3T3-L1 cells, Hoxa5 is important for adipocyte
differentiation.
DISCUSSION
We have adopted MeDIP-seq25,31 analysis to directly test whether
long-term HFD exposure affects the DNA methylation proﬁle of
the mouse adipose tissue and to identify the consequences of
these changes. We have shown a greater number of hypermethy-
lated compared with hypomethylated regions in the gene
elements of the HFD-exposed animals indicating that, in associa-
tion with obesity, this nutritional regimen induces increased DNA
methylation in this part of the genome. Consistent with our
ﬁnding, human obesity has been shown to be associated with
gene element hypermethylation in the skeletal muscle.38 In
addition, very recent analysis of global DNA methylation proﬁles
of adipose tissue from severely obese individuals showed
increased methylation in the gene bodies and 3' UTRs compared
with the same subjects examined upon bariatric surgery
and weight loss.39
Figure 4. Metabolic parameters of HFD-treated mice upon STD
rescue. Mice were either maintained under STD for 7 months
(STD/STD) or returned (and maintained for two further months) to a
STD after 5-month HFD treatment. Animals maintained under STD
or HFD for 5 months (respectively, STD, HFD) are also shown for
comparison. (a) Body weight; (b) fasting blood glucose; (c) glucose
AUC during GTT. Data are means± s.e.m. (n= 8 for STD; n= 8 for
HFD; n= 8 for STD/STD; n= 8 for HFD/STD). **Po0.01 ***Po0.001,
****Po0.0001. STD/STD mice maintained on STD diet through the
entire protocol; HFD/STD, HFD-treated mice returned to STD; AUC,
area under the curve; GTT, glucose tolerance test.
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Maunakea and co-workers40,41 have recently reported that, in
mammals, methylation occurring in the gene-associated regions
mainly involve gene bodies rather than promoter 5' CGI, as o3%
of promoter-associated CGI are methylated. Similarly, our MeDIP-
seq analysis revealed that most methylated sites identiﬁed in the
mouse adipose tissue falls within the gene bodies, while
methylation peaks at the 5'-UTR and gene promoter regions only
account for a small fraction of the total number of the genome-
wide methylated regions. Our data further revealed that only a
small proportion of methylated CGI undergo methylation changes
in response to HFD exposure, suggesting that CGI methylation is
speciﬁcally affected by the nutritional intervention. In addition,
despite the important role in gene regulation of the CGI shores
and shelves,42 our study did not reveal any signiﬁcant difference
in the methylation of these regions in response to HFD, indicating
that CGI, rather than their surrounding regions, are involved in
mediating the impact of the diet on genome plasticity.
At variance from the gene-associated elements, repeated
elements, particularly the LTR and LINE families, are hypomethy-
lated in the HFD mice. Interestingly, in mice, LTR hypomethylation
is responsible for the agouti phenotype,43 while in humans, LINE
hypomethylation in the visceral adipose tissue is associated with
increased risk of metabolic syndrome in the presence of obesity.44
All together, these ﬁndings underline the potential importance of
these repetitive elements in determining pathological traits in
humans as well as in mouse models.
The level and pattern of DNA methylation are regulated by both
DNA methyltransferases (DNMT1, DNMT3A and DNMT3B) and
demethylating proteins.45 In addition, the effects of DNA
methylation on chromatin and gene expression are largely
mediated by methylated DNA reader proteins, including Methyl-
CpG-binding domain protein 3 (Mbd3 (ref. 46)). In this study, we
report that the increased methylation of several genomic regions
in adipose tissue of HFD-exposed mice is accompanied by the
Figure 5. Hoxa5 DMR methylation status and mRNA levels after STD rescue and the effect of Hoxa5 silencing on adipogenesis in vitro.
(a) Graphic representation of bisulphite sequencing of the Hoxa5-DMR in WAT from animals maintained under HFD or returned to a standard
chow diet (STD). Each horizontal row represents a single clone; the methylation percentages of 10 individual clones are indicated, with
unmethylated (○) and methylated (●) CpG sites. The data shown are representative of three mice per group. (b) qRT-PCR analysis of mRNA
expression levels of WAT Hoxa5 after returning the HFD mice to STD. Data are means± s.e.m. (n= 8 for STD; n= 8 for HFD; n= 8 for STD/STD;
n= 8 for HFD/STD). *Po0.05 ***Po0.001. (c) Effect of Hoxa5 knockdown on the extent of adipocyte differentiation was assessed by Oil Red O
staining of intracellular triglyceride, and measuring the extract’s absorbance at 490 nm. (d) qRT-PCR analysis of mRNA expression levels of
Ppary2 and C/ebpα in 3T3-L1 treated with Hoxa5-speciﬁc siRNA and controls, at different time point during differentiation. All data are
represented as means± s.e.m. of triplicates. *Po0.05.
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upregulation of MBd3 and Dnmt3a. It is possible that a causal
relationship exists between this increased MBd3 and Dnmt3a
expression and the observed hypermethylation at speciﬁc genes/
gene-associated elements occurring in mice in response to HFD
treatment. It is equally possible that the enhanced MBd3 and
Dnmt3a function impair the DNA demethylation machinery which
is, in turn, responsible for the hypermethylation revealed in the
HFD mice. Both mechanisms may also simultaneously occur.
Interestingly, however, recent studies by Kohno and co-workers47
have provided evidence for an important role of Dnmt3a in linking
environmental determinants to altered energy homeostasis.
Independent investigations have further identiﬁed evidence that
this methylase is involved both in the development of obesity and
in the obesity-related inﬂammation caused by HFD exposure.48
Demethylation events also seemed to affect several genomic
regions in the HFD-treated mice. The impact of these changes is
presently under investigation in the laboratory, as available
evidence indicates that they may well have effects on cell
phenotype.49
Investigating the functional consequences of the genome-wide
changes in DNA methylation accompanying HFD exposure led us
to recognize that most DMG that we have identiﬁed encode for
transcription factors. Interestingly, the class I Homeobox family of
transcription factors (Hox genes35) revealed a very signiﬁcant DMG
enrichment in mice treated with HFD. In these same mice, a
perturbation in the methylation of genes included into the Ppar
signaling, PI3K-AKT and insulin resistance pathways was also
detected. However, different considerations led us to focus our
attention on the Hox genes in the context of the present work.
First, besides the well-described role in controlling tissue regional
development,35 increasing evidence indicates that Hox genes are
highly expressed in the adipose tissue35 and have an active role in
controlling adipocyte functions, including differentiation,
and body fat distribution.50,51 Second, human studies further
revealed that different members of the HOX subfamily are
upregulated upon the severe weight loss following bariatric
surgery, indicating that they respond to changes in body fat
mass.39,52 Third, current evidence indicates epigenetic control of
Hox genes during neurogenesis, development and disease.53 Thus,
the contribution of diet-induced epigenetic modiﬁcations to the
control of Hox gene function in the adipose tissue deserved to be
clariﬁed. Indeed, an aberrant methylation of transcription factor
promoters may potentially trigger a completely distinct transcrip-
tional program in the hit tissues, producing a broad spectrum of
downstream transcriptional events.
In this work, we have shown that long-term HFD exposure
simultaneously changes methylation and expression of several
Hox genes. Among these genes, Hoxa5 exhibited the more robust
repression in response to diet-induced hypermethylation. The
transcriptional repression accompanying the epigenetic dysregu-
lation of Hoxa5 may have been, at least in part, caused by the
saturated fat enrichment of the diet rather than representing a
consequence of obesity, as it can be mimicked by exposing 3T3-L1
adipocytes to palmitate. It remains possible, however, that obesity
per se or speciﬁc obesity-associated traits further contribute to
Hoxa5 dysregulation.
The downregulation of Hoxa5 expression may contribute to the
adipose tissue functional changes and remodeling that accom-
pany weight gain determined by HFD exposure. Indeed, HOXA5
expression increases during differentiation of human primary
adipocytes and is differentially regulated in various adipose tissue
districts.54,55 Consistently, we report that the expression of Hoxa5
is modulated during in vitro adipogenesis in 3T3-L1 and its mRNA
levels were higher in the adipocyte fraction than in the stromal
vascular fraction of WAT from lean mice. In addition, Hoxa5
silencing was accompanied by an impaired differentiation,
paralleled by an altered adipogenic gene expression and
decreased lipid accumulation. These ﬁndings, and the crucial role
of the Hox genes in developmental processes, highlight the
potential role of Hoxa5 as regulator of differentiation and/or
commitment of adipogenic precursor cells.
Previous studies reported that Hoxa5 inhibits angiogenesis,56
while angiogenesis inhibitors improve obesity in animal models.51
Blood vessels not only supply nutrients and oxygen to individual
adipose cells, they also serve as a cellular reservoir to provide
adipose precursor and stem cells that control adipose tissue mass
and function.57 It is possible therefore that HFD-induced down-
regulation of Hoxa5 negatively affects recruitment of new adipose
cell precursors or contribute to the adipose cell dysfunction that
often accompany adipose tissue expansion in response to caloric
excess.
HFD-exposed mice returned to a standard chow diet for a
further 2-month period underwent simultaneous weight loss and
almost complete rescue of Hoxa5 mRNA levels. Importantly, Hoxa5
methylation also returned to levels comparable with control
animals fed the standard chow diet for an identical period of time.
This ﬁnding supported the role of diet-induced Hoxa5 methylation
in controlling mRNA expression of this gene. Similar to the HFD-
exposed mice, obese human individuals achieving profound
weight loss after bariatric surgery treatment also revealed
improved HOXA5 expression in adipose tissue.52 Whether
quantiﬁcation of Hoxa5 expression can be exploited to assess
response to caloric restriction in animals and in humans, is
presently being investigated in the laboratory.
In conclusion, we have used MeDIP-seq analysis to verify
whether the exposure to HFD modiﬁes the DNA methylation
proﬁle in mouse adipose tissue and obtain indications on the
consequence of these changes on adipocyte function. Our work
reveals that the level of Hoxa5 mRNA expression, whose function
is implicated in fat tissue remodeling in response to changes
in body fat mass, is repressed in association with the methylation
changes caused by the nutritional intervention. Thus, environ-
mental cues may generate adipose tissue dysfunction by inducing
epigenetic modiﬁcations. Rescue of Hoxa5 methylation and
function in response to standard chow diet indicates that its
expression may represent a potential tool to quantify obesity
response to nutritional intervention.
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